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Abstract
Utilizing the K18-hACE2 mice model to develop protective COVID-19 vaccines
Ting Y. Wong
The ongoing Coronavirus Disease 2019 (COVID-19) pandemic is caused by the respiratory virus
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Similar to other respiratory
viruses, SARS-CoV-2 is transmitted through inhalation of respiratory droplets and aerosols from
infected individuals. Once inhaled, SARS-CoV-2 utilizes the receptor binding domain (RBD) on
the spike protein to bind to human Angiotensin Converting Enzyme 2 (hACE2) receptor to gain
entrance into host cells to begin viral replication. SARS-CoV-2 infection can result in mild to
severe cases of COVID-19 ranging from asymptomatic infections, cold or flu like symptoms to
respiratory failure. The onset of the pandemic in 2019 triggered a push to develop vaccines and
therapeutics to prevent and treat SARS-CoV-2 infections. At the end of 2020, companies such as
Moderna and Pfizer began to administer the first COVID-19 mRNA vaccines, and now in 2022,
there are ten World Health Organization (WHO) approved vaccines with many more vaccines in
clinical trials and pre-clinical development. At this time, approximately 12 billion doses have been
administered worldwide accounting for 61% of the global population being fully vaccinated.
However, with the continual emergence of SARS-CoV-2 variants of concern (VOC), each
harboring new mutations that can negatively impact vaccine efficacy, there is a need to study and
develop new vaccine approaches to improve immunity against VOC. Here, we devised three
approaches to help improve vaccine efficacy against SARS-CoV-2 using the pre-clinical Keratin
promoter 18-human Angiotensin Converting Enzyme 2 (K18-hACE2) mouse model. First, we
evaluated the pathogenesis and response of VOC against human convalescent plasma (HCP)
obtained from patients infected with the ancestral strain of SARS-CoV-2. Second, we assessed
the vaccine efficacy of four adjuvanted Beta VOC or ancestral strain derived RBD Virus-like

particle (VLP) vaccines against Alpha and Beta VOC challenge. Third, we evaluated intranasal
administration of a RBD carrier protein-based vaccine adjuvanted with a lipid A mimetic. K18hACE2 challenge models were used to establish SARS-CoV-2 VOC lethal challenge doses for
Alpha, Beta, and Delta. Once a lethal viral dose was determined for each VOC, we evaluated the
VOC response against polyclonal antibodies obtained from high titer HCP in a passive
immunization study. The objective of the study was to assess the efficacy of antibodies derived
from the ancestral strain on emerging VOC since binding and neutralizing antibodies against
SARS-CoV-2 are the main correlates of protection for measuring immunity against SARS-CoV-2.
Passive immunization of HCP and challenge using ancestral strain, Alpha, Beta or Delta resulted
in protection against ancestral strain (100% survival), partial protection against Alpha (60%), and
no protection against Beta or Delta challenge (0% survival). Survival outcomes of passive
immunization and VOC challenge were also reflected on disease outcomes, viral RNA levels in
the lung, brain, and nasal wash (Delta challenge only), and lung pathology. Despite poor
outcomes, human RBD and nucleocapsid IgG levels remained stable in the serum and lung in
the HCP treated and VOC challenged animals. Therefore, the VOC challenge mouse model
established in this study was further used to study vaccine efficacy. Additionally, the HCP passive
immunization study demonstrated to us that antibodies generated against the ancestral strain
may not protect against VOC. Therefore, to better improve vaccine efficacy against VOC, Beta
specific RBD antigens were utilized to study the efficacy of a VLP delivery approach in a murine
challenge model. In this study, vaccines were formulated with RBD from either the ancestral strain
(Wu) or Beta VOC conjugated to Hepatitis B surface antigen (HBsAg) VLP and adjuvanted with
Aluminum hydroxide (Alum) or Squalene-in-water emulsion (SWE) and compared against Pfizer
mRNA vaccine. Overall, all RBD-VLP vaccines generated RBD binding antibodies against
multiple VOC RBD, broadly neutralizing antibodies against VOC RBD, decreased viral burden in
the lung and brain, and lowered inflammation in the lung similar to Pfizer mRNA. However, only
Beta and Wu RBD VLP adjuvanted with Alum, and Beta RBD VLP adjuvanted with SWE were

able to protect mice (100% survival) against both Alpha and Beta challenge. Next, we evaluated
intranasal (IN) vaccination as an approach to improve vaccine efficacy against SARS-CoV-2. We
developed a prototype RBD vaccine conjugated to a diphtheria toxoid carrier protein Economical
CRM197 (EcoCRM) and adjuvanted with a toll-like receptor agonist 4 (TRL4), Bacterial Enzymatic
Combinatorial Chemistry (BECC) called BReC-CoV-2 (BECC+ RBD-EcoCRM COVID-19
vaccine). Overall, IN immunization with BReC-CoV-2 resulted in protection against SARS-CoV2, decreased viral burden in the lung, brain and nasal wash, generated high levels of RBD IgG in
the serum and lung that were capable of neutralizing VOC RBD, as well as induced mucosal IgA
in the lung and nasal wash compared to intramuscular (IM) vaccination of BReC-CoV-2.
Furthermore, heterologous IN prime and IM boost strategy with BReC-CoV-2 resulted in
protection (100% survival) against a lethal Delta challenge. Altogether, the three approaches to
improve vaccine efficacy demonstrated that the addition of VOC vaccine antigens accompanied
with immunostimulatory adjuvants can improve vaccine responses to VOC and intranasal
immunization can enhance vaccine protection by inducing mucosal antibody responses at the site
of infection. Together, these vaccine approaches can help improve vaccine efficacy against
emerging VOC in future COVID-19 vaccines.
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Chapter 1: Introduction
1.1 COVID-19 pandemic
In late December 2019, multiple pneumonia cases caused by an unidentified respiratory pathogen
was detected in Wuhan, Hubei Providence, China, and linked to the Huanan Seafood Wholesale
Market (1,2). As the year 2019 ended and 2020 began, the unidentified respiratory pathogen was
unveiled through genetic sequencing as a novel coronavirus named Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2) (1,2). The newly identified coronavirus was closely
monitored by the World Health Organization (WHO) and declared a public health emergency of
international concern at the end of January (1,2). In February 2020, the disease caused by SARSCoV-2 was coined Coronavirus Disease 2019 (COVID-19), with cases increasing to over 160,000
cases world-wide (1,2). On March 11, 2020, the WHO declared COVID-19 a pandemic, initiating
shut down and stay-at-home orders world-wide. As soon as the genetic sequence for SARS-CoV2 was known, vaccine development began (1,2). Due to an abundance of previous research on
similar coronaviruses, as well as more than 30 years of research on development of mRNA
technology, Pfizer-BioNTech and Moderna administered the first mRNA COVID-19 vaccines
under emergency use authorization in December 2020.
1.2 SARS-CoV-2 Pathogenesis and disease
Transmission of SARS-CoV-2 can occur through inhalation of aerosols or respiratory droplets of
infected individuals. SARS-CoV-2 establishes infection in the host, utilizing structural proteins as
well as other non-structural and accessory proteins. The RNA virus is composed of four main
structural proteins including spike, membrane, envelope, and nucleocapsid that play crucial roles
in pathogenesis. Unlike the other structural proteins, the spike protein of SARS-CoV-2 remains
an important target for vaccine and therapeutic development. The spike protein is composed of
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two subunits, S1 and S2, and is responsible for viral entry into host cells. The S1 and S2 are
divided by S1 and S2 cleavage sites (3). Therefore, the S1 subunit of the spike protein contains
the receptor binding domain (RBD), which allows for the binding of the spike protein to the host
human angiotensin converting enzyme 2 (ACE2). In turn this enables the protease cleavage at
the S2 site, triggering S2 subunit fusion of the host and virion membranes (3–6). The membrane
protein of SARS-CoV-2 is the most abundant structural protein with the main role of viral particle
assembly (5). Envelope protein of SARS-CoV-2 engages in viral assembly as well as plays a role
in viral lysis, release of virions once inside of the host cell, and activates the inflammasome (5–
7). Nucleocapsid is the only structural protein on the inside of the virion and is responsible for
protecting the viral RNA by forming ribonucleoprotein complexes. Nucleocapsid could also play a
role with interfering with host immune responses (5,6,8).
Once SARS-CoV-2 begins replication in the upper respiratory tract, different symptoms of COVID19 can occur ranging from asymptomatic to mild to severe. Dissemination of SARS-CoV-2 and
rapid replication of SARS-CoV-2 in the lungs can result in severe cases of COVID-19, which can
cause hyperactivation of the immune system causing increased inflammation, lung damage, and
respiratory failure. However, SARS-CoV-2 does not have a single organotropism for pulmonary
tissue, but can cause disease in other organ systems expressing ACE2 such as the
cardiovascular, vascular, gastrointestinal, renal, as well as the central nervous system (4,9–14).
1.3 Immune responses against SARS-CoV-2 infection
The body defends against foreign invaders using the innate and adaptive immune system.
Typically, during viral infection, the first responder to the infection is the innate immune system.
The innate immune system provides rapid, non-specific response to the pathogen by inhibiting
entry of virus into the cell, destroying infected cells, triggering inflammation, and thereby slowing
the establishment of infection and signaling for help of the adaptive immune system (15). Key
innate immune features involved with SARS-CoV-2 infection include the induction of type I and
type III interferon responses. Induction of interferons during the beginning of infection are
2

important to the severity of COVID-19. Limited or delayed interferon responses can result in
severe, life-threatening COVID-19 disease (16). Therefore, due to the intrinsic ability of SARSCoV-2 to avoid triggering anti-viral interferon responses, establishment of infection can manifest
in severe COVID-19 symptoms in naïve individuals (16).
The adaptive immune system, on average, needs approximately 6-10 days after initial infection
to generate antigen specific B and T cells to control and eliminate infection (17). Three main
adaptive immune system components play a large role in eliminating SARS-CoV-2 infection: 1)
CD4+ T-cells 2) CD8+ cytotoxic T-cells and 3) B-cells and antibodies. During viral infection, CD4+
T-cells can function by activating cytotoxic T-cells, maturating B-cells, and triggering the release
of anti-viral cytokines. CD8+ T-cells, with the help of CD4+ T-cells, can kill infected cells with the
release of cytotoxic granules. CD4+ T-cells can also differentiate into T follicular helper cells, which
can promote the affinity maturation of B-cells and result in the production of SARS-CoV-2 specific
antibodies that can help neutralize SARS-CoV-2. B-cells can also generate SARS-CoV-2 specific
antibodies including IgM, IgG and IgA contributing to systemic and mucosal protection. Even
though a majority of patients who are infected with SARS-CoV-2 generate antibodies against
SARS-CoV-2, studies have shown that neutralizing antibodies during a primary infection does not
likely contribute to reducing viral load and disease burden in infected patients (17–19).
Convalescent individuals that have recovered from COVID-19 develop memory against SARSCoV-2. Immune memory cells acquired during infection such as memory CD4+ T-cells, CD8+T
cells and B-cells can be triggered during re-infection with SARS-CoV-2 and can persist at least
up to 8 months post infection (20). T-cells play an important role in controlling and decreasing
disease severity in acute SARS-CoV-2 infection; however, SARS-CoV-2 specific antibodies,
particularly spike neutralizing antibodies, are necessary for protection against secondary infection
(21).
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1.4 SARS-CoV-2 Variants of Concern
One year after SARS-CoV-2 was discovered in Wuhan, China, strains of SARS-CoV-2 containing
mutations on the spike protein were detected and began negatively impacting vaccine and
therapeutic development for COVID-19. Reports of increased transmission, infectivity, and
immune evasion arose due to the newly emerging strains. Thus, the World Health Organization
(WHO) developed a system to classify and monitor variants of concern (VOC) of SARS-CoV-2.
VOC are characterized as variants of SARS-CoV-2 harboring mutations that can cause increased
transmissibility, probability of severe disease including hospitalization or death, evasion of
neutralizing SARS-CoV-2 antibodies due to vaccination or infection, and lastly, decreased
effectiveness of therapeutics, vaccines, treatments, and detection assays (WHO and CDC).
Throughout the two years of the pandemic, there has been 5 alarming SARS-CoV-2 VOC (Fig.
1). On December 2020, the WHO declared both Alpha (B.1.1.7) and Beta (B.1.351) as VOC
(Fig.1). Alpha was first detected in the United Kingdom and contained two major concerning
mutations on the spike protein, D614G and N501Y (RBD) (22). D614G mutation on the spike
protein is known to increase viral replication, whereas the N501Y mutation on the RBD of spike
protein allows the spike protein to bind with higher affinity to host receptors, promoting increased
transmissibility (GAVI). Beta VOC was first discovered in South Africa, and harbors two additional
mutations on the RBD compared to Alpha VOC, E484K and K417N (22). E484K and K417N
mutations on the RBD increase the virus evasiveness from neutralizing antibodies generated
against infection with the original strain or vaccination. Overall, Beta VOC did not have as high of
frequency in the population as the Alpha variant, and eventually slowly disappeared from
circulation (23). Approximately one year following the designations of Alpha and Beta VOC, the
Gamma VOC was detected in Brazil in January 2021 (Fig.1). Similar to the Beta variant, the
Gamma variant contained N501Y and E484K mutations on the RBD, but accumulated a key new
mutation on the RBD, K417T, which promoted enhanced binding to host cells increasing
transmissibility of the variant (22). As Alpha and Gamma were still in circulation in the population,
4

Delta was declared a VOC in May 2021 (Fig.1). Delta VOC was first detected in India and
contained the same D614G mutation as the previous variants of concern; however, unlike the
previous variants, Delta obtained three to four new mutations on the spike, and RBD protein such
as P681R, L452R and T478K (22). P681R mutation on the spike protein can cause increased
probability of severe disease, L452R mutation on the RBD was found to promote infectivity of the
Delta variant, and mutation T478K on the RBD was responsible for enhanced immune evasion
(22). As the world was recovering from the damage brought on by the Delta variant, Omicron
emerged as the most current and dominant circulating variant of concern in November 2021
(Fig.1). Omicron was first detected in South Africa, and unlike the predecessor SARS-CoV-2
VOC, Omicron harbored more than 50 viral mutations, 30-40 mutations on the spike protein, and
approximately 15 mutations on the RBD alone. These newly acquired mutations on the spike
protein have made Omicron highly transmissible by increasing the ability of the variant to evade
immune responses such as neutralizing antibodies generated from vaccination and previous
infection with other strains of SARS-CoV-2 as well as approved monoclonal antibody therapeutics
(24–29). Currently, Omicron has 5 lineages: BA.1, BA.2, BA.3, BA.4, and BA.5. Although BA.1
and BA.2 were the predominant circulating strains of Omicron in late 2021 into early 2022,
currently BA.4 and BA.5 are the dominant global subvariants (30–33).

5

RBD, black represents mutations on the spike protein. Red represents current predominant VOC.

Figure 1. Timeline of the emergence of SAR-CoV-2 variants of concern. Amino acid changes in purple represents mutations on the
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1.5 COVID-19 Vaccines
The WHO has approved eleven vaccines for Emergency Use Listing worldwide (Table 1). Vaccine
platforms utilized include protein subunit, mRNA, non-replicating adenovirus, and inactivated
virus all formulated with either the spike protein or inactivated virus from the ancestral strain of
SARS-CoV-2. Thus far, non-replicating adenovirus vaccines such as Ad26.COV.S (Jansen),
Vaxzevria (Oxford/AstraZeneca), Covishield (Serum Institute of India), and Convidecia/Ad5-nCoV
(CanSino) have been approved in 310 countries, making the adenovirus COVID-19 vaccines the
most widely approved COVID-19 vaccine platform in the world. Closely following adenovirusbased vaccines, mRNA vaccines including Comirnaty Pfizer/BioNTech) and Spikevax (Moderna)
have approval in 232 countries and are FDA approved in the United States. After mRNA vaccines,
inactivated viral vaccines such as Bharat Biotech Covaxin, Sinopharm Covilo, and Sinovac
CoronaVac are approved for use in 161 countries. Lastly, protein subunit vaccines developed by
Novavax (Nuvaxovid) or manufactured by the Serum Institute of India (COVOVAX) have been
granted approval in 43 countries.
1.5.1 Non-replicating adenovirus COVID-19 vaccines.
Adenovirus vectors have been historically used for gene therapy; however, advancement of
adenovirus vector technology has allowed for the application of adenoviruses in vaccines and
cancer immunotherapies (34). Adenovirus vectors used for COVID-19 vaccines are attenuated
DNA viruses most commonly originating from humans or chimpanzees with the genes responsible
for replication removed and substituted with target genes of interest such as the spike protein.
Vaccine adenovirus vectors function by infecting host cells and incorporating the gene encoding
spike protein into the nucleus of the cell which is transcribed into mRNA to eventually produce
the spike protein. Ad.26.COV2-S utilizes a non-replicating human adenovirus serotype 26 as the
vector to express the pre-fusion stabilized spike protein of ancestral SARS-CoV-2 (35). Phase 3
clinical trials showed that a single dose of Ad.26.COV2-S exhibited 66.9% vaccine efficacy
against moderate to severe COVID-19 14 days post vaccination and 66.1% vaccine efficacy 28
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days post vaccination (36). At the time of the phase 3 clinical trial, Beta was the predominant
variant amongst clinical trial participants (86 out of 91 cases) in South Africa (36). Additionally,
ChAdOX1-nCoV (Vaxzevria), unlike Jansen’s vaccine utilizes a chimpanzee adenoviral vector.
Similar to Ad.26.COV2-S, ChAdOX1-nCoV also expresses the ancestral spike protein; however,
without S2 stabilizing mutations (37). In phase 3 clinical trials, two doses of ChAdOX1-nCoV
resulted in 74% vaccine efficacy against mild COVID-19 (38). However, genomic sequencing of
SARS-CoV-2 samples in the participant pool revealed a low frequency of variants of concern (38).
Nevertheless, recent studies assessing ChAdOX1-nCoV protection against severe COVID-19
caused by the Delta variant showed a 90% vaccine efficacy after two doses of ChAdOX1-nCoV
(39). The most recent WHO approved vaccine, Convidecia/Ad5-nCoV (CanSino) utilizes a nonreplicating human adenovirus 5 to express the full-length spike protein (35). Phase 3 clinical trials
demonstrated that one dose of Convidecia/Ad5-nCoV resulted in 57.5% efficacy against mild
COVID-19 and 90% effectiveness against severe COVID-19 (40). Omicron, Alpha and the
ancestral strain were detected in the Convidecia/Ad5-nCoV phase 3 clinical trial (40). The
advantages provided by adenoviral vaccines include thermostability, ease of scalability, and the
ability for the vector to induce a robust immune response (35). However, disadvantages to
adenoviral vector vaccines include previous immunity generated from human adenoviruses
limiting immunogenicity of the vaccine, as well as thrombocytopenia, a rare but serious side effect
induced by vaccination (35,41).
1.5.2 mRNA COVID-19 vaccines.
The COVID-19 pandemic provided the first opportunity for mRNA vaccines to be used in humans.
The contribution of multiple scientists and over 30 years of research has culminated in the rapid
development and rollout of COVID-19 mRNA vaccines (42). Development of mRNA vaccines
began in the 1980s with the synthesis of mRNA in the laboratory along with the utilization of lipids
to deliver mRNA (43). Advancements in the stabilization of mRNA progressed into the first preclinical studies in mice with cancer mRNA therapy, and mRNA vaccines for influenza in the 1990s
8

(44). In the early 2000s, methods were developed to manufacture lipid nanoparticles which
eventually lead to the first lipid nanoparticle mRNA vaccines for influenza in clinical trials in 2015
(43). Other mRNA based vaccines that were also developed and evaluated in clinical trials include
vaccines against HIV, rabies, and Zika (45).
Current approved COVID-19 mRNA vaccines developed by Pfizer/BioNTech (46) and Moderna
(47) are formulated with mRNA encoding pre-fusion spike protein from the ancestral strain of
SARS-CoV-2 encapsulated within lipid nanoparticles (LNPs). COVID-19 mRNA vaccines utilize
LNP delivery systems to protect mRNA from degradation and to promote entry into the host cell.
Once inside the host cell, mRNA is transcribed into the spike protein and is expressed on the
surface of the cell where they are displayed to antigen presenting cells to initiate immune
responses. In clinical trials, two doses of either Pfizer/BioNTech or Moderna mRNA vaccines
provided high vaccine efficacy (over 95%) against the Delta variant; however, vaccine efficacy
sharply dropped against the Omicron variant to 65.5% and 75.1% respectively, decreasing rapidly
in efficacy over time after the second dose. The third dose of either Pfizer/BioNTech or Moderna
mRNA vaccines provided an increase in vaccine efficacy to 67.7% and 73.9% respectively (48).
Ten weeks after the third dose, Pfizer/BioNTech mRNA vaccine efficacy waned from 67.7% to
45.7%, whereas Moderna mRNA vaccine efficacy dropped from 73.9% to 64.4% after five to nine
weeks following the third dose against Omicron infection (48). Advantages of mRNA vaccine
technology include safety of the vaccine, speed of producibility and scalability in cell free
bioreactors as well as the ability to express multiple antigens at once within one vaccine. However,
despite many doses of mRNA vaccines distributed world-wide, cold-chain requirements for mRNA
vaccines deter distribution to low-income countries.
1.5.3 Protein subunit vaccines
In general, protein subunit vaccines are considered to be the conventional method of
immunization. Protein-based vaccines can include full or subunits of proteins that can be
assembled on nanoparticles, virus-like particles (VLPs), or carrier proteins. Typically, most
9

protein-based vaccines are adjuvanted to enhance antigen specific immune responses. Despite
the common use of protein vaccines, there is only one COVID-19 protein subunit vaccine,
Nuvaxovid/COVOVAX, that has been currently approved by the WHO. Nevertheless, there are
over 46 protein-based vaccines in clinical development (49). Unlike mRNA or adenovirus
vaccines, Nuvaxovid/ COVOVAX is composed of ancestral strain full-length spike protein
produced in insect cells. The spike protein is displayed on nanoparticles, and adjuvanted with
Matrix-M, a saponin extracted from soap bark trees (50–52). In phase 3 clinical trials, two doses
of Nuvaxovid resulted in 100% protection against COVID-19 caused by non-variants of concern
of SARS-CoV-2 and demonstrated 92.6% vaccine efficacy against primarily the Alpha variant
which was the predominant variant at the time of the study (51). Regardless of the slower
development period of protein-based vaccines for COVID-19, this platform offers advantages
such as: familiarity with the platform, safety amongst immunocompromised individuals, and
thermostability (53). However, there are disadvantages including longer development to
implementation periods of the vaccine into the population compared to adenovirus and mRNA
platforms.
1.5.4 Inactivated SARS-CoV-2 vaccines
Over 11 billion COVID-19 vaccines have been distributed worldwide (54). Despite only approved
for use in 160 countries, approximately 5 billion of inactivated SARS-CoV-2 vaccines have been
administered globally. (54). Currently, CoronaVac developed by Sinovac, leads in the most
vaccines distributed and used world-wide with almost 2.5 million doses allocated (54). Approved
inactivated SARS-CoV-2 vaccines are developed by chemically inactivating live ancestral SARSCoV-2 with beta-propiolactone, and adjuvanting the dead virus with aluminum hydroxide (55,56).
Vaccine efficacy of CoronaVac, Covaxin, and Covilo showed 81.3%, 93.4%, and 79% respectively
against severe COVID-19 after two doses (57–59). Advantages of using inactivated virus
vaccines include speed of development and ease of manufacturing, thermostability which allows
vaccines to be distributed to low-income countries, and capability of administration to
10

immunocompromised individuals (60). Similar to mRNA, adenovirus and protein based COVID19 vaccines, inactivated SARS-CoV-2 have demonstrated waning vaccine efficacy against the
Omicron variant of SARS-CoV-2. However, due to increased immune evasion of Omicron towards
inactivated vaccines, different boosting strategies with other vaccine platforms such as mRNA,
are recommended for protection against VOC (25,61).
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Table 1: Eleven WHO approved COVID-19 vaccines.
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1.6 Adjuvants for COVID-19 vaccines
Currently, there are a variety of adjuvants used for approved intramuscular vaccines as well as
new adjuvants that are being developed to help stimulate a safe and robust immune response.
Conventionally, adjuvants are utilized in vaccine formulations to enhance the immunogenicity of
the candidate vaccine antigen, promote longevity of the vaccine response, and provide dose
sparing for vaccine antigens. Current approved adjuvant platforms traditionally used in
intramuscular protein subunit vaccines or inactivated vaccines include Alum, oil in water
emulsions, lipid A, Cytosine phosphoguanosine (CpG), and the AS0 adjuvant systems (AS01,
AS03, and AS04). Thus far, approved COVID-19 vaccines have utilized adjuvants such as LNPs
for mRNA vaccines as well as saponin or Matrix M used by Novavax. However, COVID-19
vaccines under pre-clinical as well as clinical development have utilized other adjuvants to
enhance vaccine responses. Here, common adjuvants used for vaccine development and novel
vaccine adjuvant platforms are discussed.
1.6.1 Alum
Aluminum hydroxide or Alum is the most frequently used adjuvant in vaccines. Alum has been
used in vaccine formulations to prevent bacterial, viral, or parasitic diseases such as Diphtheria,
Tetanus, Pertussis, Haemophilus influenzae, human papillomaviruses (HPV), Japanese
encephalitis, bacterial meningitis, pneumococcus, shingles, SARS-Cov-2, and malaria. In
general, Alum stimulates a strong antibody mediated response through mechanisms such as
triggering tissue damage through the induction of uric acid activation of dendritic cells to promote
a Th2 facilitated response (62,63). Alum also can cause the release of neutrophil extracellular
traps. The DNA released from neutrophils can also help mediate a Th2 induced humoral response
(64,65). Currently, alum adjuvants are used in WHO approved inactivated viral vaccines, as well
as protein subunit and virus like particle vaccines adjuvanted with alum are being evaluated in
pre-clinical studies. Studies performed in mice demonstrated that alum adjuvanted COVID-19
vaccines generated increased neutralizing antibody titers (66).
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1.6.2 Toll like receptor agonist
Toll-like receptors (TRLs) are pattern recognition receptors located either on the cell surface
(TLR1, TLR2. TR4, TLR5, TLR6) or in endosomes (TLR3, TLR7, TLR8, and TLR9) (15). TLRs
are most commonly found on innate immune cells such as dendritic cells, monocytes,
macrophages and neutrophils, and play an important role in recognizing pathogen-associated
molecular patterns (PAMPs), such as lipid polysaccharides (LPS) for Gram-negative bacteria or
nucleic acid (15). Overall, activation of TLRs with appropriate PAMPs can trigger the release of
pro-inflammatory cytokines that can stimulate the immune response to the pathogen. Therefore,
adjuvant platforms that utilize the activation of TLRs can help stimulate the appropriate cellular
and humoral immune responses to vaccine antigens. Adjuvants such as Monophosphoyl lipid
(MPL) and CpG are agonist for TLR4 and TLR9 respectively.
MPL is a low toxicity lipid A derived from the LPS of Salmonella. Since MPL is a TLR4 agonist, it
can activate antigen presenting cells such as dendritic cells to elicit a pro-inflammatory Th1 driven
immune response (67). In licensed vaccines, MPL is formulated with the AS0 adjuvant systems
developed by GlaxoSmithKline (68). In the adjuvant system AS04, MPL is adsorbed to alum.
AS04 is used in licensed vaccines for hepatitis B (HBV) and HPV and studies have demonstrated
that the addition of MPL to alum generated improved vaccine efficacy in the HPV and HBV
vaccines, increased antibody response to pathogen, and increased longevity of the vaccine
immune response compared to alum alone (62,68). MPL is also combined in the adjuvant system
AS01 with saponin (QS-21) and delivered in liposomes (69). AS01 is currently used in vaccine
formulations for shingles in older adults (70). Together, MPL and QS-21 provide synergistic
affects when administered together and can promote both a strong cellular and functional
antibody response (70). TLR4 agonist adjuvants can enhance the immune response of a vaccine
by generating robust cellular and antibody responses. However, few methods exist for developing
novel TLR4 agonists that can be used as safe and efficacious adjuvants in vaccines. Bacterial
Enzymatic Combinatorial Chemistry (BECC) is a novel method developed to generate lipid A
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mimetics that are TLR4 agonist by harnessing LPS on Gram-negative bacteria. In general, BECC
generates TLR4 agonists by reprogramming the lipid A biosynthesis pathway in Gram-negative
bacteria by the addition of exogenous or removal of endogenous lipid A modifying enzymes under
different temperature conditions (71). The BECC method provided two candidate lipid A mimetics,
BECC438 and BECC470, that could be used as vaccine adjuvants. Pre-clinical studies in murine
models have demonstrated that BECC adjuvants improved the vaccine efficacy in protein subunit
vaccines for both bacterial and viral pathogens such as Yersinia pestis, Bordetella pertussis,
Staphylococcus aureus, HPV, influenza A, and SARS-CoV-2 (72–75). Both BECC438 and
BECC470 elicited a balanced cellular and functional antibody driven response to the vaccine
antigen overall improving vaccine efficacy.
Lastly, CpG is a TLR9 agonist adjuvant that has been used in licensed vaccines such as Heplisav,
to prevent HBV infections. When formulated in vaccines, CpG induced a Th1 skewed response
that can stimulate the activation of B and NK cells (62). CpG, similar to MPL, can be used in
combination with other adjuvants such as alum to increase immunogenicity of the vaccine
response. SARS-CoV and MERS-CoV vaccine studies with CpG and alum showed increased
production of neutralizing antibodies and stimulated robust cellular response (76,77). Additionally,
CpG has been used in a two-dose virus like particle SARS-CoV-2 vaccines that are currently in
phase 1 clinical trials (78).
1.6.3 Oil in water adjuvants
Oil in water adjuvants have been commonly used in vaccines to increase immunogenicity. MF59,
Montaninde ISA 51, ISA 720 and AS03 are all oil in water adjuvants that have been used in human
vaccine clinical trials. Particularly, MF59 is utilized in licensed influenza vaccines for the elderly
(Fluad) as well as for the pandemic influenza vaccines (79). The composition of MF59 includes
squalene obtained from shark liver, and the surfactants Tween 80 and Span 85 combined into oil
droplets. MF59 functions to stimulate the recruitment of antigen presenting cells to the injection
site leading to enhanced antigen uptake and trafficking into the draining lymph nodes, resulting
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in the activation of B and T-cells. Vaccines formulated with MF59 stimulate a strong CD4+ T-cell
response that can overall promote the production of affinity maturated functional antibodies as
well as enhance the durability of the antibody responses compared to alum. Additionally, studies
have demonstrated that MF59 can limit the amount of antigen needed to mount an immunogenic
response. MF59 has been used in vaccine formulations for SARS-CoV and MERS in pre-clinical
studies which demonstrated that the addition of MF59 to spike protein induced elevated levels of
neutralizing antibodies as well as stimulated both CD4 and CD8 T-cell responses (66). Currently,
pre-clinical studies are underway evaluating SARS-CoV-2 inactivated and protein subunit
vaccines adjuvanted with MF59 (66).
The COVID-19 pandemic has emphasized the on-going global vaccine disparity. As a result of
the vaccine disparity, developing countries have less access to vaccines to prevent infectious
diseases. The establishment of non-profit companies such as the Vaccine Formulation Institute
(VFI) in Switzerland allowed for the focus on providing adjuvants, vaccine adjuvant research, and
pre-clinical vaccine development to aid developing countries, as well as to offer open access to
available adjuvants to the vaccine community (80). VFI developed a squalene in water emulsion
(SWE) adjuvant similar to MF59 to aid in the global distribution and development of vaccines.
Together with Seppic, they have generated and manufactured Good Manufacturing Practice
(GMP) grade SWE that is open access to the vaccine community. SWE similar to MF59 is
composed of squalene, and surfactants sorbitan trioleate similar to Span 85, and polyoxyethylene
sorbitan monooleate. SWE has been utilized in pre-clinical studies evaluating vaccine candidates
for both bacterial and viral pathogens such as Polio, Influenza, RSV, Rabies, SARS-CoV-2 and
group A Streptococcus (81–85). COVAC-2, a SARS-CoV-2 protein subunit vaccine formulated
with S1 protein and SWE, is of the first COVID-19 vaccine adjuvanted with SWE to enter phase
1/2 clinical trials (86,87).
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1.7 Vaccine nanoparticles and carrier proteins
Nanoparticles are utilized in vaccine formulations as antigen delivery systems that can enhance
the immunogenicity of candidate vaccine antigens. In general, antigens can be delivered on the
surface of the nanoparticle or encapsulated within the nanoparticle. Nanoparticle material can
include lipid nanoparticle (LNP), virus-like particle (VLP), protein, polymer, micelle, and liposomes
with each nanoparticle possessing a unique method of displaying and delivering vaccine antigen
(88). WHO approved COVID-19 vaccines that utilize the nanoparticle delivery system include
Moderna and Pfizer-BioNTech mRNA vaccines (LNPs) and Novavax protein subunit vaccine
(Micelle). LNPs are commonly used to deliver nucleic acid encoding vaccine antigen such as the
mRNA COVID-19 vaccines in order to help prevent the degradation of the nucleic acid. The LNP
also holds immunostimulatory properties and can act as an adjuvant to increase immunogenicity
of nucleic acid vaccines. Other than Moderna and Pfizer-BioNTech mRNA COVID-19 vaccines
which are WHO approved, there are approximately 14 additional nucleic acid derived COVID-19
vaccines in clinical trials (88). The Micelle delivery system is currently used by the Novavax protein
subunit vaccine, Nuvaxovid to display the full-length spike protein. Micelles are normally derived
from amphiphilic compounds, such as Tween 80 used by the novavax vaccine, and allows for the
presentation of antigens in their native conformations (88).
VLPs are another vaccine antigen delivery platform that have been used in COVID-19 vaccine
development. VLPs are viral structural proteins utilized to display vaccine antigen. Homologous
antigen display (same antigen) on the VLP can elicit highly specific neutralizing antibodies against
the displayed antigen whereas heterologous display on the VLP (multiple antigens) can allow for
the induction of more cross-reactive B-cells which can lead to increased breadth of neutralizing
antibodies against multiple variant types (88). Furthermore, there are over five COVID-19 VLP
vaccines in clinical trials and numerous VLP vaccine being evaluated in pre-clinical studies. The
company Medicago has developed a Coronavirus-like particle vaccine (CoVLP) produced in
plants that displays the pre-fusion spike protein adjuvanted with AS03 which has completed phase
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3 clinical trials (89). Additional VLP vaccines in clinical trials include RBD antigen displayed on
Hepatitis B surface antigen (HBsAg) using SpyBiotech SpyTag/SpyCatcher technology. SpyTag
and SpyCatcher is a protein conjugation system derived from Streptococcus pyogenes and allows
for the spontaneous conjugation of the vaccine antigen to the surface of the VLP (90). SpyTag is
located on the vaccine antigen and the SpyCatcher is on the surface of the VLP, together this
conjugation system can display antigen in high density on the VLP increasing the immunogenicity
of the vaccine antigen (84). The RBD HBsAg VLP vaccine was developed by the Serum Institute
of India and is in Phase 1/2 clinical trials in Australia (91).
Similar to VLPs, vaccine antigens can also be displayed on bacterial carrier proteins. Carrier
proteins are commonly used for polysaccharide vaccines against encapsulated bacteria to induce
a T-cell dependent response. Licensed carrier proteins include, diphtheria toxoid, tetanus toxoid,
CRM197, and Haemophilis protein D (92). Particularly, CRM197, is a detoxified diphtheria toxin and
has been used in licensed vaccines for Haemophilis influenzae, Streptococcus pneumoniae, and
Neisseria meningitidis. Additionally, FinaBio has developed an E. coli expression system to
increase manufacturability of CRM197 and has been used to as a carrier protein for not only
encapsulated bacteria but also for viral proteins and bacterial peptides (93,94). Therefore, similar
to VLPs, protein-based vaccine antigens conjugated to bacterial carrier proteins can increase
immunogenicity to the vaccine antigen by increasing the number of antigens displayed on the
carrier protein compared to the soluble form of the protein.
1.8 COVID-19 vaccine immunological correlates of protection
Generally, there are three types of immunity against COVID-19: 1) convalescence after SARSCoV-2 infection, 2) vaccine mediated immunity, and 3) hybrid immunity, a combination of both
immunity from infection and vaccination. Generation of immunity to COVID-19 could result in
protection from SARS-CoV-2 infection, severe disease, hospitalization, and death. In order to
evaluate immunological protection, types of immune responses are measured to assess the
contribution of the response to protection, defined as an immunological correlate of protection.
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Generation of neutralizing antibodies and binding antibodies against SARS-CoV-2 are key
components of protection of the three types of immunity. Convalescence after SARS-CoV-2
infection can elicit SARS-CoV-2 specific antibody responses dominated by mucosal IgA at the
site of infection such as in the upper respiratory tract which includes the nasal cavity, pharynx,
and trachea, as well as induce a systemic antibody response dominated by serum IgG transported
to the lower respiratory tract such as the lung (Fig. 2A)(41). Intramuscular vaccine mediated
responses are driven by robust systemic IgG production; however, lack induction of mucosal IgA
in the upper respiratory tract (Fig. 2B)(41). Lastly, hybrid immunity or vaccine break through
immunity caused by infection and vaccination, or vaccination and infection lead to the generation
of both mucosal IgA due to infection and systemic IgG responses caused by both vaccination and
infection (Fig. 2C)(95). Additionally, cellular responses such as CD4+ and CD8+ T cell responses
also contribute to limiting the severity of disease(17). Studies performed in non-human primates
demonstrated that polyclonal antibodies from convalescent rhesus macaques were able to protect
against SARS-CoV-2 challenge in a dose dependent manner without the assistance of cellular
immune responses (96). Also in the same study, depletion of CD8+ T-cells in convalescent rhesus
macaques with waning SARS-CoV-2 antibody titers decreased protection against SARS-CoV-2
challenge in the upper respiratory tract (96). For vaccine mediated immunity, neutralizing
antibodies also play a large role in protection. Passive immunization studies conducted in nonhuman primates showed that polyclonal antibodies obtained from rhesus macaques immunized
with Moderna mRNA-1273 COVID-19 vaccine protected hamsters from SARS-CoV-2 challenge
(97). Human vaccine studies demonstrated the importance of neutralizing and binding IgG
antibodies against spike and RBD to protection with the ChADoX1 nCOV-19, Moderna mRNA1273, and Pfizer Bio-N-Tech BNT162b2 COVID-19 vaccines (98,99). Furthermore, hybrid
immunity, denoted by SARS-CoV-2 infection before COVID-19 vaccination, or vaccine break
through immunity described as SARS-CoV-2 infection after COVID-19 vaccination offered the
highest levels of neutralizing antibody titers against SARS-CoV-2 when compared to vaccine
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mediated only and convalescent responses. Studies concluded that hybrid and vaccine break
through immunity provided increased breadth, potency, and longevity of neutralizing antibody
responses against SARS-CoV-2 (100,101). Overall, neutralizing antibodies generated against
SARS-CoV-2 are the main correlate of protection for immunity against SARS-CoV-2 infection
(102). More immune correlates of protection to SARS-CoV-2 are currently being investigated,
such as T-cell responses and other functional antibody roles including antibody mediated
complement activation and other Fc mediated effector functions (103,104).
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Figure 2. Types of SARS-CoV-2 immunity. A) SARS-CoV-2 convalescent immunity B) Intramuscular vaccine mediated
immunity C) Immunity acquired through infection and vaccination (hybrid) or vaccination and infection (vaccine break through).

1.9 Animal models to study COVID-19
Animal models provide a pre-clinical avenue to study SARS-CoV-2 pathogenesis, transmission
as well as vaccine and therapeutic efficacy. Animal models offer advantages such as control over
variables in the study; for example, time frame of study, virus dose used in animals, and ability to
assess and necropsy all tissue samples. However, there are also disadvantages in using animal
models, including animals used not reciprocating similar disease or immune phenotypes observed
in humans. Mice, hamsters, ferrets, and non-human primates (NHPs) currently represent the
models that have been most frequently utilized to study SARS-CoV-2 (Fig. 3) (105).
1.9.1 Mice
Utilizing mouse models to study SARS-CoV-2 have been useful to evaluate pathogenesis of
SARS-CoV-2 as well as to examine vaccine and therapeutic efficacy. However, conventional wildtype inbred, and outbred mice strains cannot be used as a lethal SARS-CoV-2 challenge model
because these mice lack the human ACE2 receptor needed for SARS-CoV-2 infection. Previous
studies have shown that the ancestral strain of SARS-CoV-2 could not bind to the mouse ACE2
receptor and that wild-type mice were not susceptible to ancestral SARS-CoV-2 challenge(106–
108). However, with the emergence of SARS-CoV-2 variants of concern, studies have shown that
the Alpha and Beta variants of concern could bind to mouse hACE2, replicate in the in the lung
and trachea to high viral RNA burden, and cause pathological damage to the upper and lower
respiratory tract (109,110). Despite the ability of the SARS-CoV-2 variants of concern to bind to
mouse ACE2 receptor, wild-type mice do not become morbid, show drastic weight or temperature
loss, or demonstrate outward disease manifestations (111). Nevertheless, a lethal challenge
model would be ideal to evaluate protection against SARS-CoV-2 challenge.
Therefore, transgenic mice that expressed human ACE2 were used to establish a lethal challenge
mouse model of SARS-CoV-2 to evaluate vaccine and therapeutic efficacy. The most widely used
lethal transgenic mouse model is the K18-hACE2 (B6. Cg-Tg (K18-ACE2)2Prlmn/J) mice
developed by McCray and Perlman to originally study SARS-CoV challenge since both viruses
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utilized the same human ACE2 receptor for infection. The K18-hACE2 mice utilize the human
keratin 18 promoter to express human ACE2 in epithelial cells including in the lung, liver, kidney,
brain, heart, and the gastrointestinal tract (112–114). K18-hACE2 mice intranasally challenged
with SARS-CoV-2 resulted in morbidity, demonstrating severe weight and temperature loss, lack
of grooming and hunched appearance, lethargic activity, eye closure, and rapid or slowed
respiration (75,115,116). Lethality in the K18-hACE2 model could be contributed to the viral
dissemination into the brain. Overall, the K18-hACE2 mouse model provides a lethal SARS-CoV2 challenge model that can be used to measure overall vaccine protection and therapeutic
efficacy. However, due to the high expression of human ACE2 in the K18-hACE2 mouse, this
model does not recapitulate the disease observed in humans, in particular, the lethal brain
infection. Other human ACE2 transgenic mouse models to study SARS-CoV-2 infection include
the lethal AC70 transgenic mouse lineage utilizing a cytomegalovirus immediate early enhancer
and chicken β-actin promoter to express human ACE2 (117), and the non-lethal mouse ACE2
promoter human ACE2 transgenic mouse model (118).
1.9.2 Syrian Hamsters
In contrast to the human ACE2 transgenic mouse model, the Syrian hamster model is not a lethal
model of SARS-CoV-2 infection and portrays a similar respiratory disease phenotype as humans.
Studies have demonstrated that SARS-CoV-2 spike protein can bind to Syrian hamster ACE2 to
initiate infection, thus not needing further genetic altering to express human ACE2 (119).
Intranasal challenge with SARS-CoV-2 in Syrian hamsters resulted in initial weight loss of the
hamsters, elevated viral replication in the respiratory tract, and histopathology in the lungs;
however, due to the mild to moderate disease outcomes, hamsters usually recover from infection
after 2 weeks post challenge. Furthermore, unlike the mouse challenge models, Syrian hamsters
can be used to evaluate transmission of SARS-CoV-2 which can be beneficial for vaccine and
therapeutic studies (120–122). Conversely, even though Syrian hamsters are a useful tool to
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study SARS-CoV-2 transmission and evaluate vaccine and therapeutic efficacy, research using
the hamster model is restricted due to the lack of reagents for immunological analysis (105).
1.9.3 Ferrets
Ferrets share similar disease outcomes during SARS-CoV-2 infection compared to humans.
Similar to hamsters, SARS-CoV-2 can bind to ferret ACE2 receptor and infect cells. Intranasal
SARS-CoV-2 challenge in ferrets result in similar clinical symptoms as in humans such upper
respiratory symptoms including runny nose, wheezing, and sneezing. Other symptoms similar to
human COVID-19 shown in ferrets also include lethargy and diarrhea. Viral replication in ferrets
is maintained in the upper respiratory tract particularly in the nose and oropharynx, with limited
lung pathology (105). Interestingly, ferrets have been historically used to study transmission in
respiratory viruses such as influenza; therefore, this model of transmission has also been applied
to study SARS-CoV-2 transmission (123). Studies have demonstrated that ferrets can transmit
SARS-CoV-2 to non-challenged ferrets through direct contact as well as their aerosolized
particles (124,125). Overall, ferrets are a robust model to study SARS-CoV-2 in the context of
vaccine break through cases, and transmission.
1.9.4 Non-human primates
Non-human primates have been an important model used to evaluate vaccine and therapeutic
efficacy before entering human clinical trials. Rhesus macaques, cynomolgus macaques, and
African green monkeys are the most frequently used non-human primates to study COVID-19.
SARS-CoV-2 challenge studies performed in rhesus macaques demonstrated that disease
outcomes were similar to mild to moderate COVID-19 observed in humans (126,127). Rhesus
macaques challenged with SARS-CoV-2 showed viral shedding in the nose, viral replication in
both the upper and lower respiratory tract, as well as mild lung histopathology (126,128).
Cynomolgus macaques provided a asymptomatic model for SARS-CoV-2 infection, showing
limited clinical symptoms, viral shedding from the nasal and oral pharynx, and replication in both
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the upper and lower respiratory tract (129). Lastly, the African green monkey model established
a severe COVID-19 phenotype, supported by higher viral replication in the respiratory tract
compared to rhesus macaques and cynomolgus macaques, as well as developed substantial viral
pneumonia (130). Furthermore, COVID-19 vaccine efficacy studies have utilized the rhesus
macaque as the primary non-human primate model. Pfizer-BioNTech (131), Moderna (132), and
Oxford/AstraZeneca (133) as well as other vaccine platforms have evaluated their vaccine
candidates in rhesus macaques before entering clinical trials or simultaneously during clinical
trials (134–136).
1.10 SARS-CoV-2 mucosal immune response
The mucosal immune system is derived from mucosa-associated lymphoid tissue (MALT) which
is composed of three main compartments in humans: 1) gut associated lymphoid tissue (GALT),
2) nasopharynx lymphoid tissue and tonsils (NALT) and 3) bronchus associated lymphoid tissue
(BALT) (137). In general, these mucosal lymphoid tissues are comprised of induction sites where
antigens from a pathogen or vaccine are sampled by microfold cells, processed by antigen
presenting cells such as dendritic cells in order to stimulate T-cells which can help promote the
activation of IgA secreting B-cells. The mucosal induction sites such as the NALT are composed
of two major zones: 1) follicle and 2) parafollicular zone (137). The follicle zone largely contains
germinal center B cells whereas the parafollicular zone is comprised of T cells and dendritic cells.
In the follicle zone, mucosal B-cells in the germinal centers undergo T-cell dependent B-cell
somatic hypermutation and class switch recombination favoring IgA (137). After activation in the
induction sites, B and T-cells then travel to effector mucosal tissue sites, for example the nasal
cavity in the upper respiratory tract, where antigen specific T-cells can help B-cells further
differentiate into IgA secreting plasma cells to help alleviate infection (138). Since SARS-CoV-2
is a respiratory pathogen, induction of the mucosal immune response mostly relies on the NALT
and tonsils in humans, and NALT in rodents. The BALT contributes little to mucosal immunity in
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humans, since BALT is rarely present adults and only present during childhood and/or
adolescence.
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Figure 3. Summary of animal models used to study SARS-CoV-2.

The antibody response in the respiratory tract is composed heavily of secretory IgA in the upper
respiratory tract and IgG in the lower respiratory tract. Secretory IgA plays an important role in
the mucosal immune response towards respiratory pathogen infection or vaccination. Functions
of secretory IgA in the mucosae include removal of foreign antigen, neutralization, and
agglutination. In the upper respiratory tract, secretory IgA is the predominant immunoglobulin
accounting for approximately 70% of the immunoglobulin pool whereas IgG accounts for
approximately 80% in the lung (137). Furthermore, mucosal lymphoid tissue is responsible for
eliciting the majority of secretory IgA in the upper respiratory tract while IgG found in the lower
respiratory tract comes from systemic circulation (137). Overall, SARS-CoV-2 infection generates
the production of both secretory IgA and IgG in the respiratory tract; however, during
intramuscular COVID-19 vaccination only, there is a robust production of systemic IgG but limited
induction of secretory IgA in the upper respiratory tract (41)(Fig. 2).
Cellular responses can also contribute to the mucosal immune response against respiratory
pathogens. Generally, antibodies are responsible for protection against secondary infection
whereas cellular responses can provide the ability to prevent severe disease by eliminating
infected cells as well protect against future infection by assisting B-cells to produce high affinity
antibodies (17). CD4+ T-cells help activate and help drive B-cell maturation and differentiation into
plasma cells in the mucosal induction and effector sites, as well as can also promote activation of
cytotoxic CD8+ T-cells that can eliminate infected cells. Memory T-cells including T effector
memory cells and T resident memory cells also contribute largely to the durability of the immune
response to a respiratory pathogen, in particular T resident memory (TRM) cells (139). TRM cells
that reside in the respiratory tract are generated after infection or nasal vaccination. Overall, the
function of TRM cells in the respiratory tract is to respond quickly to local infection by coordinating
local immune responses to clear the active infection (137,140). Moreover, studies have shown
that CD4+ and CD8+ TRM cells can provide protection against influenza and respiratory syncytial
viral infection in the respiratory tract (141).
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1.11 Nasal vaccination
SARS-CoV-2 infection is acquired through inhalation of respiratory droplets and/or aerosols. The
mucosal immune response plays a large role at initially controlling respiratory infection through
humoral and cellular mediated responses. Therefore, immunization at the site of infection could
provide optimal protection against SARS-CoV-2. Nasal vaccination similar to SARS-CoV-2
infection can provide the necessary protection in the mucosal tissue in regard to generation of
antigen specific IgA in the upper respiratory tract as well as stimulate a systemic IgG response in
the lung (41). Currently, the only approved intranasal vaccine for human use is Flumist, a vaccine
for influenza. Flumist is a live attenuated vaccine containing cold adapted attenuated influenza A
and B viruses that can only replicate within lower temperatures found in the nose (142–144).
Intranasal administration with Flumist provides protection by generating both a mucosal IgA and
systemic IgG response, with an overall efficacy of approximately 60-70%, comparable to the
intramuscular influenza vaccine (145). Interestingly, there are no approved intranasal COVID-19
vaccines for human use; although, many intranasal vaccines are in pre-clinical and clinical trials.
Intranasal vaccine platforms utilized include vectored based vaccines such as adenovirus,
Newcastle disease virus, live attenuated influenza virus, parainfluenza virus, and respiratory
syncytial virus as well as SARS-CoV-2 live attenuated virus and recombinant protein vaccines
are currently in phase I, II, and III clinical trials globally (143,146,147). Most of the vectored
intranasal vaccines in clinical trials utilize the full-length spike protein, for example, adenovirus
vectored ChAdOx1 nCoV-19 (AstraZeneca/University of Oxford) and ChAd-SARS-CoV-2-S
(Bharat Biotech International Limited/University of Washington St. Louis) (148–151). Though,
Ad5-nCoV nasal vaccine developed by CanSino Biologics with the Beijing Institute of
Biotechnology use the RBD as the candidate vaccine antigen (147). At this time, CoviLiv is the
only nasal SARS-CoV-2 live attenuated vaccine in clinical trials. CoviLiv, developed by the
company Codagenix, is formulated with attenuated ancestral strain of SARS-CoV-2 (147,152).
Lastly, there are two nasal protein subunit vaccines in clinical trials, CIGB-669 developed by
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Center of Genetic Engineering and Biotechnology in Cuba, and Razi Cov Pars, developed by the
Razi Vaccine and Serum Research Institute in Iran (147). CIGB-669 utilizes the RBD as the
vaccine antigen with Hepatitis B core antigen whereas Razi Cov Pars uses the spike trimer
adjuvanted with oil in water adjuvant system RAS-01 (Razi Adjuvant system-1) (153).
1.12 COVID-19 vaccine overview
All current WHO approved vaccines are administered through the intramuscular route. Despite
these intramuscular COVID-19 vaccines preventing severe disease, hospitalization, and death,
we are still facing transmission of SARS-CoV-2 and vaccine break through cases. We
hypothesize, intranasal vaccination can help mitigate vaccine break through cases and viral
transmission because nasal vaccination can induce mucosal immunity at the site of infection.
Intramuscular vaccination with the current approved COVID-19 vaccines offers robust systemic
immune responses such as the presence of neutralizing antibodies in the lower respiratory tract
and strong CD4+ and CD8+ T-cell responses (17). COVID-19 mRNA vaccine studies
demonstrated that secretory IgA was detected in the saliva in patients vaccinated with mRNA
vaccines; however, higher SARS-CoV-2 IgA titers were observed at convalescence, or with hybrid
immunity (154). In contrast to intramuscular immunization, nasal immunization similar to
respiratory infection can elicit both localized protection in the mucosal tissue as well as systemic
induction of neutralizing antibodies. Studies have shown that nasal vaccination can induce high
levels of secretory IgA in the upper and lower respiratory tract as well as stimulate systemic IgG
in the lower respiratory tract (41). Furthermore, the optimal level of protection from SARS-CoV-2
infection originates from both infection and vaccination (100,101). Infection and vaccination or
vice versa generates magnitude, breadth and durability of antibody and cellular responses against
SARS-CoV-2 (100). Therefore, to harness the level of protection acquired from infection and
vaccination into a vaccine strategy, a heterologous prime and boost strategy can be utilized.
Studies have demonstrated that an intramuscular prime and intranasal boost can promote both
robust systemic and mucosal immunity as well as induce T and B cell memory responses (155).
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1.13 Premise
The COVID-19 pandemic allowed for a surge of global scientific research and collaborations in
order to reach a common goal of preventing the spread of COVID-19. The overall premise of this
body of work is to contribute to the world-wide effort of defeating SARS-CoV-2 through the
utilization of pre-clinical models to study the mechanisms of immunity against SARS-CoV-2 via
passive and active immunization. The lethal K18-hACE2 mouse model played an instrumental
role in the study of SARS-CoV-2 pathogenesis as well as evaluation of the correlates of protection
in prototype vaccine formulations. The work performed in chapter 2 established the passive
immunization and challenge model in K18-hACE2 transgenic mice to study antibody mediated
protection against SARS-CoV-2 VOC. Chapter 2 emphasized the importance of functional
antibodies against SARS-CoV-2 and the significance of broadly neutralizing antibodies against
SARS-CoV-2 VOC through passive immunization with convalescent plasma (HCP) obtained from
a patient infected with the ancestral strain of SARS-CoV-2. Passive immunization with HCP
resulted in total protection from the ancestral strain of SARS-CoV-2 and Alpha, partial protection
against Beta, and no protection against Delta. Overall, this study demonstrated that the passive
immunization model can be utilized to evaluate SARS-CoV-2 antibody efficacy against emerging
VOC which can provide vital information for developing future therapeutics and vaccines.
In chapter 3, the K18-hACE2 mouse challenge model was utilized to evaluate the vaccine efficacy
of RBD-VLP vaccines against Alpha or Beta challenge. RBD-VLP vaccines were developed by
the Serum Institute of India and Spy Biotech utilizing the Hepatitis B surface antigen decorated
with the homologous display of RBD from the ancestral strain of SARS-CoV-2 and/or Beta
adjuvanted with either Alum or SWE. Four RBD-VLP formulations administered intramuscularly
in three doses were compared to the standard 2 dose Pfizer-BioNTech mRNA vaccine series.
Overall, the combination of ancestral strain RBD-VLP with Beta RBD-VLP adjuvanted with Alum
and the ancestral strain RBD-VLP adjuvanted with SWE provided protection against both Alpha
and Beta challenge similar to the Pfizer-BioNTech mRNA vaccine.
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Lastly, in chapter 4, we developed a prototype vaccine formulated with RBD conjugated to the
bacterial carrier protein EcoCRM adjuvanted with a TLR4-agonist BECC470 (BReC-CoV-2).
Intranasal administration of BreC-CoV-2 resulted in the induction of both systemic IgG and
localized IgA response which led to the overall protection against the ancestral strain of SARSCoV-2. A heterologous prime and boost strategy was also implemented with BReC-CoV-2 where
BreC-CoV-2 was administered intramuscularly first then given intranasally as a boost. The
heterologous vaccine strategy resulted in 100% protection against a lethal Delta variant challenge
in the K18-hACE2 mouse model.
Overall, the following chapters utilize the K18-hACE2 mouse model to establish a platform to
study vaccine efficacy against SARS-CoV-2 challenge. The results demonstrated the importance
of the antibody mediated responses against SARS-CoV-2 as well as the significance of the
contribution of mucosal immunity to protection against SARS-CoV-2. Furthermore, the story
represented here establishes the pipeline that can be used to improve on vaccine efficacy for
future COVID-19 vaccines.
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2.1 ABSTRACT
SARS-CoV-2 variants of concern (VoC) are impacting responses to the COVID-19 pandemic.
Here, we utilized passive immunization using human convalescent plasma (HCP) obtained from
a critically ill COVID-19 patient in the early pandemic to study the efficacy of polyclonal antibodies
generated to ancestral SARS-CoV-2 against the Alpha, Beta, and Delta VoC in the K18 human
angiotensin converting enzyme 2 (hACE2) transgenic mouse model. HCP protected mice from
challenge with the original WA-1 SARS-CoV-2 strain; however, only partially protected mice
challenged with the Alpha VoC (60% survival) and failed to save Beta challenged mice from
succumbing to disease. HCP treatment groups had elevated receptor binding domain (RBD) and
nucleocapsid IgG titers in the serum; however, Beta VoC viral burden in the lung and brain was
not decreased due to HCP treatment. While mice could be protected from WA-1 or Alpha
challenge with a single dose of HCP, six doses of HCP could not decrease mortality of Delta
challenged mice. Overall, these data demonstrate that VoC have enhanced immune evasion and
this work underscores the need for in vivo models to evaluate future emerging strains.

2.2 IMPORTANCE
Emerging SARS-CoV-2 VoC are posing new problems regarding vaccine and monoclonal
antibody efficacy. To better understand immune evasion tactics of the VoC, we utilized passive
immunization to study the effect of early-pandemic SARS-CoV-2 HCP against, Alpha, Beta, and
Delta VoC. We observed that HCP from a human infected with the original SARS-CoV-2 was
unable to control lethality of Alpha, Beta, or Delta VoC in the K18-hACE2 transgenic mouse model
of SARS-CoV-2 infection. Our findings demonstrate that passive immunization can be used as a
model to evaluate immune evasion of emerging VoC strains.
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2.3. INTRODUCTION
The evolution of Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) variants of concern
(VoC) has been a source of escalating epidemiological alarm in the currently ongoing coronavirus
disease 2019 (COVID-19) pandemic. SARS-CoV-2 VoC have emerged and are thought to be
more infectious and more lethal than the early 2020 original Wuhan-Hu-1 or USA-WA1/2020 (WA1) strains (115–117). The VoC B.1.1.7, also known as Alpha variant (first identified in the United
Kingdom (118)), and B.1.351 also known as Beta variant (first identified in South Africa (119)),
were two SARS-CoV-2 VoC that rapidly spread around the world and exhibited high levels of
infectivity and therapeutic resistance (117,120–125). Both VoC contain important mutations in the
receptor binding domain (RBD) of the spike (S) viral glycoprotein (118,119) that are predicted to
impact binding to the human angiotensin converting enzyme 2 (hACE2) viral receptor and
enhance viral entry to host cells (126–130). In particular, Alpha contains the D614G and N501Y
mutations in the SARS-CoV-2 S RBD which are theorized to increase the ability of the virus to
bind to hACE2 (126,128). Beta possesses these key mutations in the S RBD, in addition to the
K417N and E484K mutations which are not directly implicated in altered viral transmission and
hACE2 binding (130,131). In December 2020, the VoC, B.1.617.2 (Delta) of SARS-CoV-2 first
appeared in India, becoming quickly the global predominant circulating variant; however, this
distinction could be soon displaced by the novel Omicron variant (132–134). Th most common
Delta variant has two important mutations on the viral S RBD, L452R and T478K, allowing for
increased infectivity, transmissibility, as well as its ability of escaping neutralizing antibodies (135–
137). The culmination of high infectivity, therapeutic resistance, and key changes in their viral
genome suggests that VoC may have an impact on pathogenicity in animal models of SARSCoV-2, with a subsequent impact on evaluating vaccines and therapeutics.

The K18-hACE2 transgenic mouse model (138) of SARS-CoV-2 infection was established by
several groups in 2020 (139–141). K18-hACE2 transgenic mice infected with SARS-CoV-2 exhibit
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significant morbidity and mortality, viral tropism of the respiratory and central nervous systems,
elevated systemic chemokine and cytokine levels, significant tissue pathologies, and altered
gross clinical measures (140–143). The generation of this mouse model has led to numerous
studies of SARS-CoV-2 infection for a variety of purposes including understanding SARS-CoV-2
related immunity, and therapeutic/vaccine testing (139,144–149). As the world experiences an
increase in the number of SARS-CoV-2 VoC, it is imperative to adapt existing preclinical animal
infection models to these newly emerging VoC. Specifically, it is critical to understand if the K18hACE2 transgenic mouse model first, is useful for studying SARS-CoV-2 VoC infection dynamics
and second, if it exhibits any differences after challenge with newly emerged SARS-CoV-2 VoC.
An investigation of these key points will provide context for studies important for developing new
therapeutics and prophylactics as the COVID-19 pandemic continues and as new VoC emerge.
Neutralizing antibodies against SARS-CoV-2 induce by either natural infection or vaccination
serve as an important component of protection against secondary SARS-CoV-2 infection (150);
however, according to the WHO and recent data, Omicron variant appears to be able to easily
infect fully vaccinated. The S protein is a major target of neutralizing antibodies, with RBD
encompassing 90% of the neutralizing antibodies within convalescent sera (151,152). Emergence
of new VoC with mutations in the S protein and in the RBD could decrease the efficacy of
neutralizing antibodies not originally generated against the VoC. Studies have shown that Nterminal domain S and RBD monoclonal antibodies generated against the original SARS-CoV-2
strain lose neutralization activity against VoC especially when administered as a monotherapy
(121,153,154). Human convalescent plasma (HCP) also has demonstrated a decrease in
neutralizing antibody efficacy against the VoC that specifically harbor the E484K mutation in the
S RBD (121,123). Here, we evaluated the polyclonal antibodies of HCP obtained from a patient
infected with the original strain of SARS-CoV-2 against the Alpha, Beta, and Delta VoC in the
K18-hACE2 transgenic mouse model. Our findings indicate that when compared to the original
WA-1 strain, Alpha, Beta and Delta VoC are more resistant to HCP polyclonal antibodies in the
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K18-hACE2 transgenic mouse model. This passive immunity model allows for comparison of in
vivo activity of human antibodies and extends upon in vitro studies and will likely assist us
understanding immunity among VoC.
2.4 METHODS:
Ethics and biosafety
The HCP used in this study was obtained under West Virginia University (WVU) IRB no.
2004976401 (155). HCP was obtained from a single individual with PCR-confirmed SARS-CoV2 infection in March 2020. Experiments with live SARS-CoV-2 were conducted in Biosafety Level
3 (BSL-3) at Texas Biomedical Research Institute (TBRI IBC BSC20-004) or at WVU (IBC 20-0903). All BSL-3 animal experiments were conducted under WVU IACUC protocol no. 2009036460.

Assessment of human IgGs against WA-1 SARS-CoV-2 S RBD and N
Human IgGs against WA-1 SARS-CoV-2 S RBD and N were quantified using ELISA as described
(156). WA-1 S RBD (2 µg/mL) or N (1 µg/mL) proteins were coated on plates and blocked with
3% milk in 0.1% Tween 20 +PBS (PBS-T). Plates were washed three times with PBS-T (200 µL)
and virus inactivated samples (25 µL) from human plasma or infected mice were added to 100 µL
of sample buffer (1% milk + 0.1% Tween 20 diluted in PBS) and serially diluted (5-fold) down the
plates. The final row was left with 100 µL of sample buffer as a negative control. Plates were
incubated for 10 minutes at room temperature shaking at 60rpm and subsequently washed four
times with PBS-T (200 µL). Secondary antibody (100 µL 1:500 anti-human IgG HRP, Invitrogen
31410) was added and plates were incubated for 10 minutes at room temperature shaking at 60
rpm. After incubation, plates were washed five times with PBS-T (200 µL) and SigmaFAST OPD
(Sigma-Aldrich P9187, 100 µL) was added to each well of the plate. OPD development was
stopped with 25 µL of 3 M hydrochloric acid and plates were read at an absorbance of 492 nm on
a Synergy H1 plate-reader. Binding antibody units (BAU) were calculated based on the NIBSC
1st WHO International Standard (NIBSC code 20/136).
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Area under the curve analysis was completed in GraphPad Prism v.9.
Meso Scale Discovery COVID-19 ACE2 Neutralization assay
SARS-CoV-2 challenged serum was analyzed using the SARS-CoV-2 Plate 11 Multi-Spot 96well, 10 spot plate following the manufacturer protocol (catalog #: K15458U-2) on the MSD
QuickPlex SQ120. The 10 spots contained RBD from different SARS-CoV-2 VoC: 1) B.1427,
B.1.429, B.1.526.1 2) B.1.351, B.1.351.1 3) B.1.525, B.1.526, B.1.618, P.2, R.1 4) P.1 5)
B.1.526.2 6) B.1.17 7) B.1.17+E484K, P.3 8) B.1.617, B.1.617.1, B.1.617.3 9) AY.3, AY.4, AY.5,
AY.6, AY.7, AY.12, AY.14, B.1.617.2, B.1.617.2+Δ144 and 10) A (WT). Three dilutions of serum,
1:10, 1:50 and 1:100 were analyzed for each mouse to perform Area Under the Curve analysis
on the electrochemiluminescence using GraphPad Prism v.9.

Viral growth and in vitro analysis of SARS-CoV-2 replication
SARS-CoV-2 USA-WA-1/2020 (NR-52281) (WA-1), B.1.1.7/Alpha (NR-54000), and B.1.351/Beta
(NR-54008) strains were obtained from BEI Resources, and SARS-CoV-2 Delta variant B.1.617.2
hCoV-19/USA/WV-WVU-WV118685/2021 (GISAID Accession ID: EPI_ISL_1742834) was
obtained from a patient sample at WVU. These strains were propagated in Vero E6 cells (ATCCCRL-1586) as described (140,157). Vero E6 cells for viral titrations (6-well plate, 106 cells/well)
were infected with 10-fold serial dilutions of SARS-CoV-2. At 72 hours post-infection, cells were
fixed overnight with 10% formalin (Sigma HT501128-4L), permeabilized and immunostained with
1µg/mL of a SARS-CoV cross-reactive N protein antibody 1C7C7, kindly provided by Dr. Thomas
Moran at the Icahn School of Medicine at Mount Sinai. For viral growth kinetics, Vero E6 cells (6well plate, 106 cells/well, triplicates) were infected (multiplicity of infection, MOI 0.01) with SARSCoV-2 WA-1, Alpha or beta. At the indicated times after viral infection (12, 24, 48 and 72 hours),
tissue culture samples were collected and titrated by plaque assay as described (140).

Genome sequencing of SARS-CoV-2 VoC
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SARS-CoV-2 viral RNA from all stocks used for in vitro analyses was deep sequenced according
to the method described (158). Briefly, we generated libraries using KAPA RNA HyperPrep Kit
(Roche KK8541) with a 45 min adapter ligation incubation including 6-cycle of PCR with 100 ng
RNA and 7 mM adapter concentration. Samples were sequenced on an Illumina Hiseq X machine.
Raw reads were quality filtered using Trimmomatic v0.39 (159) and mapped to a SARS-CoV-2
reference genome (Genbank Accession No. MN985325) with Bowtie2 v2.4.1 (160). Genome
coverage was quantified with MosDepth v0.2.6 (161). We genotyped each sample for low
frequency VoC with LoFreq* v2.1.3.1 (162) and filtered sites with allele frequencies less than
20%. SARS-CoV-2 viral RNA from stocks used for K18-hACE2 transgenic mouse infection was
deep sequenced and reads were aligned to the MN908947.3 reference genome using BWA
v.0.7.17 (163) and trimmed for base-calling quality using iVar v.1.3.1 (164) with default
parameters. Consensus sequence and individual mutations relative to the reference genome
were determined using iVar, with a minimum allele frequency of 30% used as a threshold for
calling a mutation. Coverage was computed using samtools mpileup v.1.11 (165). Lineage was
confirmed using pangolin v.2.3.5 and pangoLEARN v.2021-03-16 (166). Authentication of the
Betastock was performed using metagenomic sequencing as described (167,168). Viral RNA was
treated with Turbo DNase I (Thermo Fisher). cDNA was generated from random hexamers using
SuperScript III reverse transcriptase, second strand was generated using Sequenase 2.0, and
cleaned using 0.8× Ampure XP beads purification on a SciClone IQ (Perkin Elmer). Sequencing
libraries were generated using two-fifths volumes of Nextera XT on ds-cDNA with 18 cycles of
PCR amplification. Libraries were cleaned using 0.8×Ampure XP beads and pooled equimolarly
before sequencing on an Illumina NovaSeq (1×100bp run). Raw fastq reads were trimmed using
cutadapt (-q 20) (169). To interrogate potential resistance alleles, reference-based mapping to
NC_045512.2 was carried out using our modified Longitudinal Analysis of Viral Alleles (LAVA https://github.com/michellejlin/lava) (170) pipeline. LAVA constructs a candidate reference
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genome from early passage virus using bwa (163), removes PCR duplicates with Picard, calls
variants with VarScan (171,172), and converts these changes into amino acid changes with
Annovar (173). The genome sequence for strain Betais accession number QWE88973. The
genome sequence of the Betacontained the expected mutations spike and has a wild type furin
cleavage site. A 52aa deletion was observed in orf7a; however, it is not expected that this deletion
has any impact on the in vivo infection capacity of this strain as orf7a mutants are observed in
surveillance. Beta VoC was able to effectively colonize and cause morbidity in experiments
presented in this study.

Challenge of K18-hACE2 transgenic mice with SARS-CoV-2 VoC and treatment with HCP
SARS-CoV-2 WA-1 and Alpha and Beta VoC were thawed from -80oC and diluted in infection
medium (Dulbecco’s Modified Eagle Medium 4/.5g/L glucose + 2% fetal bovine serum + 1%
HEPES + 1% penicillin/streptomycin at 100 units/µg/mL) to a concentration of 106 plaque forming
units (PFU) /mL in the WVU BSL-3 facility. Delta VoC was diluted to a 104 PFU/dose from a
2.4x105 PFU/mL stock in 1X Dulbecco’s phosphate buffered saline. Male eight to ten weeks old
B6.Cg-Tg(K18-hACE2)2Prlmn/J mice (Jackson Laboratory 034860) were anesthetized with a
single intraperitoneal dose of ketamine (Patterson Veterinary 07-803-6637, 80 mg/kg) + xylazine
(Patterson Veterinary 07-808-1947, 8.3 mg/kg) and 50 µL infectious dose was administered with
a pipette intranasally, 25 µL per nare. HCP, 500 µL, or healthy human sera (HHS) with known
anti-SARS-CoV-2 IgGs and neutralizing Abs (nAbs) were administered intraperitoneally at this
time. For the Delta VoC challenge study, 500 µL HCP was administered for 6 consecutive days
(Figure 6A). Mice were monitored until awake and alert.

Cumulative disease scoring of SARS-CoV-2 challenged mice
Mice were scored daily on a scale encompassing appearance (score of 0-2), eye health (score of
0-2), respiration (score of 0-2), activity (score of 0-3) and weight loss (score of 0-5). Appearance
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included visual identification of a combination of mild to severe piloerection (0-2) or lack of
grooming (0-2). Eye health scores were defined by observation of squinting (1), prolonged eye
closure not related to sleep (2), or eye discharge (0-2) depending on severity. The maximal
combined score for eye health was 2. Respiration (assessed visually) outside the range of 80240 breaths per minute required mandatory euthanasia and scored as 2. Respiration that was
abnormal in regularity was scored as 1. Activity was scored as slow (1), immobile (2), or collapsed
and immobile (3). Weight loss was scored as 0-5% (0), 5-10% (1), 10-15% (2) 15-20% (3), >20%
(4-5). All mice with weight loss greater than 20% were humanely euthanized. Rectal temperature
was also monitored daily throughout the experiments.

Euthanasia and necropsy of SARS-CoV-2 challenged mice
Euthanasia was conducted by administering 200 µL of pentobarbital (Patterson Veterinary 07805-9296, 390 mg/kg diluted in 0.9% sterile NaCl) and cardiac puncture. Blood was aliquoted into
gold serum separator tubes (BD 365967) and centrifugated at 15,000 x g for 5 min. Serum was
removed and stored in 1.5 mL tubes at -80oC until needed. Lungs were removed from animals
and the right lobes of the lung were homogenized in 1mL of PBS in Miltentyi C tubes (Miltenyi
Biotec 130-096-334) using the m_lung_02 program on a Miltenyi gentleMACS tissue dissociator.
An aliquot of each lung homogenate (300 µL) was added to 100 µL of TRIReagent (Zymo
Research R2050-1-200) and stored at -80oC. Remaining homogenates (300 µL) were spun down
at 15,000 x g and the supernatants collected. Pellets were frozen at -80oC until use. Brain tissue
was removed from animals and split down the mid-line. The right brain was added to 1 mL of PBS
in Miltenyi C tubes and homogenized using the m_lung_02 program. An aliquot of each
homogenate (500 µL) was added 167 µL aliquots of TRIReagent and stored at -80oC until use.
Remaining homogenates were frozen at -80oC until use. To inactivate virus from tissue samples,
1% v/v Triton X-100 (Sigma-Aldrich T8787) (141) was added to each sample and incubated for 1
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hour at room temperature. Inactivated samples were then removed from the BSL-3 High
Containment facility.

Evaluating viral copy number in SARS-CoV-2 challenged tissues
RNA from homogenized virus-inactivated lung and brain tissues of SARS-CoV-2 infected mice
was extracted using the Direct-zol RNA MiniPrep Kit (Zymo Research R2051) following the
manufacturer’s instructions. RT-PCR and qPCR were performed by generating a master mix of:
10 µL of TaqMan RT-PCR Mix from the Applied Biosystems TaqMan RNA to CT One Step Kit
(Thermo-Fisher Scientific 4392938), 900 nM (1.8 µL) of (ATGCTGCAATCGTGCTACAA) forward
nucleocapsid primer (141), 900 nM (1.8 µL) of (GACTGCCGCCTCTGCTC) reverse nucleocapsid
primer (141), 250nM (0.5 µL) of TaqMan probe (56-FAM/TCAAGGAAC/ZEN/AACATTGCCAA/
3IABkFQ), 0.5 µL of TaqMan RT enzyme from the Applied Biosystems TaqMan RNA to CT One
Step Kit (Thermo-Fisher Scientific 4392938), 100 ng of RNA, and RNAse/DNAse free water to
make a 20 µL total reaction volume. Samples were run in triplicate in Microamp Optical 96-well
Fast Reaction Plates (Thermo-Fisher Scientific 4306737) through the following protocol: reverse
transcription at 48oC for 15 minutes, activation of AmpliTaq Gold DNA polymerase at 95oC for 10
minutes, and 50 cycles of 95oC denaturing for 10 seconds followed by 60oC annealing for 60
seconds. Samples were run on an Applied Biosystems StepOnePlus Real-Time PCR System.
Samples with undetectable virus were assigned a value of 1. CT values and copy numbers were
calculated and analyzed in Microsoft Excel and GraphPad Prism v.9.0.0.
Cytokine analysis of serum-treated SARS-CoV-2 VoC challenged mice
Virus-inactivated serum samples or lung supernatants from SARS-CoV-2 VoC infected mice were
added to a custom 8-plex Mouse Magnetic Luminex Assay (R&D Systems LXSAMSM-08)
including IL-6, TNF, IFN-γ, IL-10, IL-27, IL-1β, IL-2, IL-13, and IL-17 at the recommended dilution
factor (2-fold dilution). Cytokine arrays were read on a Luminex MagPix instrument.
Lung Histopathology
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Left lobes of lungs were fixed in 10 mL of 10% neutral buffered formalin. Fixed lungs were paraffin
embedded into 5 μm sections. Sections were stained with hematoxylin and eosin (H&E) and sent
to iHisto for pathological analysis. Lungs were scored by a pathologist for chronic and acute
inflammation in the lung parenchyma, blood vessels, and airways. Pathologist was blinded to the
experimental groups but was aware of groups that were challenged with SARS-CoV-2. Each
mouse was scored individually using a standard qualitative toxicologic scoring criteria: 0-none; 1minimal; 2-mild; 3-moderate; 4-marked; 5-severe. Chronic inflammation was marked by
lymphocytes, plasma cells, and alveolar macrophages in the parenchyma, blood vessels and
airway. Acute inflammation was scored by the presence of neutrophils and edema in the
parenchyma, blood vessels and airway.

Statistical analyses
All statistical tests were performed on groups with n ≥ 5 in GraphPad Prism v.9.0.0. To compare
two-groups, student’s t-tests were used. To compare three or more groups, one-way ANOVA
(parametric data) or Kruskal-Wallis (non-parametric data) were used followed by Tukey’s
(parametric data) or Dunn’s (non-parametric data) multiple comparisons tests. To compare
grouped data, two-way ANOVA with no correction was performed followed by Tukey’s multiple
comparison test. To assess statistical differences between Kaplan-Meyer curves, Mantel-Cox logrank tests were performed.

2.5 RESULTS
Evaluating human antibodies against original SARS-CoV-2 for their ability to protect VoC
challenged mice. The emergence of SARS-CoV-2 VoC requires re-investigation of their
pathogenesis and unique properties. Our goal for this part of the study was to determine if
ancestral virus specific antibodies raised in humans would be able to provide protection against
Alpha and Beta VoC challenge in K18-hACE2-mouse challenge model. HCP was extensively
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used early in the COVID-19 pandemic, but currently it is no longer used as a standard of care.
The selected HCP for these studies originated from a patient with severe COVID-19 disease in
2020 and contained 236 antibody binding units (WHO COVID-19 International Standard; BAU).
This HCP was compared to other 48 HCP samples from COVID-19 patients taken back in spring
of 2020 (Fig. 1A). Next, the selected HCP was compared to serum obtained from pre-vaccine and
post Pfizer mRNA vaccinated healthy volunteers.

The selected HCP sample was able to

neutralize Wuhan, Alpha, Beta, and Delta RBD to ACE2 binding using the MSD hACE2-RBD in
vitro neutralization assay (Fig. 1B). These data indicate that the selected HCP had high binding
and neutralization capacity. In vitro cell culture growth experiments were performed to
characterize the Alpha and Beta VoC. The Beta variant appeared to have a modest increase in
PFU/ml after 24 hours of growth in vitro (Fig. 1CD); however, it had a relatively similar growth
curve compared to the original WA-1 strain and Alpha VoC. One caveat about using Alpha or
Beta challenge strains in mice, is that it is possible the mutations in RBD will allow for binding and
engagement of the mouse ACE2 receptor. Mouse adapted SARS-CoV-2 strains are used to
challenge wild type, non-transgenic mice (174) and VoC strains are known to replicate in wild type
mice (175). We performed a study with Alpha and Beta VoC in wild type C57BL6/J mice; however,
morbidity or mortality was not observed (Fig. 1E). We observed low disease scores, and very
little detectable viral RNA in the lungs of the wild type challenged mice (Fig. 1FG). Based on
these data, we do not believe there is much concern about using Alpha or Beta in mice because
it appears their ability to infect through mouse ACE2 is limited.

Viral challenge and effects of HCP treatment on disease progression in mice challenged
with SARS-CoV-2 VoC. K18-hACE2 transgenic mice were passively immunized with HCP via
intraperitoneal administration at day 0 and subsequently challenged with 105 PFU (lethal dose) of
WA-1, Alpha, or Beta VoC (Fig. 2A). WA-1 challenged mice that received human serum from
healthy individuals (HHS) exhibited a temperature drop, weight loss, and high cumulative disease
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scores (Fig. 2BEH). Mice treated with HCP had normal temperature regulation, maintained
weight, and had low disease scores (Fig. 2BEH). Protection from WA-1 lethal challenge in HCP
treated mice was expected since convalescent humans have immunity against re-challenge.
Challenge with Alpha VoC in HHS treated mice resulted in high temperature loss by day 4 post
challenge, up to 20% weight loss, and high cumulative disease scores (Fig. 2 CFH). However,
Alpha VoC challenged mice treated with HCP maintained body temperature in two of five animals
and similar trends were observed for their body weight loss (Fig. 2CF). These data suggested
that HCP was less successful at protecting mice from Alpha VoC challenge compared to WA-1.
Disease scores also reflected these observations as HCP treatment was unable to fully suppress
disease (Fig. 2H). Unlike WA-1 or Alpha VoC challenged mice, Beta VoC challenged mice treated
with HCP compared to HHS had no significant differences by any metric measured (Fig. 2DGH).
HCP treatment was unsuccessful in preventing disease and morbidity induced by the Beta VoC.
Collectively, these data showed that HCP treatment was able to fully protect against WA-1;
partially protect against Alpha VoC; but failed to protect against Beta VoC (Fig. 3AB).

Effects of HCP treatment on viral RNA burden in lungs and brain of challenged mice. To
determine the viral distribution between the lungs and brain of challenged mice, qRT-PCR was
used to quantify nucleocapsid copy number. HCP treatment significantly decreased viral RNA
down to the lower limit of detection (LLOD) in the lung of the WA-1 and Alpha challenged mice
compared to HHS (Fig. 3C). Similarly, HCP treatment was also able to decrease the Alpha VoC
viral burden down to the same low level. Beta variant challenged mice had two logs lower RNA
and HCP treatment was able to decrease two of the mice down to the LLOD. A lethal dose of
SARS-CoV-2 WA-1 is known to infiltrate the brain of K18-hACE2 transgenic mice (141,176). As
expected, brain WA-1 viral copy numbers were decreased due to HCP treatment (Fig. 3D).
Similarly, three of five Alpha VoC challenged mice had low viral RNA detected in their brain (Fig.
3D), which correlated with their temperature, weight, and survival data (Fig. 2 and 3). Surprisingly,
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HCP treatment did not decrease brain Beta VoC virus RNA copies, further demonstrating the
ability of Beta VoC to break through antibody protection that was derived against original Wuhan
or WA-1-like viruses (Fig. 3D).

Human and mouse IgG levels in convalescent plasma treated K18-hACE2 transgenic mice
infected with SARS-CoV-2 VoC. To determine the level of IgGs delivered to HHS and HCP
treated mice, we analyzed whether human anti-SARS-CoV-2 IgGs were present within the lung
and sera of animals treated with HCP or HHS through the course of infection (Fig. 4AB). Data
demonstrate that significant quantities of human anti-SARS-CoV-2 IgGs targeting both the RBD
and nucleocapsid proteins were present at two days post-challenge in HCP-treated relative to
HHS-treated mice (data not shown). Overall, these data indicate that passive immunization
resulted in persistence of human antibodies in mice through the experimental timeframe studied.

HCP treatment lowered chronic and acute inflammation in the lung caused by SARS-CoV2 challenge. Histopathology analysis was performed to characterize disease manifestation in the
lung due to inflammation caused by WA-1, Alpha, and Beta challenge during HHS and HCP
treatments (Fig. 5). Chronic inflammation was denoted as presence of lymphocytes, plasma cells
and alveolar macrophages, whereas acute inflammation was characterized by neutrophils and
edema in the lung parenchyma, vasculature, and bronchi. Total inflammation was determined by
the addition of chronic and acute inflammation scores. HHS treatment groups challenged with
WA-1, and with Alpha and Beta VoC had the highest chronic and acute inflammation scores in
the lung parenchyma and surrounding blood vessels compared to the HCP treated mice (Fig.
5ACDE). HHS treated mice challenged with WA-1 and Alpha VoC had the highest average total
inflammation scores of 7.4 and 8.8, respectively; whereas Beta VoC challenged mice had an
average total inflammation score of 4.0 (Fig. 5CD). HCP treatment groups challenged with WA1, and Alpha and Beta VoC also had mixed chronic and acute inflammation albeit lower total
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inflammation compared to HHS treated mice (Fig. 5BCD). HCP treated mice challenged with WA1 had the highest average total inflammation score (4.0), characterized by more chronic
inflammation than acute (Fig.5CD). Mice treated with HCP and challenged with Alpha VoC had
an average inflammation score of 4.4 and decreased acute inflammation compared to HHS
treatment (Fig. 5D). Interestingly, HHS and HCP treated mice challenged with Beta VoC had low
lung inflammation (Fig. 5CD), which correlated with the low viral RNA burden of Beta VoC (Fig.
3C). Overall, HHS treated, and SARS-CoV-2 challenged mice had elevated levels of both chronic
and acute inflammation compared to the HCP treated and challenged mice.

HCP passive immunization was insufficient to protect against Delta VoC challenge. Delta
VoC contains mutations on the RBD that compromise antibody neutralization (137). We further
evaluated whether polyclonal antibodies in the HCP generated from an original virus immune
plasma could protect mice from a lethal Delta VoC challenge. Here, we used a challenge dose of
104 PFU/dose of Delta VoC instead of a 105 PFU/dose as we previously used for WA-1, Alpha,
and Beta VoC. In pilot studies, we demonstrated that 104 PFU/dose of Delta VoC resulted in 100%
morbidity in K18-hACE2 transgenic mice (data not shown). Thus, mice were administered HCP
(n=5) or PBS (n=5) intraperitoneally and concurrently intranasally challenged with a lethal Delta
VoC dose on day 0 (Fig. 6A). HCP treated mice received treatment for 5 consecutive days after
the first dose on day 0. All mice were monitored for disease for 7 days (Fig. 6A). Mice that did not
receive HCP treatment succumbed to Delta VoC challenge by day 6 and had elevated cumulative
disease scores (Fig 6BC). However, only 20% of mice that received 6 treatments of HCP survived
the Delta VoC challenge and had disease scores similar to untreated mice (Fig. 6BC). Viral RNA
burden mirrored survival and disease scores for both HCP treated and untreated mice. Lung,
brain, and nasal wash (NW) of the HCP treated mice had similar levels of viral RNA compared to
untreated mice indicating that HCP treatment did not block viral replication (Fig. 6DEF). Overall,
polyclonal antibodies generated against the ancestral SARS-CoV-2 strain did not protect mice
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from Delta VoC challenge suggesting that the Delta VoC is resistant to polyclonal antibodies
generated against Wuhan-lineage virus strains.

2.6 DISCUSSION
SARS-CoV-2 VoC are constantly evolving and dramatically impacting the ongoing COVID-19
pandemic. Since the beginning of the pandemic, three major infection waves have occurred: 1)
original virus, 2) Alpha variant, and 3) Delta variant, with a recent wave starting directed by the
novel Omicron (B.1.1.529) VoC. Approved vaccines are implemented all around the world with 8
billion total doses administered meaning 1 dose per person in the world. However, there are
massive inequities in vaccine coverage with US/Canada, Latin America, Asia-Pacific, and Europe
with ~60-70% vaccination with one dose, whereas Africa is only at 10% coverage with one dose.
Overall, the world is at 56% vaccine coverage with one dose. All current vaccines are designed
against the original virus spike antigen sequence, but two major waves have been fueled by the
Alpha and Delta VoC. Vaccine re-development will always be a challenge and new VoC have
been constantly arising.
Alpha and Beta VoC spike antigens were extensively studied by binding and neutralization assays
that suggested antibodies generated by infection or vaccination would be able to provide
protection. Ultimately relatively low numbers of vaccine breakthrough occurred. In order to
confirm the in vitro predictions regarding Alpha and Beta VoC, we designed this study to use a
passive immunization model in K18-hACE2 transgenic mice to compare antibody dependent
immunity between original virus vs. VoC. Our observations suggest that Alpha VoC is partially
neutralized in K18-hACE2 transgenic mice treated with HCP (Fig. 2 and 3), whether the Beta VoC
was not sufficiently neutralized to prevent lethality in this model system (Fig. 2 and 3). HCP
treatment dramatically decreased viral RNA burden of the lungs and brain in WA-1 and Alpha
VoC challenged mice, but minimal to no decrease was observed in mice challenged by the Beta
VoC (Fig. 3CD), which likely contributed to the morbidity and mortality caused by the Beta VoC.
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Low viral burden in the lung correlated with low chronic or acute inflammations scores (Fig. 5).
Antibody breakthrough and aggressive pathogenesis suggested that the Beta VoC was going to
likely be a variant of high concern. When Beta variant appeared, it was able to impact vaccine
trial efficacy studies and seemed poised to infect vaccinated people (35,177,178). However, the
Beta VoC peaked at a total of 12% genome worldwide frequency by April 2021. Thus, it seems
likely that the Beta VoC was not highly transmissible, and our passive immunization model does
not take this variable into consideration.
HCP as a treatment was used widely since the onset of the COVID-19 pandemic (179–181), but
its efficacy was questionable (182–185) and convalescent plasma therapy for COVID-19 has
been replaced as a treatment by monoclonal antibodies. In this study, we used HCP from an
early pandemic COVID-19+ severe disease patient to understand how antibodies generated
against the original SARS-CoV-2 strain would function against Alpha and Beta VoC. In December
2020, the Delta VoC appeared in India and by mid-2021, this VoC was the dominant variant found
in genomic surveillance. To build upon our observations regarding Alpha and Beta VoC in the
HCP passive immunity model with K18-hACE2 transgenic mice, we next aimed to evaluate the
Delta VoC. Our pilot studies indicated a massive histopathological and inflammatory gene
expression in Delta VoC vs. Alpha VoC challenged mice (data not shown). We reasoned that the
Delta VoC was more aggressive and would likely need a lower dose to be fully virulent compared
to WA-1 strain and would also require more HCP in order to neutralize the virus in vivo. Thus, we
challenged mice with a lower dose of 104 PFU and HCP treatment was provided daily out to 6days post challenge. Unexpectedly, even though we provided 6X more HCP, mice were morbid
with high disease scores and high viral burden (Fig. 6). It is now well appreciated that Delta VoC
can cause breakthrough cases in previously infected as well as vaccinated humans (186,187).
Currently, with the highly mutated Omicron VoC, passive immunity and active immunization
studies in pre-clinical models will be important to determine the breakthrough capacity of this new
VoC. Furthermore, HCP or mAb passive studies can inform the scientific community about
63

enhanced virulence or immune subversion of VoC and we anticipate this passive model can be
applied going forward for rapid responses to characterize new variants.

In summary, this study provides insights into differences in SARS-CoV-2 VoC pathogenicity in
K18-hACE2 transgenic mice in relation to antibody immunity. Passive immunization of mice with
human antibodies can allow for robust characterization of breakthrough capacity (134,188). This
study demonstrates increased disease pathology for mice challenged with Alpha and Beta VoC,
and the lack of protection from HCP in mice challenged with Beta or Delta VoC. These data
corroborate observations about Beta and Delta VoC in human populations. The human
convalescent plasma passive immunity model presented here can be useful in supporting in vitro
studies and facilitate decision making and planning of research priorities around the overall
immune evasion characteristics of SARS-CoV-2 variants.
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2.8 FIGURES

Figure 1. Characterization of early pandemic human convalescent plasma and in vitro
characterization of SARS-CoV-2 variants.
(A) RBD human IgG Binding antibody units (BAU) of SARS-CoV-2 + (red dots) compared to
SARS-CoV-2 – patients (white dots).

HCP dotted line indicate the BAU of the human

convalescent plasma from a severe COVID-19 patient utilized in passive immunization studies in
K18-hACE2 transgenic mice. HHS dotted line indicate the BAU of the healthy human serum used
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in passive immunization studies in K18-hACE2 transgenic mice. (B) ACE2-RBD neutralization
was assayed, and the human convalescent plasma utilized was more capable of neutralizing
receptor binding than mRNA vaccinated human sera. The heat map depicts the log10 AUC of
electro chemiluminescent (ECL) values. (C) Plaque morphology of SARS-CoV-2 WA-1, Alpha or
Beta infected VeroE6 cells. (D) Quantification of viral replication of SARS-CoV-2 variants in
VeroE6 cells over time was quantified. Statistical analysis of viral replication was completed by
two-way ANOVA followed by Tukey’s multiple comparison test, or RM ANOVA followed by
Tukey’s multiple comparison test. **** = P < 0.0001 relative to WA-1, #### = P < 0.0001 relative
to Alpha. C57BL6/J Mice were infected with 105 pfu SARS-CoV-2 VoC monitored for survival (E)
and disease score (F). (G) Challenge with Alpha or Beta variants resulted in low detectable virus
at day 11 post challenge.
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Figure 2 Effect of convalescent plasma treatment on SARS-CoV-2 VoC infection in K18hACE2 transgenic mice. (A) Passive immunization and SARS-CoV-2 challenge schematic. Mice
were challenged with 105 PFU of SARS-CoV-2 WA-1 and VoC and simultaneously treated
intraperitoneally with 500 µL HHS or HCP on day 0. Mice were monitored for temperature (B-D),
body weight (E-G) and cumulative clinical score (H) over the 7-day course of infection.
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Figure 3 Survival and viral infection of serum-treated K18-hACE2 transgenic mice infected
with SARS-CoV-2 VoC. Kaplan-Meyer survival curves of mice infected with Alpha, beta, or WA1 treated with HHS (A) or early pandemic SARS-CoV-2 HCP (B). Viral copy numbers in the lung
(C) and brain (D) of infected mice. LLOD = lower limit of detection based on a standard curve.
Statistical significance of survival curves was assessed with the Mantel-Cox test. For HHS, WA1 vs Alpha P = 0.0143; WA-1 vs BetaP = 0.9372 and Alpha vs BetaP = 0.0027. For HCP, WA-1
vs Alpha P = 0.1336; WA-1 vs BetaP = 0.0031 and Alpha vs BetaP = 0.0290. Statistical
significance between viral copy number was assessed by a Kruskal-Wallis test followed by Dunn’s
multiple comparisons test. n > 3 subjects per group. P values for significant differences are
reported.
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Figure 4 Human anti-SARS-CoV-2 IgGs in serum-treated K18-hACE2 transgenic mice
challenged with SARS-CoV-2 VoC. Area under the curve (AUC) analyses of anti-RBD IgG
levels in the serum (A) or lung (B) of HHS or HCP VoC challenged mice. Statistical significance
between AUCs was assessed by a Kruskal-Wallis test followed by Dunn’s multiple comparisons
test. n > 3 subjects per group.
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Figure 5 Histopathological analysis of VoC challenged lungs. Left lobes of lungs from HHS
and HCP treated and SARS-CoV-2 challenge mice were subjected to H&E staining (A) 200X
magnification of the lung in HHS treated and SARS-CoV-2 challenged mice (B) 200X
magnification of the lung in HCP treated and SARS-CoV-2 challenged mice (C) Total chronic
inflammation scores of each mouse. (D) Total acute inflammation score of each mouse. (E) Total
inflammation score (chronic + acute) for each mouse. All statistical analysis was performed using
Kruskal-Wallis test with Dunn’s multiple comparisons test. All results represented as mean ±SD.

71

Figure 6 HCP passive immunization was insufficient to protect against Delta variant
challenge. (A) Experimental workflow of passive immunization study with HCP and challenge
with lethal dose of Delta variant (104 PFU/dose). (B) Kaplan Meier survival curve comparing Delta
challenged mice that received either 1XDPBS vehicle or HCP. (C) Cumulative disease scores
comparing Delta challenged mice that received either 1XDPBS vehicle or HCP. SARS-CoV-2
nucleocapsid RNA copies in A) lung, B) brain, and C) nasal wash of untreated and HCP treated
and challenged mice. All statistical analysis was performed using Welch’s t test. P = 0.0491.
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3.1 Abstract
The ongoing COVID-19 pandemic has contributed largely to the global vaccine disparity.
Development of protein subunit vaccines can help alleviate shortages of COVID-19 vaccines
delivered to low-income countries. Here, we evaluated the efficacy of a three-dose Virus-like
particle (VLP) vaccine composed of Hepatitis B surface antigen (HBsAg) decorated with the
Receptor Binding Domain (RBD) from Wuhan and/or Beta SARS-CoV-2 strains adjuvanted with
either aluminum hydroxide (Alum) or squalene in water emulsion (SWE). RBD HBsAg vaccines
were compared to the standard two doses of Pfizer mRNA vaccine. Alum adjuvanted vaccines
were composed of either RBD HBsAg conjugated with Beta RBD alone (β RBD HBsAg+Al) or a
combination of both Beta RBD HBsAg and Wuhan RBD HBsAg (β/Wu RBD HBsAg+Al). RBD
vaccines adjuvanted with SWE were formulated with Beta RBD HBsAg (β RBD HBsAg+SWE) or
without HBsAg (β RBD+SWE). Both alum adjuvanted RBD HBsAg vaccines generated functional
RBD IgG against multiple SARS-CoV-2 Variants of Concern (VOC), decreased viral RNA burden
and lowered inflammation in the lung against Alpha or Beta challenge in K18-hACE2 mice.
However, only β/Wu RBD HBsAg+AlOH was able to afford 100% survival to mice challenged with
Alpha or Beta VOC. Furthermore, mice immunized with β RBD HBsAg+SWE induced cross
reactive neutralizing antibodies against major VOC of SARS-CoV-2, lowered viral RNA burden in
the lung and brain, and protected mice from Alpha or Beta challenge similar to mice immunized
with Pfizer mRNA. However, RBD+SWE immunization failed to protect mice from VOC challenge.
Our findings demonstrate that RBD HBsAg VLP vaccines provided similar protection profiles to
the approved Pfizer mRNA vaccines used worldwide and may offer protection against SARSCoV-2 VOC.
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3.2 Importance
Global COVID-19 vaccine distribution to low-income has been a major challenge of the pandemic.
To address supply chain issues, RBD Virus-like particle (VLP) vaccines that are cost effective
and capable of large-scale production were developed and evaluated for efficacy in pre-clinical
mouse studies. We demonstrated that RBD-VLP vaccines protected K18-hACE2 mice against
Alpha or Beta challenge similarly to Pfizer mRNA vaccination. Our findings showed that the VLP
platform can be utilized to formulate immunogenic and efficacious COVID-19 vaccines.
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3.3 Introduction
SARS-CoV-2 is the causative agent of the COVID-19 pandemic that has caused more than 446
million cases and over 6 million deaths worldwide. Since January 2020, when the genome of the
ancestral strain of SARS-CoV-2 was first released, new variants of concern (VOC) have emerged
such as Alpha, Beta, Gamma, Delta, and currently, Omicron. Mutations harbored on the Receptor
Binding Domain (RBD) of the spike protein of SARS-CoV-2 such as N501Y and E484K of early
VOC (Alpha, Beta, and Gamma) were responsible for increased transmission of SARS-CoV-2
(1,2). Later VOC, such as Delta contained additional mutations on the RBD, L452R and T478K,
which were associated with increased infectivity, transmissibility, and evasion of neutralizing
antibodies (3,4). Omicron, the current predominant variant of SARS-CoV-2 has 30 mutations on
spike protein alone (15 of these are in the RBD) that has led to vaccine breakthrough cases and
evasion of monoclonal antibody therapeutics (5). Overall, due to the emergence of VOC,
increased vaccine breakthrough cases have been apparent and need to be addressed by the
production of vaccines that can broadly neutralize VOC.
Currently, there are 10 WHO-approved COVID-19 vaccines granted for Emergency Use Listing
or full approval. These include vaccines formulated with mRNA (Moderna and Pfizer/BioNTech),
non-replicating Adenovirus (Jansen, Oxford/AstraZeneca and Serum Institute of India), or protein
subunit (Novavax and Serum Institute of India) that utilize the ancestral strain of SARS-CoV-2
spike protein as the vaccine antigen. Bharat Biotech, Sinopharm (Beijing), and Sinovac have also
developed approved inactivated SARS-CoV-2 virus vaccines. Overall, Adenovirus non-replicating
viral vector COVID-19 vaccines globally lead in approval for use in the most countries (290
countries) followed by the mRNA platform (222 countries), inactivated SARS-CoV-2 (155
countries), and lastly protein subunit (38 countries) (6).
Surprisingly, there is only one approved recombinant protein vaccine formulation, even though
historically subunit vaccines have been used for prevention of many infectious diseases. Novavax
has developed the first WHO approved recombinant protein COVID-19 vaccine in partnership
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with the Coalition for Epidemic Preparedness Innovations (CEPI), and manufacturing
collaborations with the Serum Institute of India. The vaccine is formulated with lipid nanoparticle
decorated with SARS-CoV-2 spike protein adjuvanted with a Saponin derived Matrix-M adjuvant
(7,8). In a phase 3 clinical trial in the United States and Mexico, Novavax vaccine demonstrated
100% vaccine efficacy against moderate to severe COVID-19, and 92.6% efficacy against the
variants of concern at that time (not including the Delta variant) (9). Globally, there are also 6
other protein subunit vaccines that are approved for emergency use in Taiwan, China, Russia,
Belarus, Turkmenistan, Cuba, Venezuela, and Iran.
With the increase of COVID-19 vaccine development around the world, to date only 56% of the
global population is fully vaccinated with 2 doses of a COVID-19 vaccine (10). Global vaccine
disparities are evident especially amongst countries in Africa, South America, Eastern Europe,
Middle East, and some countries in South Asia. The development of recombinant protein subunit
COVID-19 vaccines can help alleviate global vaccine disparities and inequities by increasing the
availability of safe and efficacious vaccines to lower-income countries.
To meet the demand of COVID-19 vaccine distribution to lower-income countries, vaccine
candidates must have: 1) increased manufacturability and scalability 2) reduced production costs
3) thermostability 4) limited series of doses with long lasting immune responses and 4) generate
broadly neutralizing antibodies across VOC. COVID-19 protein subunit vaccines can help address
the challenges in developing vaccines for low-income countries. All WHO approved COVID-19
vaccines utilize the full-length spike protein as the vaccine antigen. Although, the spike protein is
an immunogenic target, given its size, it is less manufacturable than the RBD. The RBD has
become an antigen of interest for protein-based vaccines due to the ability of RBD to be cost
efficiently produced in high yields, stability at elevated temperatures, as well as include
neutralizing epitopes (11,12). Although, RBD is not sufficiently immunogenic on its own,
conjugation to protein nanoparticles, virus-like particles (VLP), or bacterial carrier proteins can
elevate immunogenicity by increasing the amount of antigen presented to the immune system
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(13–15). Likewise, adjuvants can help boost antigen specific immune responses in vaccines
leading to robust cellular and humoral activation. Historically, Aluminum hydroxide (Alum) has
been used as an adjuvant for multiple approved protein-based vaccines due to its ability to drive
a strong antibody response. Recently, oil-in-water emulsions adjuvants such as MF59 have been
utilized to improve the immunogenicity of influenza vaccines to older and immunocompromised
populations(16). Alternatively, a Squalene in water emulsion (SWE) adjuvant similar to MF59, has
been designed to provide dose-sparing qualities to vaccines by decreasing the amount of antigen
necessary for administration. Pre-clinical vaccine studies performed with SWE demonstrated both
improved humoral and cellular responses against both viral and bacterial pathogens (17–25).
Overall, adjuvants can help limit the vaccine doses needed to be administered as well as increase
the duration of the immune response which can benefit low-income countries and alleviate the
global vaccine deficit.
In this study, we evaluated a VLP based protein subunit vaccine developed by the Serum Institute
of India (SII) and SpyBiotech in comparison to standard Pfizer mRNA vaccine. Experimental
vaccines were composed of Hepatitis B surface antigen (HBsAg) VLP decorated with Beta and/or
Wuhan RBD and adjuvanted with either Aluminum hydroxide or a squalene in water emulsion
(SWE). We hypothesized that 1) combination of both Beta RBD HBsAg and Wuhan RBD HBsAg
would provide protection against SARS-CoV-2 VOC compared to Beta RBD HBsAg and 2)
conjugation of RBD to HBsAg is necessary to elicit an immunogenic response and protect mice
against SARS-CoV-2 VOC. Here, we evaluated 4 experimental RBD HBsAg VLP vaccines
compared to Pfizer mRNA against Alpha or Beta challenge in the K18-hACE2 mouse model. Our
findings demonstrate that three doses of Beta RBD HBsAg and Wuhan RBD HBsAg adjuvanted
with Alum provided better protection against both Alpha and Beta variants similar to Pfizer mRNA
vaccination compared to Beta RBD HBsAg adjuvanted with Alum. Additionally, three doses of
RBD HBsAg adjuvanted with SWE generated RBD IgG antibody responses against a breadth of
VOC comparable to two doses of Pfizer mRNA vaccine and elicited protection against Alpha and
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Beta VOC whereas RBD without HBsAg adjuvanted with SWE failed to protect mice against
SARS-CoV-2 challenge.

3.4 Methods
Animal welfare and Biosafety. B6.Cg-Tg(K18-ACE2)2Prlmn/J mouse vaccine and SARS-CoV2 challenge studies were executed under IACUC protocol number 2009036460. All mice were
humanely euthanized based on the disease scoring system (26), and no deaths occurred in the
cage.

All SARS-CoV-2 challenge studies were conducted in the West Virginia University

Biosafety Laboratory Level 3 facility under the IBC protocol number 20-04-01. SARS-CoV-2
samples were either inactivated with 1% Triton per volume or Trizol before exiting high
containment.

Production of antigen and vaccine compositions. RBD protein was cloned, expressed in
Komgataella phaffi and purified as previously described (27–29). RBD-SpyTag antigens were
conjugated overnight onto the HBsAg-SpyCatcher VLP (30,31). Beta RBD used in vaccine
formulations was engineered to include mutations L452K and F490W to increase
manufacturability and scalability as previously described (13). Vaccine formulations are shown
in Supplementary Table 1.

Mouse immunization. Female B6.Cg-Tg(K18-ACE2)2Prlmn/J mice were purchased from
Jackson Laboratory (stock no: 034860) at 4 weeks old. K18-hACE2 mice receiving experimental
RBD vaccines were primed at 9 weeks old, boosted 3 weeks later (12 weeks old), and were
administered third dose 2 weeks post 2nd dose (14 weeks old) with 50μL of vaccine through the
intramuscular route in the right leg. Pfizer mRNA immunized K18-hACE2 mice were primed at 9
weeks old with and boosted 3 weeks later (12 weeks old) intramuscularly with 50μL of vaccine in
the right leg.
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Serological analysis
Pre-challenged serum from vaccinated mice was analyzed for RBD specific IgG using the SARSCoV-2 Plate 11 Multi-Spot 96-well, 10 spot plate following the manufacturer protocol (catalog #:
K15455U) on the MSD QuickPlex SQ120. The 10 spots contained the following RBD antigens,
common designations, and lineages: 1) Epsilon - L452R (B.1.427; B.1.429; B.1.526.1) 2) Beta K417N, E484K, N501Y (B.1.351; B.1.351.1) 3) Eta, Iota, Zeta - E484K (B.1.525; B.1.526; B.1.618;
P.2; R.1) 4) Gamma - K417T, E484K, N501Y (P.1) 5) New York - S477N 6) Alpha - N501Y
(B.1.1.7) 7) UK, Philippines - E484K, N501Y (B.1.1.7+E484K; P.3) 8) Kappa - L452R, E484Q
(B.1.617; B.1.617.1; B.1.617.3) 9) Delta - L452R, T478K (AY.3; AY.4; AY.4.2; AY.5; AY.6; AY.7;
AY.12; AY.14; B.1.617.2; B.1.617.2+Δ144) and 10) Wuhan. Serum obtained from non-vaccinated
and vaccinated animals at 2 weeks post prime and 4 weeks post 2nd dose were evaluated for IgG
titers against 10 different VOC RBDs. Non immunized mice sera were diluted at 1:1000, whereas
vaccinated mice sera obtained at 2 weeks post prime was diluted at 1:4000-1:512000 and
vaccinated sera obtained at 4 weeks post 2nd dose was diluted at 1:32000-1:4096000. Titer cut
off value was determined by the sum of the average values for non-vaccinated mice added to 2X
the standard deviation of non-vaccinated mice electrochemiluminescent (ECL) values. The
reciprocal of the dilution showing ECL values above the cutoff were reported as the final titer.
Statistical analysis was performed on n ≥ 8 mice per group of serum analyzed.

SARS-CoV-2 propagation and mouse challenge
Alpha (NR-54000) and Beta (NR-54008) SARS-CoV-2 variants were obtained from BEI
Resources. Alpha and Beta VOC were propagated in Vero E6 cells (ATCC-CRL-1586) and resequenced before use in mouse challenge. K18-hACE2 mice were anesthetized using an
intraperitoneal injection of ketamine (Patterson Veterinary 07-803-6637, 80 mg/kg) / xylazine (07808-1947, 8.3 mg/kg) and were intranasally challenged with 50uL of 104 PFU/dose of Alpha or
Beta variant, 25uL per nare. Mice were monitored until fully recovered from the anesthesia.
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Disease monitoring of SARS-CoV-2 challenged mice
Challenged K18-hACE2 mice were evaluated daily through both in-person health assessments in
the BSL3 and SwifTAG Systems video monitoring for 11 days. Disease assessments of the mice
were scored based on five criteria: 1) weight loss (scale 0-5), 2) appearance (scale 0-2), 3) activity
(scale 0-3), 4) eye closure (scale 0-2), and 5) respiration (scale 0-2) as previously described
(15,26). Briefly, cumulative disease scoring was calculated by adding the disease scores of each
mouse from each group. Morbid mice that were euthanized during the study, before day 11,
retained their disease score for the remainder of the experiment.

Euthanasia and tissue collection
Challenged mice that were assigned a disease score of 5 or above or reached the end of the
experiment were euthanized with an IP injection of Euthasol (390mg/kg) (Pentobarbital) followed
by secondary measure of euthanasia with cardiac puncture. Blood from cardiac puncture was
collected in BD Microtainer gold serum separator tubes (BD 365967), centrifuged at 15,000 x g
for 5 minutes and serum was collected for downstream analysis. Lungs were separated into right
and left lobes. Right lobe of the lung was homogenized in 1mL of PBS in gentleMACS C tubes
(order number: 130-096-334) using the m_lung_02 program on the gentleMACS Dissociator.
300μL of lung homogenate was added to 1000μL of TRI Reagent (Zymo research) for
downstream RNA purification and 300 μL of lung homogenate was centrifuged at 15,000 x g for
5 minutes and the lung supernatant was collected for downstream analyses. Brain was excised
from the skull and was homogenized in 1mL PBS in gentleMACS C tubes using the same setting
as lung on the gentleMACS Dissociator. 1000μL of TRI Reagent was added to 500μL of brain
homogenate for RNA purification.

qRT-PCR SARS-CoV-2 viral copy analysis of lung and brain
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As previously described by Wong et. al. (15,26), RNA purification of the lung and brain were
performed using the Direct-zol RNA miniprep kit (Zymo Research R2053) following the
manufacturer protocol and SARS-CoV-2 copy numbers were assessed through qPCR using the
Applied Biosystems TaqMan RNA to CT One Step Kit (Ref: 4392938).

Meso Scale Discovery COVID-19 ACE2 neutralization assay
SARS-CoV-2 challenged serum was analyzed using the SARS-CoV-2 Panel 22 Multi-Spot 96well, 10 spot plate following the manufacturer protocol (catalog #: K15458U-2 and K15562U-2
respectively) on the MSD QuickPlex SQ120. Panel 22 was utilized for spots containing Beta
(B.1.351), Alpha (B.1.1.7), Delta (AY.3; AY.4; AY.4.2; AY.5; AY.6; AY.7; AY.12; AY.14; B.1.617.2;
B.1.617.2+Δ144), Gamma (K417T, E484K, N501Y (P.1), Omicron (B1.1.529; BA.1), and Wuhan.
Serum dilution of 1:5 was analyzed on the MSD neutralization assay and ECL values of both the
blank (calibrator diluent 100) as well as the average biological replicate ECL values were utilized
for analysis to calculate percent inhibition for each mouse.

Lung Histopathology
Left lobes of lungs were fixed in 10 mL of 10% neutral buffered formalin and paraffin embedded
into 5 μm sections. Sections were stained with hematoxylin and eosin (H&E) and were analyzed
by iHisto. Lungs were scored by a pathologist for chronic and acute inflammation in the lung
parenchyma, blood vessels, and airways as previously described (15,26).

Statistical analyses
All statistical analyses were performed using GraphPad Prism version 9. Statistical analyses were
performed with n ≥ 4 for K18-ACE2 mice studies challenged with Alpha or Beta variants. Error
bars represent standard deviation.

Ordinary one-way ANOVA with Dunnett’s multiple

comparisons test was used with single pooled variance for data sets following a normal
96

distribution and Kruskal-Wallis with Dunn’s multiple comparisons test for non-parametric
distributed datasets. Kaplan-Meier survival curves were utilized, and Log-rank (Mantel-Cox) test
were used to test significance of survival between sample groups.

3.5 Results
RBD VLPs adjuvanted with Alum or SWE and Pfizer mRNA immunizations elicited robust
immunogenicity in K18-hACE2 mice. In this study, RBD HBsAg VLP vaccines utilized the
SpyCatcher/SpyTag conjugation platform to display the RBD of the spike protein of SAR-CoV-2
on HBsAg (Fig. 1A). The SpyCatcher/SpyTag platform utilizes the SpyCatcher bound to the
HBsAg and the SpyTag bound to RBD to form a covalent bond between antigen and VLP to allow
for a high quantity of RBD to be displayed on the surface of HBsAg without masking important
epitopes (13,32,33) (Fig. 1A). This technology has been used to improve the immunogenicity of
viral vaccines against human cytomegalovirus, influenza, and HIV (34–37). Here, our studies
were comprised of two main goals. First, since the emergence of VOC has negatively impacted
vaccine efficacy, we wanted to assess the immunogenicity and protection profiles of using the
VOC Beta variant RBD compared to utilizing both ancestral SARS-CoV-2 RBD and Beta variant
RBD as the target vaccine antigens conjugated to HBsAg. Lastly, the second goal was to evaluate
the effect of adjuvanting RBD HBsAg or RBD alone with SWE on immunogenicity and protection
with the aim of providing a stronger immune response compared to the Alum adjuvant.
In order to evaluate our experimental goals, K18-hACE2 mice were intramuscularly immunized
with three doses of either 1) PBS (NVC) (n=10) 2) β RBD HBsAg+Al (n=10) 3) β/Wu RBD HBsAg
+ Al (n=9) 4) β RBD HBsAg+SWE (n=10) or 5) β RBD+SWE (n=10) (Supp. Table 1, Fig.1B). After
the initial vaccination, mice were administered the second dose 3 weeks after prime and the third
dose, 2 weeks after the second dose of vaccine. Pfizer mRNA vaccination was administered at
3µg which is 1/10 the human dose to mice as 2 doses following the same human vaccine schedule
with the two doses separated by 3 weeks (Fig. 1 B, Supp. Table 1). To assess the immunogenicity
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of RBD HBsAg vaccines adjuvanted with either Alum or SWE compared to the Pfizer mRNA,
serological analysis of serum IgG was measured against ten variant RBDs at 2 weeks post prime
and 4 weeks post second dose (Fig. 1B). β RBD HBsAg and β/Wu RBD HBsAg adjuvanted with
Alum elicited similar RBD IgG levels at 2 weeks post prime and 4 weeks post 2nd dose (Fig. 1CD).
At two weeks post prime, no significant differences were detected between β RBD HBsAg or β/Wu
RBD HBsAg adjuvanted with Alum against Wuhan, Alpha, Beta, or Delta RBD strains (Supp.
Table 2). Four weeks after the second dose, mice immunized with β/Wu RBD HBsAg+Al
generated higher levels of anti-Wuhan RBD (1336889 AU/mL) (Fig.1E, Supp. Fig.1B) and antiDelta RBD (1536000 AU/mL) IgG (Fig. 1F, Supp. Fig.1H) compared to Wuhan RBD (1075200
AU/mL) and Delta RBD (1113600 AU/mL) IgG levels in mice vaccinated with β RBD HBsAg+ Al
(Fig. 1E-H, Supp. Fig.1B, H). Higher levels of Wuhan and Delta specific RBD IgG suggested that
the combination of ancestral and Beta RBD improved the production of cross-reactive antibodies
between SARS-CoV-2 strains. Overall, no significant differences between RBD IgG levels were
detected between β RBD HBsAg and β/Wu RBD HBsAg adjuvanted with Alum against Wuhan,
Alpha, Beta, or Delta RBD strains at 4 weeks post 2nd dose (Supp. Table 2).
RBD HBsAg adjuvanted with SWE began to elicit RBD IgG titers post prime, with the highest titers
generated against Beta (54400 AU/mL), Delta (54400 AU/mL), Epsilon (60800 AU/mL), Eta, Iota,
Zeta (73600 AU/mL), Gamma (80000 AU/mL), and Kappa (108800 AU/mL) RBD variants
(Fig.1C). Additionally, at two weeks post prime, RBD HBsAg adjuvanted with SWE immunization
generated significantly increased RBD IgG levels compared to Alum adjuvanted RBD HBsAg
vaccines, suggesting that SWE improved the initial antibody responses to the RBD variants (Fig
1C, E-H, Supp. Fig.1, Supp. Table 2). Two-weeks after the third vaccine dose, RBD IgG levels in
all β RBD HBsAg+SWE vaccinated mice increased significantly amongst Wuhan, Alpha, Beta,
and Delta RBD variants compared two weeks post prime (Fig. 1E-H, Supp. Fig.1). RBD HBsAg
adjuvanted with SWE generated significant RBD IgG levels compared to β RBD+SWE (Supp.
Table 2). Furthermore, mice that received three doses of RBD+SWE generated a lower RBD IgG
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response compared to the other vaccine formulations suggesting that the HBsAg VLP was
required to develop an immunogenic RBD specific IgG response against SARS-CoV-2 VOC (Fig
1D-H). Interestingly, RBD HBsAg+SWE vaccine generated comparable RBD IgG across all VOC
similar to Pfizer mRNA. At 2 weeks post prime, Pfizer mRNA vaccination generated increased
RBD IgG levels amongst all RBD variants compared to other RBD HBsAg vaccine formulations
(Fig.1C, Supp. Fig. 1, Supp. Table 2). Overall, mice immunized with two doses of Pfizer mRNA
or three doses RBD HBsAg+SWE had the highest RBD IgG titers compared to the other vaccine
formulations across all RBD variants (Fig. 1CD, Supp. Fig.1) Altogether, RBD HBsAg conjugate
vaccines elicited immunogenic RBD IgG responses against SARS-CoV-2 VOC. Therefore, we
hypothesized that RBD-VLP immunization would protect mice against Alpha or Beta SARS-CoV2 challenge.
β/Wu RBD HBsAg+Al, β RBD HBsAg+SWE, and Pfizer mRNA vaccines provided protection
against lethal challenge with Alpha or Beta SARS-CoV-2 in K18-hACE2 mice. Next, to
evaluate the protection profile of RBD HBsAg vaccines adjuvanted with either Alum or SWE
compared to Pfizer mRNA, vaccinated and non-vaccinated K18-hACE2 mice were challenged
with a lethal 104 PFU/dose of Alpha or Beta SARS-CoV-2 (Fig. 2A). Four to five mice from each
vaccine group were challenged with either Alpha or Beta SARS-CoV-2, and five mice that were
not challenged with SARS-CoV-2 was used as a control. During the 11-day challenge period,
mice were monitored and scored based on the severity of disease symptoms including
temperature and weight loss, activity, appearance, respiration, and eye health (Fig. 2A) (15,26).
The disease scoring method was also used to determine humane euthanasia points throughout
the course of challenge (26). In this study, we utilized survival instead of plaque forming assays
as a strong indicator of protection. All PBS vaccinated mice (No Vaccine Challenged (NVC))
challenged with Alpha became morbid by day 6 post challenge and were humanely euthanized
(Fig.2B), whereas PBS vaccinated mice (NVC) challenged with Beta also had a low survival rate
(20% survival). Mice immunized with β RBD HBsAg+Al had partial survival (60% survival) against
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Alpha challenge (Fig.2B) and performed better against Beta challenge with 80% survival (Fig.
2C). Whereas mice immunized with both Beta and Wuhan RBDs HBsAg adjuvanted with Alum
afforded mice 100% survival against Alpha or Beta challenge (Fig.2BC). Mice immunized with β
RBD HBsAg adjuvanted with SWE were 100% protected against Alpha or Beta challenge (Fig.
2BC). However, without the HBsAg, survival decreased in mice immunized with RBD+SWE
against Alpha (60% survival) or Beta (40% survival) challenge (Fig.2BC). Similar to the β/Wu RBD
HBsAg+Al and β RBD HBsAg+SWE, Pfizer mRNA also provided 100% protection against Alpha
or Beta challenge (Fig.2BC). Overall, immunization with both Beta and Wuhan RBD antigens
conjugated onto HBsAg VLP increased protection against Alpha or Beta challenge compared to
immunization with Beta RBD HBsAg. Additionally, SWE adjuvanted RBD HBsAg vaccines were
also able to protect mice from lethal challenge doses of Alpha or Beta VOC.
Poor survival was correlated in the daily increasing disease scores. Cumulative disease scores
inversely mirrored the Kaplan-survival curve of the non-vaccinated or vaccinated mice and helped
predict when mice would become morbid. Moribund mice in the NVC groups showed severe
weight and temperature loss which paralleled the increase of the cumulative disease scores
starting at day 5 post challenge (Supp. Fig.2, Fig. 2DE). Immunized mice had overall lower
disease scores compared to NVC. Mice immunized with β RBD HBsAg+Al challenged with Alpha,
or Beta showed elevated disease scores beginning at day 5 for Alpha challenged and day 6 for
Beta challenged mice that mirrored survival data, whereas mice immunized with β/Wu RBD
HBsAg+Al did not show disease progression and maintained weight and temperature through the
course of the study (Fig.2DE, Supp. Fig.2). SWE adjuvanted β RBD HBsAg immunized mice
challenged with Alpha, or Beta had little to no detectable signs of disease and sustained weight
and temperature throughout the course of the study (Fig.2DE, Supp. Fig.2). However, without the
HBsAg VLP, mice immunized with β RBD+SWE challenge with Alpha or Beta experienced a sharp
increase of disease scores starting at days 5 and 6 post challenge, as well as dramatic weight
and temperature loss (Fig.2DE, Supp. Fig.2). Pfizer mRNA immunized mice also did not
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demonstrate disease onset during the study (Fig.2DE, Supp. Fig.2). Overall, survival and disease
scores of the vaccinated K-18 hACE2 mice indicated that β/Wu RBD HBsAg+Al compared to β
RBD HBsAg+Al and β RBD HBsAg+SWE compared to β RBD+SWE provided better protection
encompassing survival and prevention of disease against Alpha or Beta challenge.

Adjuvanted RBD VLP and mRNA vaccines significantly decreased viral RNA burden in the
lung compared to no vaccine, VOC challenged animals. To corroborate survival and disease
data, viral RNA burden was measured in the lung and brain of VOC challenged animals. Both
β/Wu RBD HBsAg+Al and β RBD HBsAg+Al immunized mice significantly decreased Alpha and
Beta viral RNA burden in the lung compared to NVC (Fig.3A). However, in the brain, β/Wu RBD
HBsAg+Al was capable of significantly lowering viral RNA burden against Alpha or Beta challenge
but β RBD HBsAg+Al did not lower Alpha or Beta viral RNA burden (Fig.3B). The elevated levels
of viral RNA in the brain in β RBD HBsAg+Al immunized mice suggested that dissemination into
the brain increased mortality. β RBD HBsAg+SWE significantly lowered Alpha or Beta viral RNA
burden to the limit of detection in both the lung and the brain compared to NVC and RBD+SWE
(Fig. 3AB). β RBD+SWE failed to lower viral RNA burden compared to NVC Alpha or Beta in both
the lung and brain suggesting that the Hepatitis B antigen VLP is necessary for a significant
decrease of viral RNA burden (Fig.3AB). Lastly, Pfizer mRNA was also able to significantly reduce
viral Alpha or Beta RNA in both the lung and brain (Fig.3AB). Altogether, this data suggested that
both Beta and Wuhan RBDs are necessary in the Alum adjuvanted vaccine to prevent VOC
dissemination into the brain. Furthermore, β RBD HBsAg+SWE similar to Pfizer mRNA can
diminish viral replication and dissemination in the both the lung and brain.
RBD HBsAg+SWE vaccination generated cross neutralizing antibodies against VOC.
Neutralizing antibodies of SARS-CoV-2 provide the first line of defense for COVID-19 vaccine
protection (38,39). Since the antigens used in the β RBD HBsAg+Al and β/Wu RBD HBsAg+Al
vaccine formulations in this study originated from Wuhan or Beta SARS-CoV-2 it is important to
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determine vaccine generation of cross neutralizing antibodies against the various VOC. To
evaluate antibody cross-neutralizing capacity of the RBD HBsAg VLP vaccines against Beta or
Alpha VOC challenge, in vitro human ACE2 to RBD VOC binding were assessed using the MSD
neutralization assay platform. In this study, the RBD of the five major Variants of Concern, Alpha,
Beta, Gamma, Delta, and Omicron VOC were evaluated compared to the ancestral strain of
SARS-CoV-2. Mice vaccinated with β RBD HBsAg+Al or β/Wu RBD HBsAg+Al had similar
neutralization profiles across the RBD VOC; however, there was a reduction of neutralization
against Omicron RBD in both challenge with Beta or Alpha VOC (Fig.4, Supp.Fig.3). However,
mice vaccinated with β RBD HBsAg adjuvanted with SWE along with mice vaccinated with mRNA
generated robust neutralizing antibodies across all RBD VOC (Fig.4). β RBD HBsAg adjuvanted
with SWE provided a significant induction of cross neutralizing antibodies that could inhibit the
binding of hACE2 to Wuhan, Alpha, Beta, Delta, and Omicron RBD compared to NVC (Fig.4,
Supp. Fig 3). However, immunization with β RBD+SWE did not generate significant neutralizing
titers against VOC RBD suggesting that HBsAg is needed to produce functional antibodies
against SARS-CoV-2 (Fig. 4 and Supp. Fig. 3). Thus, the neutralizing antibody profiles
demonstrate that RBD HBsAg VLP vaccines provided breath of neutralizing antibodies against all
major VOC similar to Pfizer mRNA immunization compared to unconjugated RBD vaccines.

β/Wu RBD HBsAg+Al and Pfizer mRNA vaccinations lowered both acute and chronic
inflammation in the lung during Alpha or Beta challenge. COVID-19 can cause severe
inflammation in the lungs (40). Therefore, histopathological analysis was performed on nonvaccinated or vaccinated mouse lungs at time of euthanasia due to morbidity or the end of the
experiment at day 11 to investigate whether RBD HBsAg VLP vaccines in this study alleviated
inflammation from Alpha or Beta challenge. Chronic and acute inflammation was assessed in the
lung parenchyma, blood vessels, and airways (Supp. Fig.4AB). The presence of infiltrating
lymphocytes and plasma cells characterized chronic inflammation and acute inflammation was
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identified by recruitment of neutrophils and edema (Supp. Fig.4AB). Total inflammation scores
were determined by the addition of both chronic and acute inflammation scores. Mice in the NVC
group challenged with either Alpha or Beta exhibited mixed inflammation comprising of both
chronic and acute inflammation present in the lung parenchyma and blood vessels showing large
aggregates of inflammatory cells (Fig.5AB, Supp. Fig. 4CDEF). NVC groups challenged with
Alpha, or Beta had average inflammation scores (average of total inflammation between chronic
and acute scores) of 4.6 and 4.2 respectively (Fig.5DE). Mice immunized with β RBD+SWE and
challenged with Alpha or Beta experienced higher chronic and acute inflammation scores than
NVC groups with an average inflammation score of 7.2 and 5.2 respectively (Fig. 5DE, Supp Fig.
4CDEF). β RBD+SWE immunized mice challenged with Alpha also had significantly elevated
chronic and acute inflammation scores and significantly increased acute inflammation scores in
Beta challenged mice compared to NVNC (Fig. 5C, Supp. Fig. 4CDEF). Additionally, RBD+SWE
vaccinated lungs also showed an infiltration of alveolar macrophages, neutrophils, presence of
eosinophilic material, and exhibited vascular thrombosis which may indicate the poor disease
prognosis of β RBD+SWE vaccinated mice (Supp. Fig.5). Interestingly, β RBD HBsAg+SWE
vaccinated mice challenged with Alpha, or Beta also demonstrated relatively increased chronic
and acute inflammation levels compared to other protective vaccines (β/Wu RBD HBsAg+Al and
Pfizer mRNA) with average inflammation scores of 3.2 and 2.6 (Fig. 5DE). Alveolar macrophages
and eosinophilic material in the alveoli were also found in β RBD HBsAg+SWE vaccinated in
lungs primarily in the Alpha challenged group suggesting SWE adjuvant may be more
inflammatory than Alum adjuvant (Fig. 5AB). β/Wu RBD HBsAg+Al and β RBD HBsAg+Al lungs
had similar low chronic and acute inflammation scores against Beta challenge; however, β/Wu
RBD HBsAg+Al immunization was able to significantly decrease total chronic inflammation scores
against Alpha challenge compared to NVC (Fig. 5DE). Pfizer mRNA also demonstrated lowered
chronic and acute inflammation compared to NVC (Fig. 5, Supp. Fig. 4CDEF). Overall, mice
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immunized with SWE formulations had elevated inflammation in the lung compared to vaccines
adjuvanted with Alum or Pfizer mRNA.
3.6 Discussion
As the pandemic continues, global vaccine disparities remain a major problem. In lower income
areas of the world, such as in Africa, 16% or less of the population have received a single dose
of a COVID-19 vaccine. Organizations such as the WHO, Gavi, and CEPI have teamed together
to provide global access to COVID-19 vaccines and treatments. However, due to many issues
involving lack of funds, supply, and participation from upper income countries, these organizations
have faced setbacks providing vaccines to lower-income countries. Despite these difficulties, at
the end of 2021, these organizations delivered approximately 300 million doses to primarily 144
low- and middle-income countries (41). With 194 or more COVID-19 vaccine candidates in preclinical stages and greater than 120 vaccines in clinical trials, there is a possibility that the
production of these vaccines can help alleviate the supply chain issues. The development of
protein-based subunit COVID-19 vaccines can especially aid in relieving supply as well as
delivery and storage issues to lower-income countries. Protein-based vaccines are distinguished
by inexpensive manufacturing cost as well as stability at a wide range of temperatures for
shipment and storage, all of which can benefit low-income countries (42,43).
Currently, the spike nanoparticle protein vaccine developed by Novavax is the only WHO
approved protein subunit vaccine in distribution. Nevertheless, at this time, there are over 46
protein-based vaccines under clinical investigation (44). However, there are no approved COVID19 VLP vaccines that are authorized for human use currently. Interestingly, three COVID-19
protein decorated VLP vaccines are in phase 1-3 clinical trials. CoVLP developed by Medicago is
composed of a plant based VLP decorated with the ancestral spike protein and adjuvanted with
Adjuvant System 03 (ASO3). In phase 3 clinical trials, the vaccine efficacy of CoVLP was 69.5%
effective at preventing symptomatic infections and 78.8% against moderate-severe COVID-19
infections across multiple VOC (45,46). The second COVID-19 VLP vaccine in clinical trials is
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VBI-2902a. VBI-2902a is developed by VBI Vaccines and formulated with Wuhan spike protein
displayed on enveloped virus like particles derived from murine leukemia virus adjuvanted with
Alum (47). In pre-clinical trials, VBI-2902a induced neutralizing antibodies against SARS-CoV-2
as well as decreased viral burden and lung inflammation in SARS-CoV-2 challenged hamsters
(47). Furthermore, in phase 1 clinical trials, VBI-2902a was well tolerated amongst recipients and
generated functional antibody titers (48). Lastly, SARS-CoV-2 VLP Vaccine, developed by The
Scientific and Technological Research Council of Turkey is in phase 1 clinical trials. SARS-CoV2 VLP Vaccine is composed of SARS-CoV-2 membrane, envelope, nucleocapsid and spike
protein decorated on a VLP adjuvanted with alum and CPGoDN-K3 (49). Additionally, despite
most protein vaccines utilizing the spike protein as the main vaccine antigen, there are multiple
RBD based protein vaccines in clinical trials. For example, manufacturers such as Serum Institute
of India, Biological E, and SK Bioscience have developed RBD based protein vaccines, as well
as other institutes such as Finlay Vaccine Institute and The Center for Genetic Engineering and
Biotechnology in Cuba, and Texas Children’s Hospital and Baylor College of Medicine (27,50).
Altogether, the numerous protein COVID-19 vaccines that are under pre-clinical and clinical
investigation can help alleviate the global shortage of COVID-19 vaccines.
Here, four experimental protein subunit COVID-19 vaccines utilizing a Hepatitis B surface antigen
Virus-like particle decorated with RBD as the vaccine antigen, adjuvanted with either Alum or
SWE, were evaluated in K18-hACE2 mice against Alpha or Beta challenge (51–53). All
experimental RBD HBsAg VLP vaccines were compared to the standard 2 dose Pfizer mRNA
vaccine. Our first goal was to assess the correlates of protection associated with utilizing both
ancestral SARS-CoV-2 and Beta RBD VLP in a vaccine formulation compared to Beta RBD VLP.
Interestingly, only RBD HBsAg from both Beta and Wuhan in one formulation adjuvanted with
Alum was able to fully protect mice against Alpha or Beta challenge (100% survival) (Fig.2) and
decreased viral RNA in the lung and brain. Whereas β RBD HBsAg+Al provided partial protection
from Alpha (60% survival) or Beta (80% survival) challenge (Fig.2), and significantly lowered viral
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burden in the lung against Alpha or Beta challenge (Fig. 3). However, both alum adjuvanted RBD
HBsAg vaccines were able to generate functional antibodies against RBD (Fig.1, Fig. 2) and
decrease inflammation in the lung (Fig.5). Next, our second goal was to evaluate whether HBsAg
VLP was necessary for protection as well as assess the outcome of utilizing SWE instead of Alum
adjuvant on vaccine efficacy and immunogenicity. Beta RBD HBsAg adjuvanted with SWE
vaccinated K18-hACE2 mice were protected against both Alpha or Beta challenge, induced a
robust systemic RBD IgG response (Fig. 1), generated broadly neutralizing antibodies against
VOC RBDs (Fig. 4), and lowered viral RNA burden in the lung and brain (Fig. 3) similar to the
outcome of Pfizer vaccinated mice. Without the HBsAg VLP, RBD alone adjuvanted with SWE
was not able to protect mice from Alpha or Beta challenge (Fig.2) or induce an immune response
(Fig. 1,4). We acknowledge our study contained limitations such as not measuring infectious
particles through plaque forming units (PFUs) in the murine challenge studies. However, in this
study we prioritized using survival as a measure of protection instead of determining infectious
viral burden. Studies have shown that after day 2 of challenge, PFUs begin to decrease (54,55).
In our vaccine and challenge studies, non-protected mice do not begin to become morbid until
day 5 or 6, and protected mice do not develop disease throughout the 11- day study, limiting the
possibility of obtaining infectious virus. For future murine vaccine and challenge studies with
SARS-CoV-2, we plan on performing time points at day 2 post challenge to assess PFUs as well
as day 11 post challenge to evaluate survival.
With the lack of vaccines being delivered to rural countries, it is pertinent that the COVID-19
vaccines that these countries are receiving can deliver strong, long lasting immune responses
with limited dose series. Vaccine adjuvants can help increase immune responses (both cellular
and humoral) to target antigens, as well promote long-term protection (56,57). In this study, we
used both Aluminum hydroxide or SWE to enhance the response of the RBD HBsAg antigen.
Alum has been safely used in many vaccine formulations to date and is known to elicit a strong
antibody response. The squalene in water emulsion, SWE adjuvant was developed by the non106

profit organization, Vaccine Formulation Institute, and is made available to the entire vaccine
community with the goal of accelerating the development of COVID-19 vaccines. Similar to its
counterpart MF59, oil in water emulsions also generate robust antibody responses. In this study,
Alum adjuvanted RBD HBsAg generated less breadth of cross reactive RBD IgG antibodies
across 10 VOC (Fig.1) compared to the SWE adjuvanted VLP as well as did not significantly
produce broadly neutralizing antibodies across 5 major SARS-CoV-2 VOC (Fig.4) Alternatively,
RBD HBsAg adjuvanted with SWE was able to induce robust RBD IgG response similar to the
Pfizer mRNA RBD IgG titers (Fig.1) as well as elicit a significant broadly neutralizing antibody
response against 3 out of 5 RBD VOC (Fig.4). Both vaccines offered protection to mice after
challenge with VOC; however only the SWE adjuvanted RBD HBsAg vaccine was able to induce
cross neutralizing antibodies that recognized all 10 variants of SARS-CoV-2 suggesting that SWE
elicited a stronger antibody response that was able to aid in protection. We hypothesize that since
SWE significantly elevated the broadly neutralizing antibody response in vaccinated mice
compared to Alum, that the SWE adjuvant would also increase longevity of vaccine efficacy.
However, further studies are needed to evaluate long-term protection of SWE adjuvanted RBDHBsAg vaccines. We also acknowledge in this study that three doses of the RBD HBsAg+SWE
were used to immunize mice. However, due to the dose sparing nature of SWE, vaccine efficacy
of one or two dose administration to mice of RBD HBsAg+SWE could have been further
investigated and compared to receiving three doses of vaccine.

Neutralizing antibodies against SARS-CoV-2 are the first line of vaccine protection against
COVID-19. Therefore, in this study, vaccine induced antibody responses against RBD on SARSCoV-2 were characterized. Additionally, T-cell responses including CD4 and CD8 T-cells, also
play a crucial role in controlling COVID-19 by decreasing viral replication (58–61). Evaluation of
T-cell responses are essential to understand the full protection profile generated from both SWE
or Alum adjuvanted RBD VLP vaccines. The robust RBD specific IgG antibody responses elicited
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from RBD HBsAg + SWE suggests that antigen specific CD4+ T cells are playing a role in
activating SARS-CoV-2 B-cell responses. In this study, Pfizer mRNA vaccinated mice also
generated a strong antibody response and broadly neutralizing antibodies against multiple VOC
similar to the RBD HBsAg+SWE. In humans, cellular responses remained detectable after 6
months after 2 doses of Pfizer mRNA with high detection of spike specific CD4+ T-cells (59).
Thus, we hypothesized that SWE adjuvanted RBD-VLP vaccines will elicit antigen specific B and
T cell responses compared to the Alum adjuvanted vaccines. Further investigation is needed to
evaluate the T-cell populations generated after vaccination with RBD-HBsAg adjuvanted with
SWE or Alum and how they play a role in protection during challenge with different VOC.

The target vaccine antigen utilized in this study was the receptor binding domain (RBD) of the
SARS-CoV-2 spike protein. RBD is a relatively small protein with the molecular weight of 25kDA,
whereas the full spike protein has a molecular weight of 78.3kDA. Currently, all the WHO
approved vaccines utilize the spike protein as the primary vaccine antigen. Utilization of the full
spike protein as a vaccine antigen offers numerous immunological benefits. The spike protein
offers more immunodominant T-cell epitopes that can elicit CD4+, T follicular helper cell, and CD8
responses against SARS-CoV-2 compared to RBD alone (38,62–64). Despite numerous
immunological advantages of using the spike protein compared to RBD alone, the spike protein
is more difficult to manufacture compared to RBD that can be easily expressed and produced in
large scale in microbial host such as yeast. Therefore, RBD-based vaccines may help facilitate
COVID-19 vaccine production and distribution in lower-income countries (11,65–67).

Emergence of new SARS-CoV-2 VOC have dampened vaccine effectiveness causing vaccine
breakthrough cases facilitating transmission of the virus. VOC also prompted vaccine
manufacturers to begin designing variant specific vaccines to replace vaccines derived from the
ancestral strain of SARS-CoV-2 (68). At the time of this study, outbreaks of the Beta variant had
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started to occur in South Africa triggering concerns around the world (69,70). Therefore, to
prevent further deleterious consequences from Beta, we decided to evaluate the RBD from the
Beta variant in vaccine formulations in this study. Beta unlike its predecessor Alpha, contains 9
mutations located on the spike protein (18F, D80A, D215G, R246I, K417N, E484K, N501Y,
D614G, and A701V) and from these, three mutations (K417N, E484K, N501Y) are on the RBD
(2,71). Previous studies performed with human convalescent plasma obtained from a patient
infected with the ancestral strain of SARS-CoV-2 demonstrated that convalescent plasma was
not able to protect against Beta challenge in mice (26). Furthermore, these mutations on Beta
were shown to decrease vaccine efficacy as well as reduce neutralization efficacy in monoclonal
antibody and convalescent antibody treatments (72–74). However, the frequency of detection of
Beta did not go above 13% and did not persist past July 2021 unlike Alpha or other variants
(75,76). Even though the Beta variant did not persist, our studies demonstrated that RBD HBsAg
vaccines formulated with Beta RBD HBsAg offered protection against Alpha VOC as well as
generated a breadth of neutralizing antibodies against multiple SARS-CoV-2 VOC suggesting
that these vaccines could be protective against other VOC.
In summary, RBD HBsAg is an immunogenic antigen but when adjuvanted with either Alum or
SWE provided protection to mice challenged with Alpha or Beta variant. Protection profiles
generated by RBD HBsAg vaccines were similar to those produced by mRNA Pfizer vaccination.
Evaluation of RBD HBsAg adjuvanted with Alum or SWE in pre-clinical murine studies allowed
for the advancement of these vaccines into phase 1/2 clinical trials in Australia. In the future, RBDVLP vaccines as well as other protein subunit vaccines will help alleviate the vaccine disparity
gap caused by COVID-19.

3.7 Acknowledgements
We would like to thank Serum Institute of India for providing HBsAg VLP, SpyBiotech for providing
their SpyTag and SpyCatcher technology, the Love Lab at MIT for providing the RBD antigens,
109

and SEPPIC and the Vaccine Formulation Institute for supplying SWE adjuvant. FHD and the
VDC are supported by the Research Challenge Grant no. HEPC.dsr.18.6 from the Division of
Science and Research, WV Higher Education Policy Commission. This project was supported by
the Serum Institute of India. MSD QuickPlex SQ120 in the WVU Flow Cytometry & Single Cell
Core Facility is supported by the Institutional Development Awards (IDeA) from the National
Institute of General Medical Sciences of the National Institutes of Health under grant numbers
P30GM121322 (TME CoBRE) and P20GM103434 751 (INBRE). We would also like to
acknowledge Mary Tomago-Chesney at the WVU Pathology Department for sectioning and
performing H&E staining on lung tissues, as well as Dr. Christopher Gibson (iHisto) for performing
histopathologic scoring on the lungs.
Author contributions. Studies were designed by SII, FHD, and JRB. All authors contributed to
the execution of these studies. SARA, NCD, RSJ, and JCL provided and produced RBD antigens
for vaccine formulations. SII supplied HBsAg and provided vaccines for immunization. TYW, JK,
and KSL vaccinated mice. MTW and IM prepared and provided viral stocks of Alpha and Beta
variants for murine challenge. Animal daily disease assessment, necropsy and tissue processing
were performed by FHD, MB, HAC, TYW, BPR, KSL and JRB. Serological analysis was
conducted by SII. qPCR to determine viral RNA burden was performed by BPR and OAM. MSD
neutralization was performed by MC. All authors contributed to the writing and revision of this
manuscript. Data was analyzed by TYW and FHD.

110

3.8 Figures.
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Figure 1. Characterization of RBD IgG antibody responses against 10 SARS-CoV-2 VOC
RBDs. A) Depiction of assembly of β or Wuhan RBD on HBsAg using SpyTag and SpyCatcher
technology. B) Schematic of K18 hACE2 mouse immunization and serological assessment
schedule. C) MSD V-PLEX SARS-CoV-2 IgG Panel 11 was used to determine RBD IgG levels.
Heat map depicts mean values of IgG (AU/mL) generated from each mouse RBD IgG titers were
measured against 10 VOC RBDs at 2 weeks post prime. D) 4 weeks post 2nd dose RBD IgG titers
against 10 VOC RBDs. E-H) RBD IgG titers from 2 weeks post prime and 4 weeks post 2nd dose
against Wuhan, Alpha, Beta, and Delta RBD VOC respectively. IgG titers represented as log
AU/mL. Two-Way ANOVA with Sidak’s multiple comparisons test was performed for statistical
analysis. P<0.0001 ****. Dotted line represents limit of detection for the specific RBD variant.

112

Figure 2. Evaluation of RBD-VLP and mRNA vaccine protection against VOC challenge. A)
Vaccine and challenge experimental timeline in K18-hACE2 mice. Mice were intramuscularly
administered three doses of either β RBD HBsAg+Al, β/Wu RBD HBsAg+Al, β RBD HBsAg +
SWE, or β RBD+SWE. Pfizer mRNA vaccinated mice were administered 2 doses of vaccine.
Vaccinated mice were bled every 2 weeks post vaccine dose. Mice were intranasally challenged
with 104 PFU/dose of either Alpha or Beta variant and monitored for 11 days after challenge. B)
Kaplan Meier survival curve shows percent survival of NVNC (n=5), NVC (n=5), β RBD HBsAg+Al
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(n=5) P=0.0143*, β/Wu RBD HBsAg+Al (n=5) P=0.0027**, β RBD HBsAg + SWE (n=5)
P=0.0027**, β RBD+SWE (n=5) or Pfizer mRNA (n=5) P=0.0027** challenged with Alpha. C)
Kaplan Meier survival curve of NVNC (n=5), NVC (n=5), β RBD HBsAg+Al (n=5) P=0.0411*, β/Wu
RBD HBsAg+Al (n=4) P=0.0237*, β RBD HBsAg + SWE (n=5) P=0.0143*, β RBD+SWE (n=5) or
Pfizer mRNA (n=5) P=0.0143* challenged with Beta. Log-rank (Mantel-Cox) test determined
statistical significance between NVC compared to respective vaccine groups. D-E) Daily disease
scores of Alpha or Beta challenged mice respectively.
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Figure 3. Determination of viral RNA burden in VOC challenged mice. 100ng of lung and
brain were assessed for nucleocapsid RNA copies. Violin plots depict SARS-CoV-2 RNA copies
in the A) right lobe of the lung and B) brain. Left side of the bold vertical dotted line represents
mice challenge with Alpha and right side represents mice challenged with Beta. Horizontal dotted
line represents the limit of detection calculated with the NVNC viral copy numbers. Ordinary oneway ANOVA with Tukey’s multiple comparisons test was performed for statistical analysis
amongst the Alpha or Beta challenged groups. Asterisks denote significant difference compared
to NVC and # symbol indicates significant difference compared to RBD+SWE. For lung,
P<0.0001****, P=0.0187* (NVCβ vs β RBD HBsAg+Al), P=0.0035** (NVCα vs β/Wu RBD
HBsAg+Al), P=0.0014** (NVCα vs β RBD HBsAg+SWE), P=0.0089** (NVCβ vs β/Wu RBD
HBsAg+Al), and P=0.0052** (NVCβ vs β RBD HBsAg+SWE), P=0.0014## (β RBD HBsAg+SWE
vs. β RBD+SWE). For brain, P=0.0231* (NVCα vs mRNA), 0.0452# (β RBD HBsAg+SWE vs
RBD+SWE), 0.0495* (NVCβ vs mRNA). P=0.0035** (NVCα vs β/Wu RBD HBsAg+Al),
P=0.0014** (NVCα vs β RBD HBsAg+SWE), P=0.0089** (NVCβ vs β/Wu RBD HBsAg+Al), and
P=0.0052** (NVCβ vs β RBD HBsAg+SWE).
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Figure 4. RBD HBsAg+SWE induced broadly neutralizing antibodies against VOC RBD.
MSD V-PLEX SARS-CoV-2 Panel 22 (ACE2) kit with 5 VOC and Wuhan RBD was used to
measure serum antibody neutralization in Beta challenged mice in immunized and nonimmunized mice. All values were depicted as % inhibition. Negative % inhibition values were not
represented in the analysis. Percent inhibition of neutralizing antibodies measured against A)
Wuhan, B) Alpha, C) Beta, D) Gamma, E) Delta, and F) Omicron respectively. Dotted line
represents neutralizing antibody levels of NVNC. Results represented as mean ± SD. KruskalWallis test with Dunn’s multiple comparisons test were conducted for statistical analysis. Asterisks
denote significant difference compared to NVC and # symbol indicates significant difference
compared to RBD+SWE. Wuhan. P=0.0063*. Alpha. P=0.00319* (NVC vs RBD HBsAg+SWE)
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P=0.0019** (NVC vs mRNA) Beta. P=0.0081* (NVC vs mRNA. Gamma. P=0.0151* (NVC vs
mRNA), P=0.0461# (RBD HBsAg+SWE vs RBD+SWE).

Delta. P=0.0319* (NVC vs RBD

HBsAg+SWE), P=0.0045**(NVC vs mRNA). Omicron. P=0.0213* (NVC vs mRNA), P=0.0029**
(NVC vs RBD HBsAg+SWE).
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Figure 5. Histopathological analysis of the lung in vaccinated mice challenged with VOC.
A) H&E-stained lungs from vaccinated groups that were Alpha challenged. B) H&E-stained lungs
from vaccinated groups that were Beta challenged. C) No vaccine no challenge (NVNC) H&Estained lungs represented at 100X magnification. D) Alpha challenged total inflammation scores
(chronic + acute inflammation scores). P=0.0213# (NVNC vs. β RBD+SWE) and P=0.0251*
(NVCα vs mRNA). E) Beta challenged total inflammation scores. P=0.0341# (NVNC vs. NVC-β),
and P=0.0062## (NVNC vs. β RBD+SWE). Red dots represent mice that were euthanized due to
morbidity before the termination of the study at day 11. Results represented as mean ± SD.
Kruskal-Wallis with Dunn’s multiple comparisons test was performed for statistical analysis.
Asterisks denote significant difference compared to NVC and # symbol indicates significant
difference compared to NVNC.
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3.9 Supplemental Figures

Supplemental Table 1. COVID-19 vaccine formulations. Composition of the five vaccines
intramuscularly administered to K18-hACE2 mice.
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RBD strain
Wuhan
Wuhan
Wuhan
Wuhan
Wuhan
Wuhan
Wuhan
Wuhan
Wuhan
Wuhan
Wuhan
Wuhan
Wuhan
Wuhan

Vaccine groups
Prime
β RBD HBsAg+Al vs β RBD HBsAg+SWE
β RBD HBsAg+Al vs Pfizer mRNA
β/Wu RBD HBsAg+Al vs β RBD HBsAg+SWE
β/Wu RBD HBsAg+Al vs Pfizer mRNA
β RBD HBsAg+SWE vs β RBD+SWE
β RBD HBsAg+SWE vs Pfizer
β RBD+SWE vs Pfizer
Boost 2
β RBD HBsAg+Al vs β RBD HBsAg+SWE
β RBD HBsAg+Al vs β RBD+SWE
β RBD HBsAg+Al vs Pfizer mRNA
β/Wu RBD HBsAg+Al vs β RBD+SWE
β RBD HBsAg+SWE vs β RBD+SWE
β RBD+SWE vs Pfizer

RBD strain
Alpha
Alpha
Alpha
Alpha
Alpha
Alpha
Alpha
Alpha
Alpha
Alpha
Alpha
Alpha
Alpha
Alpha
Alpha
Alpha

Summary
****
****
****
****
****
****
****

Adjusted P value
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001

***
****
***
****
****
****

0.0003
<0.0001
0.0007
<0.0001
<0.0001
<0.0001

Prime
β RBD HBsAg+Al vs β RBD HBsAg+SWE
β RBD HBsAg+Al vs Pfizer mRNA
β/Wu RBD HBsAg+Al vs β RBD HBsAg+SWE
β/Wu RBD HBsAg+Al vs Pfizer mRNA
β RBD HBsAg+SWE vs β RBD+SWE
β RBD HBsAg+SWE vs Pfizer
β RBD+SWE vs Pfizer
Boost 2
β RBD HBsAg+Al vs β RBD HBsAg+SWE
β RBD HBsAg+Al vs β RBD+SWE
β RBD HBsAg+Al vs Pfizer mRNA
β/Wu RBD HBsAg+Al vs β RBD HBsAg+SWE
β/Wu RBD HBsAg+Al vs β RBD+SWE
β/Wu RBD HBsAg+Al vs Pfizer mRNA
β RBD HBsAg+SWE vs β RBD+SWE
β RBD+SWE vs Pfizer mRNA

Summary
****
****
****
****
****
****
****

Adjusted P value
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001

***
****
***
**
****
*
****
****

0.0003
<0.0001
0.0001
0.0069
<0.0001
0.0123
<0.0001
<0.0001

RBD strain
Beta
Beta
Beta
Beta
Beta
Beta
Beta
Beta
Beta
Beta
Beta
Beta
Beta
Beta
Beta
Beta

Prime
β RBD HBsAg+Al vs β RBD HBsAg+SWE
β RBD HBsAg+Al vs Pfizer mRNA
β/Wu RBD HBsAg+Al vs β RBD HBsAg+SWE
β/Wu RBD HBsAg+Al vs Pfizer mRNA
β RBD HBsAg+SWE vs β RBD+SWE
β RBD HBsAg+SWE vs Pfizer
β RBD+SWE vs Pfizer
Boost 2
β RBD HBsAg+Al vs β RBD HBsAg+SWE
β RBD HBsAg+Al vs β RBD+SWE
β RBD HBsAg+Al vs Pfizer mRNA
β/Wu RBD HBsAg+Al vs β RBD HBsAg+SWE
β/Wu RBD HBsAg+Al vs β RBD+SWE
β/Wu RBD HBsAg+Al vs Pfizer mRNA
β RBD HBsAg+SWE vs β RBD+SWE
β RBD+SWE vs Pfizer

Summary
****
****
****
****
****
****
****

Adjusted P value
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001

***
****
**
***
****
**
****
****

0.0003
<0.0001
0.0016
0.0005
<0.0001
0.0038
<0.0001
<0.0001

RBD strain
Delta
Delta
Delta
Delta
Delta
Delta
Delta
Delta
Delta
Delta
Delta
Delta
Delta
Delta

Prime
β RBD HBsAg+Al vs β RBD HBsAg+SWE
β RBD HBsAg+Al vs Pfizer mRNA
β/Wu RBD HBsAg+Al vs β RBD HBsAg+SWE
β/Wu RBD HBsAg+Al vs Pfizer mRNA
β RBD HBsAg+SWE vs β RBD+SWE
β RBD HBsAg+SWE vs Pfizer mRNA
β RBD+SWE vs Pfizer mRNA
Boost 2
β RBD HBsAg+Al vs β RBD HBsAg+SWE
β RBD HBsAg+Al vs β RBD+SWE
β RBD HBsAg+Al vs Pfizer mRNA
β/Wu RBD HBsAg+Al vs β RBD+SWE
β RBD HBsAg+SWE vs β RBD+SWE
β RBD+SWE vs Pfizer mRNA

Summary
****
****
****
****
****
****
****

Adjusted P value
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001

**
****
**
****
****
****

0.0015
<0.0001
0.0032
<0.0001
<0.0001
<0.0001

Supplemental Table 2. Statistical analysis of VOC RBD IgG levels at 2 weeks post prime and 4
weeks post second boost. Two-way ANOVA mixed-effects analysis was performed with Sidak’s
multiple comparisons test for statistical analysis.
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Supplemental Figure 1. RBD IgG titers from 2 weeks post prime (prime) and 4 weeks post 2nd
dose (boost 2) against Wuhan, Alpha, Beta, and Delta RBD VOC respectively. Ordinary one-way
ANOVA with Tukey’s multiple comparisons test was performed for statistical analysis. Dotted line
represents limit of detection for the specific RBD variant. IgG titers represented as log AU/mL. A)
Wuhan RBD IgG titers from 2 weeks post prime. P<0.0001 ****. B) Wuhan RBD IgG from 4 weeks
post 2nd dose. P<0.0001****, β RBD HBsAg+Al vs. β RBD HBsAg+SWE P<0.0104*, and β RBD
HBsAg+Al vs. mRNA P<0.0177*. C) Alpha RBD IgG from 2 weeks post prime. P<0.0001 ****. D)
Alpha from 4 weeks post 2nd dose. P<0.0001****, β RBD HBsAg+Al vs. β RBD HBsAg+SWE
P<0.0032**, and β RBD HBsAg+Al vs. mRNA P<0.0060**. E) Beta RBD IgG from 2 weeks post
prime. P<0.0001 ****. F) Beta from 4 weeks post 2nd dose. β RBD HBsAg+Al vs. β RBD
HBsAg+SWE, and β RBD HBsAg+Al vs. β RBD+SWE P<0.0023**. β/Wu RBD HBsAg+Al vs. β
RBD HBsAg+SWE, and β/Wu RBD HBsAg+Al vs. β RBD+SWE P<0.0047**. β RBD HBsAg+Al
vs. mRNA P<0.0106*. β/Wu RBD HBsAg+Al vs. mRNA P<0.0191*. G) Delta RBD IgG titers from
2 weeks post prime. P<0.0001 ****. H) Delta from 4 weeks post 2nd dose. P<0.0001****. β RBD
HBsAg+Al vs. β RBD HBsAg+SWE P<0.0223*, and β RBD HBsAg+Al vs. mRNA P<0.0353*.
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Supplemental Figure 2. Evaluation of weight and temperature change from K18-hACE2
vaccinated mice against Alpha or Beta challenge. A) % weight change of NVNC and vaccinated
mice challenged with Alpha or Beta. B) % temperature change of NVNC and vaccinated mice
challenged with Alpha or Beta.

123

Supplemental Figure 3. Analysis of vaccine induced neutralizing antibodies against 5 major VOC
during Alpha challenge. MSD V-PLEX SARS-CoV-2 Panel 22 (ACE2) kit with 5 VOC and Wuhan
RBD was used to measure serum antibody neutralization in Alpha challenged mice in immunized
and non-immunized mice. All values were depicted as % inhibition. Negative % inhibition values
were not represented in the analysis. Percent inhibition of neutralizing antibodies measured
against A) Wuhan, B) Alpha, C) Beta, D) Gamma, E) Delta, and F) Omicron respectively. Dotted
line represents neutralizing antibody levels of NVNC. Results represented as mean ± SD. KruskalWallis test with Dunn’s multiple comparisons test were conducted for statistical analysis. Wuhan.
P=0.0024**. Alpha. P=0.0012**. Beta. P=0.0382* (NVC vs. RBD HBsAg+Al), P=0.0208* (NVC
vs. RBD HBsAg + SWE), P=0.0005*** (NVC vs mRNA). Gamma. P=0.0484*, P=0.0007***. Delta.
P=0.0340*, P=0.0007***. Omicron. P=0.0049**, P=0.0007***.
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Supplemental Figure 4. Chronic and acute inflammation in non-vaccinated and vaccinated
lungs. A) Example of chronic inflammation denoted by infiltration of lymphocytes and plasma
within the parenchyma shown by the asterisks, as well as surrounding blood vessels marked by
the arrow. 100X magnification. B) Example of acute inflammation denoted by neutrophils
surrounding blood vessels. 400X magnification. C) Alpha challenged chronic inflammation scores.
P=0.0322* (NVNC vs. β RBD+SWE), P=0.0470* (NVCα vs β/Wu RBD HBsAg+Al) P=0.0164*
(NVCα vs mRNA) P=0.0109* (β/Wu RBD HBsAg+Al vs β RBD+SWE) E) Beta challenged chronic
inflammation scores. E) Alpha challenged total acute inflammation scores. P=0.0101 (NVNC vs
β RBD+SWE), P=0.0101* (β/Wu RBD HBsAg+Al vs β RBD+SWE) (β RBD+SWE vs mRNA) (F)
Beta challenged total acute inflammation scores. P=0.0150*, P=0.0070**. Results represented as
mean ± SD. Kruskal-Wallis with Dunn’s multiple comparisons test was performed for statistical
analysis. Asterisks denote significant difference compared to NVC and # symbol indicates
significant difference compared to NVNC.
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Supplemental Figure 5. β RBD+SWE induced increased inflammation in the lung. A) Arrow
denotes inflammation and thrombus in the blood vessel of the lung in β RBD+SWE immunized
mouse (200X magnification).

B) 400X magnification of the lung demonstrates neutrophil

surrounding the blood vessel in β RBD+SWE immunized mouse.
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4.1 Abstract
SARS-CoV-2 is a viral respiratory pathogen responsible for the current global pandemic and the
disease that causes COVID-19. All current WHO approved COVID-19 vaccines are administered
through the muscular route. We have developed a prototype two-dose vaccine (BReC-CoV-2)
by combining the Receptor Binding Domain (RBD) antigen, via conjugation to Diphtheria toxoid
(EcoCRM®). The vaccine is adjuvanted with Bacterial Enzymatic Combinatorial Chemistry
(BECC), BECC470. Intranasal (IN) administration of BreC-CoV-2 in K18-hACE2 mice induced a
strong systemic and localized immune response in the respiratory tissues which provided
protection against the Washington strain of SARS-CoV-2. Protection provided after IN
administration of BReC-CoV-2 was associated with decreased viral RNA copies in the lung,
robust RBD IgA titers in the lung and nasal wash, and induction of broadly neutralizing antibodies
in the serum. We also observed that BReC-CoV-2 vaccination administered using an
intramuscular (IM) prime and IN boost protected mice from a lethal challenge dose of the Delta
variant of SARS-CoV-2. IN administration of BReC-CoV-2 provided better protection than IM only
administration to mice against lethal challenge dose of SARS-CoV-2. These data suggest that
the IN route of vaccination induces localized immune response that can better protect against
SARS-CoV-2 than the IM route in the upper respiratory tract.
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4.2 Introduction
As of January 2020, when the first SARS-CoV-2 genome was released, tremendous progress
has been made in developing vaccines against COVID-19. To date, there are greater than 200
vaccines being developed worldwide to combat SARS-CoV-2, the causative agent of the COVID19 pandemic (1). Currently, there are 8 vaccines that have been approved by WHO for
administration that are being used around the world and more than 8 billion COVID-19 vaccines
that have been given worldwide (2). Approved vaccinations for COVID-19 and most vaccines in
development have been administered or designed to be given through the intramuscular route.
Few COVID-19 vaccines under development are administered through the nasal route. Each
route of vaccination provides a unique protection profile for respiratory viruses. Intramuscular
vaccination produces a predominantly systemic immune response dominated mostly by serum
IgG and, resulting in minimal to no detectable mucosal immune response at the site of infection
(3,4). The vaccine response generated after intramuscular immunization can leave the upper
respiratory tract vulnerable to viral replication and dissemination because it lacks the mucosal
immune response generated by natural infection or intranasal vaccination (3). However,
intranasal vaccination may provide both a systemic and a robust local IgA response, as what
occurs during natural infection which may ultimately lead to total protection (3). In pre-clinical
studies, non-human primates vaccinated intramuscularly with Pfizer-BioNtech (BNT162b2)
intramuscularly and then challenged with SARS-CoV-2 had detectable SARS-CoV-2 RNA copies
in the nasal and oropharyngeal swabs collected after challenge (5). We hypothesize that a
vaccine must induce both mucosal and systemic immune responses to achieve sterilizing
immunity against SARS-CoV-2.
Vaccine platforms that utilize nanoparticles, carrier proteins, and virus like particles (VLPs) can
increase the immunogenicity of antigens increasing the size and quantity of the antigen presented
to the immune system(6). Novavax utilizes recombinant nanoparticle technology to increase
immunogenicity of the spike protein in their COVID-19 vaccine formulation(7). SpyBiotech and
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Serum Institute of India have developed a recombinant protein vaccine utilizing Hepatitis B
surface antigen VLP to display RBD in order to enhance immunogenicity by increasing the
quantity of RBD presented to the immune system (8). In our studies, we have generated a
recombinant COVID-19 vaccine containing the Receptor Binding Domain (RBD) of the SARSCoV-2 spike antigen conjugated to EcoCRM® (an E. coli expressed CRM197) (9). CRM197 has been
used in licensed vaccines for Streptococcus pneumoniae, Haemophilus influenzae b, and
Neisseria meningitidis to help increase the immunogenicity of polysaccharide antigens by
promoting a T cell dependent response (10–13). CRM197 has also been used to enhance the
immunogenicity of weakly immunogenic proteins. EcoCRM® has been shown to be highly
effective with poorly immunogenic malaria proteins (14) Crosslinking of CRM197 and a candidate
target antigen protein can create nanoparticle-like structures containing multiple copies of the
target antigen. This approach has been successfully used to enhance the immunogenicity of
malaria proteins (14,15).
Optimal COVID-19 vaccine immunity requires the activation of both cellular and humoral
responses in regard to 1) activation of CD4 T cells to activate B-cell maturation to produce
functional antibodies to neutralize SARS-COV-2 as well as B-memory responses and 2)
stimulation of CD8 T cell production to eliminate virus infected cells and the activation of CD8 T
memory cells (16). Bacterial Enzymatic Combinatorial Chemistry (BECC) is a novel adjuvant
methodology developed to synthesize TLR4-agonists, lipid A mimetics. The BECC system uses
lipid A biosynthetic and/or modification enzymes expressed in a bacterial background to rationally
engineer lipid A structures with altered binding to the host TLR4 receptor and immunostimulatory
properties (17). BECC adjuvants have been successfully used in both viral and bacterial preclinical vaccine formulations (18). Viral vaccine studies with Influenza virus H1N1 showed
decreased viral titers and weight loss when influenza hemagglutinin antigen was adjuvanted with
BECC470, as well as elicited a balanced Th1/Th2 immune response (19).
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Overall, the aim in this study was to evaluate the efficacy of intramuscular and intranasal
vaccination with BReC-CoV-2 against SARS-CoV-2 using the K18-ACE2 mouse challenge model
(20–25). We hypothesized that intranasal immunization which induces a combination of both
mucosal and systemic immune responses, would lead to better protection against SARS-CoV-2
than intramuscular vaccination with BReC-CoV-2. Here, we describe a series of murine
immunogenicity and challenge studies that led us to a protective vaccine formulation and route of
administration. Our findings demonstrate that unlike intramuscular administration, intranasal
administration of BReC-CoV-2 provided protection against lethal doses of both the ancestral
strain as well as Delta SARS-CoV-2.

4.3 Results
Assessing different combinations of RBD-EcoCRM® and adjuvants in vaccine formulations
against SARS-CoV-2. It has been hypothesized that nasal vaccination offers a unique protection
profile and advantages to muscular vaccination against SARS-CoV-2 (3). To test this hypothesis,
we evaluated numerous antigens and adjuvants to identify a highly immunogenic vaccine
formulation that would be subsequently evaluated in a K18-hACE2-transgeneic mouse model.
Since RBD has a small molecular weight, to improve responses to RBD, we conjugated RBD to
EcoCRM®, a genetically detoxified diphtheria toxoid carrier protein (26). The conjugation of RBD
to EcoCRM® yielded a product with approximately one EcoCRM® fused to 7-8 RBD molecules.
The purpose behind the crosslinking of RBD with EcoCRM® was to enhance the immunogenicity
and subsequent recognition of RBD by the immune system. Based on vaccine immunogenicity
screens in CD1 mice (Figure 1), we hypothesized that a TLR4-agonist adjuvant would promote a
robust antibody response. To test this hypothesis, we utilized Bacterial Enzymatic Combinatorial
Chemistry (BECC). BECCs, are a TLR4-agonist that can help drive a balanced Th1/Th2 immune
response that can help clear viral infections. We evaluated different adjuvants including: CpG
(TLR9 agonist), IRI-1501 (Beta-glucan from yeast), BECC438 (biphosphorylated lipid A), and
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BECC470 (monophosphorylated lipid A) (Supplementary table 1). In these studies, female CD1
outbred mice were immunized with the vaccine formulations indicated in Supplementary table 1,
either through an intranasal or intramuscular route. Mice were boosted 3 weeks later with the
same formulation through the same routes. Serological analysis was performed at 2 weeks post
prime and 2 weeks post boost (Fig.1). Overall, mice demonstrated modest improvement in
immunogenicity with RBD-EcoCRM® compared to RBD alone supplemented with different
adjuvant combinations, both through the IM and IN routes. Intramuscular administration of RBD
or RBD-EcoCRM® adjuvated with BECC438 resulted in similar RBD IgG titers at 2 weeks post
boost; however, when administered intranasally, RBD-EcoCRM® with BECC438 elicited greater
RBD IgG titers compared to RBD (Fig1). Intranasally, BECC470 induced similar RBD-IgG
responses formulated with RBD or RBD-EcoCRM (Fig 1A). Intramuscular vaccination with RBDEcoCRM® adjuvanted with CpG generated increased RBD IgG titers compared to intranasal
vaccination (Fig. 1AB). In humans, CpG is only administered IM and would not likely be an ideal
candidate IN adjuvant. RBD-EcoCRM® adjuvanted with BECC470 generated a robust RBD-IgG
response both intranasally and intramuscularly compared to other adjuvants tested (Fig.1).

RBD-EcoCRM® adjuvanted with BECC470 elicits robust antibody responses in CD1 mice.
In this study, we focused on further investigating RBD-EcoCRM® and BECC470 (BReC-CoV-2).
Initially, IM BReC-CoV-2 generated elevated production of RBD IgG titers after 1 week and 2
weeks post prime compared to the other vaccines (Fig.2A). We observed that IN and IM
administration of BReC-CoV-2 produced robust RBD-IgG titers in the serum after boost (Fig.2A).
The IN BReC-CoV-2 generated a 3-log increase of anti-RBD IgG 1-week post boost from 2 weeks
post prime. Whereas the IM BReC-CoV-2 produced a 2-log increase of anti-RBD IgG from 2
weeks post prime to 1-week post boost (Fig. 2A). Overall, at 1 and 2 weeks post prime IM BReCCoV-2 generated significant anti-RBD IgG titers compared to IN BreC-CoV-2 vaccination
(Supplementary data 1). However, there were no statistical differences measured between RBD
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alone and RBD-EcoCRM® with BECC470 (Supplementary data 1). An ideal COVID-19 vaccine
would need to protect long-term; therefore, we measured RBD IgG titers at 22 weeks post boost
were consistent with 2 weeks post boost in both IN and IM BReC-CoV-2 vaccinated groups
(Fig.2A). In addition to serological analyses, we also confirmed antibodies generated were able
to neutralize RBD binding to ACE2 in vitro at 2 weeks post boost (Fig. 2B). Overall, the collective
data from the pilot immunogenicity study indicated that IM and IN BReC-CoV-2 vaccines
produced long lasting strong anti-RBD IgG responses.

Intranasal administration of BReC-CoV-2 protected mice from SARS-CoV2 challenge. We
next tested the protective capacity of IN and IM BReC-CoV-2 in a SARS-CoV-2 challenge model.
K18-hACE2 mice were vaccinated with IN and IM formulations of BReC-CoV-2 (Fig. 3A). At 2
weeks post boost, IN (n=9), IM BReC-CoV-2 (n=10), and no vaccine challenged (NVC) (n=8)
groups were challenged with a 104 PFU/dose of WA-1 variant of SARS-CoV-2 and monitored for
disease outcomes for a 14-day period. We assessed disease manifestations such as weight loss,
appearance, activity, eye closure, respiration, and hypothermia (Supplementary Figure 1). Mice
were euthanized if they achieved a disease score 5 or greater, which determined that they were
morbid. We calculated the cumulative disease score by adding the total scores of each mouse in
one group. When animals become morbid and require euthanasia, we retained the animal’s score
in the sum of the remaining days of the experiment. This disease scoring system helps us predict
when mice will become morbid and is inverse to the falling Kaplan Meier curve. Throughout this
14-day period, we observed that NVC and IM BReC-CoV-2 vaccinated mice began decreasing in
weight at day 7 post challenge, whereas the IN BReC-CoV-2 vaccinated mice gradually gained
weight (Fig.3D). IN vaccinated animals compared to NVC and IM maintained stable rectal
temperatures throughout 2-week monitoring period which corroborated their disease scores (Fig.
3CE). However, NVC and IM vaccinated mice rectal temperature plummeted at days 7 and 8 post
challenge (Fig.3E). Unlike the IM, NVC was not able to recover in temperature as IM vaccinated
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mice. When evaluating the groups based on their disease scores, NVC began to increase in
disease scores at day 7 and continually increased in disease scores until day 10 (Fig.3C). IM
BReC-CoV-2 vaccinated mice peaked in disease scores at day 8, but then returned to normal
health scores throughout the rest of the challenge trial (Fig.3C). IN BReC-CoV-2 vaccinated mice
maintained low disease scores throughout the entirety of the 14-day monitoring period compared
to both the NVC and IM vaccinated mice (Fig.3C). Weight and temperature loss along with
disease scores correlated with poor survival outcome (25% survival) in NVC group (Fig. 3B). IM
vaccinated mice portrayed a better disease outcome than NVC, with 60% survival (Fig.3B), and
IN vaccinated mice experienced significant survival compared to NVC (P=0.0332) with 89%
survival (Fig.3B). Overall, the protection profile indicated that IN vaccination with BReC-CoV-2
compared to IM and NVC protected mice from SARS-CoV-2 challenge suggesting that the
mucosal immune response may play a role in driving protection from SARS-CoV2.
IN vaccination with BReC-CoV-2 decreases viral RNA burden in the lung and brain. As the
disease monitoring data suggested, IN vaccination with BReC-CoV-2 was superior in protection
compared to IM mice. To corroborate the observed disease monitoring data, the viral RNA burden
of the vaccinated mice compared to the NVC was determined. For this analysis, we measured
RNA copies of nucleocapsid to SARS-CoV-2 in the lung (Fig.4A), brain (Fig.4B), and nasal wash
(NW) for each animal (Fig.4C). In the lung, IN vaccination of BReC-CoV-2 significantly decreased
viral RNA compared to NVC and IM vaccinated BReC-CoV-2 (Fig.4A) indicating that IN
vaccination limits viral burden. Studies have shown that K18-ACE2 mice succumb to SARS-CoV2 brain infection after challenge (22,27,28). IN vaccination with BreC-CoV-2 significantly
decreased viral RNA in the brain compared to NVC suggesting that IN vaccination prevented the
dissemination of virus into the brain (Fig.4B). IN vaccination also decreased viral copies in the
NW compared to NVC and IM; however, these differences were not statistically significant (Fig.
4C). Overall, there was a significant reduction of viral RNA copies in the lung of IN vaccinated
mice compared to IM and NVC, significant decrease of viral RNA in the brain compared to NVC
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as well as fewer viral RNA copies in the NW. Decreased detection of viral RNA suggested that IN
BReC-CoV-2 diminished viral replication at the site of infection aided in survival compared to IM
BReC-CoV-2.
Both IM and IN BReC-CoV-2 RBD antibody responses increase during SARS-CoV-2
challenge. To investigate the antibody responses generated by BReC-CoV-2 vaccination, we
first analyzed RBD specific IgG production systemically and then locally in the lung. Systemic
RBD IgG was measured before challenge and after challenge with SARS-CoV-2. In order to
measure serum RBD IgG before challenge, blood was collected at 2 weeks post prime and 2
weeks post boost (Fig.5A). At 2 weeks post prime, both IN and IM begin to generate detectable
RBD IgG titers, with the IM generating higher RBD titers than both NVC and IN (Fig.5A). Both IN
and IM BReC-CoV-2 vaccinated groups induced a robust response to boosting, but IM vaccination
elicited increased RBD-IgG titers than IN and NVC (Fig.5A). Post challenge, serum RBD IgG was
significantly elevated in both IN and IM vaccinated groups compared to NVC suggesting challenge
may increase antibody production (Fig.5B). In the lung supernatant, similar to the serum, RBD
IgG were significantly increased in both the IN and IM vaccinated mice compared to the NVC
(Fig.5C) indicating no difference between the IN and IM RBD IgG titers in the lung.
IN BReC-CoV-2 generated a robust localized IgA response compared to IM vaccination.
To characterize the mucosal antibody response to BReC-CoV-2 vaccination, IgA titers were
measured in the lung and nasal wash. In the lung supernatant, NVC and IM vaccinated mice did
not generate RBD specific IgA compared to IN BReC-CoV-2 vaccination (Fig.5E). To further
confirm the findings that the mucosal antibody response was contributing significantly to
protection, anti-RBD IgA in the nasal wash was analyzed. Similar to the lung supernatant, IN
vaccination significantly increased RBD-IgA compared to the undetectable IgA amounts in the
NVC and IM vaccinated groups (Fig.5D). Serum RBD IgA titers were also examined. The results
indicated that IgA was released systemically because pre-challenge IgA was slightly elevated in
IN vaccinated mice but not in the NVC and IM groups. However, post challenge, there was no
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change in the serum RBD IgA titers in any groups (Fig.5F). In summary, both IN and IM
vaccination generated similar IgG responses in the lung and serum. However, IN vaccination
induced a stronger IgA response in the lung and NW compared to IM, suggesting that the mucosal
antibody response is potentially important in facilitating clearance of SARS-CoV-2 in the
respiratory tract.
BECC470 induces Th1/Th2 responses in both IN and IM BReC-CoV-2 vaccination. Previous
pre-clinical vaccine studies using BECC470 as an adjuvant have shown that BECC470 generated
a balanced Th1/Th2 immune response(19). To investigate the Th1 and Th2 immune response
elicited by IN and IM BReC-CoV-2 vaccination, IgG1 (Th2) and IgG2c (Th1) subtypes were
analyzed in the serum. Both IN and IM BReC-CoV-2 vaccination induced significant RBD specific
IgG2c and IgG1 responses compared to NVC (Supplementary Figure 2). IM BReC-CoV-2
vaccination also generated a significant increase in IgG1 compared to IN vaccination indicating a
Th2 biased response with IM vaccination compared to IN (Supplementary Figure 2B). NVC mice
had an expected increase in IgG2c compared to IgG1 indicating a Th1 response to viral infection
(Supplementary Figure 2). IgG2/IgG1 ratios of less than one are considered Th1-biased whereas
ratio of greater than one would indicate Th2 responses. Overall, IN and IM vaccination induced
IgG1/IgG2c ratios of 0.8 and 1.1, respectively. Both vaccines induce Th2 responses, but IN
immunization is driving slightly more Th1 antibody responses.
Both IN and IM BReC-CoV-2 vaccination induced neutralizing antibodies. Antibody analysis
of IN and IM BReC-CoV-2 vaccination detected high levels of RBD specific IgG and IgA; therefore,
we determined if these antibodies were functional in neutralizing RBD binding to ACE2. The MSD
COVID-19 ACE2 neutralization multiplex assay was used to analyze neutralization of the RBD
and spike protein of the variants of concern (VOC) (Alpha, Beta, and Gamma). Neutralization of
RBD or Spike binding to ACE2 was measured through electrical chemiluminescent (ECL) signal
intensity for NVC, IN, and IM vaccinated mice. The higher the signal the less neutralization and
the less intense the signal the more neutralization capability. Both IN and IM vaccinated mice had
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significant neutralizing antibody titers compared to NVC in the serum demonstrating that both IN
and IM vaccination generated functional antibodies (Fig.6). NVC mice, as expected, had no
neutralization against the VOCs (Fig.6). IN vaccinated mice had significantly higher neutralization
capacity than NVC for Alpha, Beta, and Gamma (Fig.6A-B); whereas IM vaccinated mice had
increased neutralization capacity compared to NVC against Beta (Fig.6C-D). For whole spike
neutralization, IN vaccination generated significant neutralizing titers against the Wuhan strain of
spike compared to IM vaccination (Fig.6A-B). Overall, IN vaccination with BReC-CoV-2 showed
superior neutralization capacity over IM in the ability to neutralize multiple VOCs RBD from
binding to ACE2.
Increased levels of serum CXCL13 in NVC and IM BReC-CoV-2 vaccinated mice indicate
poor disease prognosis. CXCL13 is an important chemokine marker for germinal center activity,
B-cell maturation, memory B-cell, and plasma cell formation. Conversely, in non-vaccinated
COVID-19 patients, increased CXCL13 levels have been shown to be a marker of a poor clinical
outcome compared to patients who survived COVID-19 (29,30). In the context of immunization
(pre-challenge), CXCL13 was detectable in IN immunized mice, but higher in IM immunized mice,
suggesting germinal centers were more active after IM immunization (Fig. 7A). After challenge,
NVC mice had higher CXCL13 compared to naïve mice as would be expected (Fig.7B). IN
immunized mice had the lowest CXCL13 levels. These data suggest that germinal centers were
not activated due to the mucosal protection and levels of circulating systemic antibodies in the IN
immunized mice.
IN BReC-CoV-2 decreased IFN-γ in the lung. SARS-CoV-2 is known to cause inflammation in
the lung and induce interferon responses (22,23,31). Therefore, we hypothesized that IN
vaccination should help decrease inflammatory markers in the lung. To test this hypothesis, we
measured inflammatory cytokines in the lung supernatant post SARS-CoV-2 challenge.
Compared to the NVC and IM vaccination, IN vaccination significantly lowered IFNγ in the lung
supernatant (Supplementary Figure 3C), whereas other pro-inflammatory cytokines remained
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similar between NVC, IN and IM (Supplementary Figure3A-D). C reactive protein (CRP) was also
measured as a marker to evaluate inflammation during SARS-CoV-2 challenge. CRP was
significantly decreased in IN and IM vaccinated groups compared to NVC in the lung
(Supplementary Figure 3D). Overall, vaccination decreased inflammation in the lung, with IN
vaccination decreasing both IFN-γ and CRP compared to NVC.
IM vaccination decreases both chronic and acute inflammation in the lung whereas IN
vaccination decreases acute inflammation only. We next hypothesized that IN vaccination
would reduce total inflammation due to decreasing inflammatory cytokines in the lung. The left
lobe of the lung was subjected to H&E staining and evaluated for histopathological analysis for
chronic and acute inflammation. Chronic inflammation was scored by the presence of recruited
lymphocytes, plasma cells, and macrophages in the parenchyma and blood vessels. Acute
inflammation was denoted by the infiltration of neutrophils and the presence of edema in the
parenchyma, blood vessels, and airways. IN vaccinated mice had increased chronic inflammation
scores (3.8) compared to NVNC (0.33), NVC (3.1), and IM (2.7) with the presence of plasma cells,
lymphocytes, and macrophages localized around blood vessels (Fig.8CDH). IN mice scored an
average inflammation score of 4.1, lower than NVC (Fig.8GH). Mice vaccinated IM with BReCCoV-2 had the lowest chronic and acute inflammation scores compared to NVNC, NVC, and IN
mice with an overall mean inflammation score of 2.8 (Fig.8EFGH). IM mice had mostly chronic
inflammation found in the parenchyma, blood vessels and bronchi (Fig.8EFG). Overall, IM
vaccinated mice had less acute and chronic inflammation than NVNC, NVC, and IN suggesting
that IN vaccination mimicked natural infection by recruiting cells into the lung to fight viral infection.
IN BReC-CoV-2 vaccination upregulates specific immune genes in response to SARS-CoV2 challenge. To capture the transcriptional profile of intranasal and intramuscular BReC-Cov-2
vaccination during SARS-CoV-2 challenge, the lung was analyzed using RNA sequencing. IN
BReC-CoV-2 compared to NVC had 174 activated genes and 130 repressed genes whereas IM
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BReC-CoV-2 compared to NVC had 82 activated genes with 167 repressed genes (Fig.9A,
Supplementary data 2). Immunoglobulin genes involved in regulating the adaptive immune
response were significantly upregulated in IN BReC-CoV-2 vaccination and challenge compared
to NVC (Fig.9B-D). Genes responsible for general T-cell regulation and activation such as Lat,
Lef1, Mill1, Trat1, Tespa1, Themis, Tox, Tcf7, H2M2, Cd163l1, Cd226, and Cd4 hint at the
presence of effector and resident T-cells in the lung (Fig.9D) However, IM vaccinated compared
to NVC only had three immunoglobulin genes (Igkv3-5, Ighv11-2, and Igkv14-126) significantly
upregulated, and no significant fold changes in the adaptive immune response gene set (Fig.9CD). Over-Representation Analysis was used to enrich GO-terms of the biological processes in IN
BReC-CoV-2 challenged mice compared to NVC. We observed gene set enrichment and
significant upregulation in genes involved in a variety of important immune responses such as
leukocyte

activation,

lymphocyte

activation,

leukocyte

mediated

immunity,

somatic

recombination, somatic diversification of immune receptors, and somatic diversification of T-cell
receptor genes (Fig.9E). Conversely, there were increased repressed genes involved in cellular
response to interleukin-1 suggesting that IN BReC-CoV-2 helped decrease inflammation in the
lung (Fig.9E). Overall, the transcriptomic data generated from sequencing the lung from IN and
IM BReC-CoV-2 vaccination during SARS-CoV-2 challenge mirrored the correlates of protection
collected throughout this study.
IM BReC-CoV-2 prime followed by IN boost afforded survival against SARS-CoV-2 Delta
variant challenge. SARS-CoV-2 Delta variant is the predominant circulating variant in the world
as of December 2021(32–34). Therefore, we wanted to evaluate whether BReC-CoV-2
vaccination can protect against Delta challenge in mice. K18-hACE2 mice were vaccinated with
2 doses of BReC-CoV-2 through the IN route, IM route and lastly, primed through the IM route
and boosted through the IN route (IM/IN). IN and IM BReC-CoV-2 vaccination generated similar
RBD IgG titers as the previous vaccine and challenge study with WA-1 (Fig. 10A). IM/IN
vaccination elicited similar RBD IgG titers as IM vaccination (Fig. 10A). NVC (n=5), IN (n=5), IM
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(n=5), and IM/IN (n=3) were challenged with a lethal 104 PFU/dose of Delta variant and monitored
similarly for disease manifestations as the previous challenge trial with WA-1 SARS-CoV-2. NVC
mice began succumbing to disease at day 6, and by day 7 post challenge, remaining mice were
morbid and were euthanized. Severity of disease caused by the Delta variant in the NVC group
was reflected by the increase of the cumulative disease scores as well as in the sharp decrease
in weight and temperature. (Fig. 10BCD). IN BReC-CoV-2 vaccinated mice had increased
survival compared to NVC (60% survival); however, 2 mice succumbed to Delta at day 7 post
challenge (Fig. 10B). Cumulative disease scores peaked at day 7 in the IN vaccinated group
mirroring the moribund mice. The morbid mice in the IN vaccinated group had increased disease
scores as well as decreased temperature and weight compared to the rest of the group. Mice
administered BReC-CoV-2 through the IM route had increased mortality compared to IN with a
40% survival rate. Disease scores reflected the morbidity of the IM vaccinated mice; however,
interestingly, IM mice that succumbed to disease had a sharp decrease in weight but maintained
temperature unlike NVC and IN moribund mice (Fig. 10 CDE). Remarkably, all mice vaccinated
with BReC-CoV-2 through IM prime and IN boost strategy survived a lethal challenge against the
Delta variant (Fig. 10B). IM/IN group maintained stable weight and temperature throughout the
course of challenge, as well as did not exhibit disease manifestations observed in NVC, IN and
IM groups (Fig.10 CDE). Viral RNA burden in the brain (Fig. 10F), lung (Fig. 10G), and NW
(Fig.10H) followed similar trends as the disease assessment and survival in IN, IM, and IM/IN
BReC-CoV-2 immunized mice. Interestingly, despite IN BReC-CoV-2 having a better survival
outcome than IM BReC-CoV-2 vaccinated mice, NVC, IN and IM groups had similar levels of viral
RNA in the brain and lung (Fig. 10FG). However, IN BReC-CoV-2 vaccinated mice had decreased
viral burden in the NW compared to NVC and IM BReC-CoV-2 (Fig. 10H). The heterologous prime
(IM) and boost (IN) strategy provided significant decrease of viral RNA in the brain, lung and NW
compared to NVC (Fig. 10FGH) suggesting that IM prime with BReC-CoV-2 followed by IN boost
prevented viral dissemination. Overall, 104 PFU/dose of SARS-CoV-2 Delta variant was a lethal
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dose in non-vaccinated mice. IM/IN BReC-CoV-2 vaccinated offered superior protection against
lethal Delta challenge compared to NVC, IN, and IM vaccination. IN BReC-CoV-2 provided
significant protection against Delta challenge compared to NVC; however, did not offer complete
protection, and IM BReC-CoV-2 supplied limited protection against Delta.

4.4 Discussion
For protection against respiratory pathogens, nasal vaccines can offer both localized protection
at the site of infection and activate systemic responses. Very few nasal vaccines have been
approved for human use. To the best of our knowledge, only two examples are on the market:
FluMist®, a live attenuated influenza FDA approved vaccine for seasonal flu and Nasovac®, an
H1N1 pandemic flu vaccine (35). The chimpanzee adenovirus vectored vaccine encoding a prefusion stabilized spike (S) protein (ChAD-SARS-CoV-2-S) is an example of an adenovirus
vectored COVID-19 vaccine that has been shown protective as a single dose nasal vaccination
in non-human primates and other models as well (36,37). AdCovid™ developed by Altimmune, is
another adenovirus vectored (replication deficient adenovirus type 5) intranasal vaccine
expressing RBD instead of the spike protein. In pre-clinical studies, a single dose of AdCovid™
offered sterilizing immunity against SARS-CoV-2 challenge and induced a robust mucosal
response in the respiratory tract in mice(38,39). However, AdCovid™ demonstrated a lack of
efficacy in phase 1 clinical trials and was discontinued. A few pre-clinical trials evaluating
intranasal vaccines utilizing a recombinant spike protein with stimulator of interferon genes
(STING) adjuvant showed robust systemic and localized immunogenicity. (40) And lastly, a live
attenuated and vectored Newcastle Disease virus expressing spike protein demonstrated
sterilizing immunity against SARS-CoV-2 when administered IN (41). Collectively, these studies
hint that IN vaccines can protect against SARS-CoV-2.
In this study, our objective was to develop and evaluate a nasal vaccine against SARS-CoV-2
using RBD conjugated to EcoCRM® adjuvanted with BECC470 (BReC-CoV-2). Before we tested
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BreC-CoV-2 in a SARS-CoV-2 challenge model, we performed an intensive immunogenicity
screen for immunogenic vaccine antigen and adjuvant combinations in outbred mice (Fig.1). We
screened 18 different vaccine combinations through both the intranasal and intramuscular route.
Using the K18 hACE2 mouse model, we demonstrated that intranasal vaccination with BReCCoV-2 offered protection against WA-1 SARS-CoV-2 compared to IM vaccination. We observed
that IN vaccination with BReC-CoV-2 increased percent survival, decreased disease scores, and
maintained weight and temperature in IN group throughout infection compared to IM and NVC
(Fig.3). Intranasal vaccination was performed with 50µL of vaccine in order to deposit vaccine in
both the upper respiratory tract and lungs. It is likely that this would cause both mucosal and
systemic immune responses. Nasal vaccination decreased viral burden in the lung compared to
IM and NVC (Fig.4), as well as increased RBD IgA titers in the lung and nasal wash compared to
IM and NVC (Fig.5). Increased neutralizing antibodies against RBD of the variants of concern
(Alpha, Beta, and Gamma) were found with IN compared to IM and NVC (Fig. 6). Intranasal
vaccination with BReC-CoV-2 decreased IFN-γ in the lung compared to IM and NVC
(Supplementary Figure 3). However, histopathological analyses showed an increase of
recruitment of lymphocytes, macrophages, and plasma cells to blood vessels in the lung
compared to IM vaccination (Fig.8). RNAseq analysis performed on the lungs demonstrated that
IN BReC-CoV-2 vaccination upregulated more genes involved in the adaptive immune response
compared to NVC and IM groups (Fig. 9). Since the Delta variant of SARS-CoV-2 is the
predominant strain in the world, a Delta challenge was performed in BReC-CoV-2 vaccinated
mice. Compared to the WA-1 challenge, IN BReC-CoV-2 had significant survival compared to
NVC and decreased disease scores. However, heterologous prime boost of BReC-CoV-2 offered
100% survival against Delta challenge (Fig. 10).
In our BReC-CoV-2 formulation we utilized a carrier protein and an adjuvant synthesized from
bacterial components. Bacterial components can serve as potent adjuvants for either bacterial or
viral vaccines. We used BECC470 as the candidate adjuvant to supplement RBD-EcoCRM.
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Compared to GSK MPLA, they are both engineered forms of lipid A, TLR4-agonists, and drive a
robust Th1 immune response, but there are significant differences in the way that they are
synthesized. BECC was developed as an alternative route to produce lipid A mimetics. It uses
novel methodology that generates products that are cost effective and easy to produce (17)..
Carrier proteins are another important vaccine component for small molecular weight antigens
such as RBD to increase antigen presentation thus immunogenicity. EcoCRM® the carrier protein
of our immunogen is a genetically detoxified diphtheria toxin originally expressed in
Corynebacterium diphtheriae(9). We used EcoCRM® which is CRM197 expressed as a soluble,
properly folded protein in the cytoplasm of an E. coli strain engineered to have an oxidative
cytoplasm(26,42). Crosslinking of a carrier protein and RBD, forming a high MW nanoparticle like
construct capable of presenting multiple molecules of RBD are likely critical for the enhanced
response to the conjugate versus RBD alone.
In our studies, we acknowledge that the K18-hACE2 mouse model contains limitations such as
increased sensitivity to SARS-CoV-2 challenge because of elevated expression of human ACE2
in the mouse compared to humans such as in the brain (25). The severity of this transgenic
challenge model does likely have a caveat because brain SARS-CoV-2 infection is atypical of
human infection (28,43). Future studies are needed to evaluate IN and IM administration of BReCCoV-2 in other rodent models such as the Syrian hamster model. The hamster model results in
pneumonia (44). Hamster ACE2 are similar to human ACE2 and disease phenotypes of SARSCoV-2 infection recapitulate those of human pneumonia and inflammation in the hamster model
(45). Unlike the K18-hACE2 mouse model, hamsters do not succumb to brain encephalitis, the
majority of the virus remain in the lungs, and may spread to the GI tract (25).
Since the K18-hACE2 mouse model is sensitive to SARS-CoV-2, it was important to determine
an appropriate lethal challenge dose to effectively evaluate vaccine protection. In previous
studies, we evaluated 104 (n=12) and 105 (n=13) PFU/dose of SARS-CoV-2 WA-1 in K18-ACE2
mice (46). We observed that 104 and 105 PFU/dose resulted in 11% survival and 0% survival,
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respectively. Our BReC-CoV-2 challenge study showed that 104 PFU/dose of WA-1 resulted in
25% survival in the non-vaccinated, challenged mice similar to the preliminary dose study. Other
studies have shown that approximately 104 PFU/dose also show similar lethality in K18-hACE2
mice and 105 PFU/dose results in 100% lethality (22,23,28). Since the WA-1 viral stock that was
used to challenge mice in this experiment was sequenced and contained no deletions in the furin
cleavage site, discrepancies in mouse survival in the 104-challenge dose could be due to
deviations in delivery of the challenge dose per mouse. To further investigate the optimal dose
for maximizing vaccine efficacy, more studies should be done characterizing the lethal and
sublethal doses of SARS-CoV-2, especially in relation to VOC strains.
In our first protection study, we challenged mice with the ancestral SARS-CoV-2 WA-1; however,
this clade of strain is currently virtually non-existent. Nevertheless, we evaluated the neutralizing
capacity of sera of BReC-Cov-2 vaccinated mice to RBD and spike proteins from the VOCs (Fig.
6). Sera from mice IN immunized with BReC-CoV-2 vaccination were able to significantly inhibit
hACE2 binding of the VOC RBDs. This suggests that IN administration of BReC-CoV-2 may be
able to protect mice challenged with these VOCs. Since the Delta variant is currently the
predominant global variant; we challenged BReC-CoV-2 vaccinated mice with Delta (Fig. 10).
Even though, IN BReC-CoV-2 significantly improve survival compared to NVC, survival rate
decreased from 89% with WA-1 challenge to 60% with Delta challenge, indicating a decrease in
vaccine efficacy against the VOC. However, we demonstrated that mice immunized through the
IM/IN vaccine strategy with BReC-CoV-2 had 100% survival against lethal Delta challenge
suggesting that the IM/IN vaccine route is the optimal vaccine strategy with BReC-CoV-2 in this
model. The RBD used in BReC-CoV-2 was generated from the WA-1 strain of SARS-CoV-2.
Therefore, mutations in RBD will decrease antibody binding and virus neutralization which is likely
causing decreased vaccine efficacy of IN and IM BReC-CoV-2.

Our data suggest that

administering a booster dose through the IN route after an IM prime might provide increased
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protection against SARS-CoV-2. Further investigation is needed to evaluate the correlates of
protection of BReC-CoV-2 IM/IN compared to IN or IM only routes with Delta challenge.
Neutralizing antibodies are important in diminishing the replication of SARS-CoV-2, whereas
CD4+ and CD8+ T-cells play a large role in clearing and controlling SARS-CoV-2 infection
(16,47,48).

Studies have shown that in humans, resident T-cells in the lung instead of in

circulation were linked with better disease prognosis and survival (49). We appreciate that in other
intranasal vaccination studies for bacterial and viral pathogens that T resident memory cells are
elevated in the lung and nasal associated lymphoid tissue (50). We hypothesize that since
BECC470 is a driver of Th1 immune responses (Supplementary Figure 2A) that IN BReC-CoV-2
will also elicit robust T resident memory responses that will contribute to protection. However,
further investigation is needed to study T resident memory cells in the lung as well as the nasal
associated lymphoid tissue in the mouse.
Next generation sequencing is a powerful platform that can be used to profile vaccine responses.
In this study we used bulk RNAseq to characterize the transcriptomic landscape of BReC-CoV-2
vaccinated lungs against WA-1 SARS-CoV-2 challenge (Fig.9). Interestingly, IN BReC-CoV-2
vaccinated and SARS-CoV-2 challenged lungs revealed activation of immunoglobulin genes
compared to NVC suggesting the presence of antibody producing B cells in the lungs which could
have contributed to protection of the IN BReC-CoV-2 mice. These data corroborate with
serological analysis of IN BReC-CoV-2 lung, where we observed the increased induction of RBD
IgG and IgA titers. Human COVID-19 studies observe the presence of memory B cells in the lung
6 months post infection which hint at the importance of memory B cells for protection against
SARS-Co-2 infection(51).Additionally, IN BReC-CoV-2 lung showed transcriptional signatures of
genes involved in T-cell signaling and differentiation, suggesting the presence of CD4+ and CD8+
T cells as well as T resident memory cells, which also has been shown in human COVID-19 cases
(51). Rag1 and rag2 were significantly upregulated in IN BReC-CoV-2 vaccination suggesting that
mature B and T cells were residing in the lung. Remarkably, we only observe differentiation in
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the immune response genes in IN BReC-CoV-2 lungs and not in the IM BReC-CoV-2 lungs hinting
that a localized immune response was occurring in the IN vaccinated. Overall, traditional RNAseq
provides a snapshot of the immune response occurring during IN and IM BReC-CoV-2
vaccination; however, it does not detail antigen specificity of the immunoglobulin genes expressed
(Fig. 9). Novel technology such as linking B cell receptor to antigen specificity through sequencing
can aid in discovering antigen specific B and T cell receptors that are crucial to a protective
vaccine response.
In summary, our study demonstrates that intranasal administration of BReC-CoV-2 confers
protection against WA-1 SARS-CoV-2 challenge in hACE2 mice compared to intramuscular
vaccination. IN administration with BReC-CoV-2 protected transgenic mice against challenge, but
also reduced viral burden in the lung, inhibited hACE2 binding of VOC RBDs, and induced high
titers of IgA in the lung and nasal wash. Importantly, we also demonstrated that BReC-CoV-2
administered via an IM prime and IN boost strategy protected transgenic mice from a lethal
challenge of the Delta variant. In the future, our goal is to evaluate BReC-CoV-2 in the Syrian
hamster model with emerging VOCs such as the Delta variant. We also want to further investigate
the mucosal IgA response of nasal BReC-CoV-2 in the lungs and nasal tissue. In summary,
intranasal vaccination with BReC-CoV-2 offered better protection at the site of infection than
intramuscular vaccination, indicating that intranasal route of this vaccine candidate can be
pursued in future studies.
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4.5 Methods
Animal welfare, Biosafety and Ethics statements.
CD1 outbred mouse immunogenicity studies were performed under the approved West Virginia
University IACUC protocol number 2004034204 whereas B6.Cg-Tg(K18-ACE2)2Prlmn/J mouse
vaccine and SARS-CoV-2 challenge studies were executed under IACUC protocol number
2009036460. All mice were humanely euthanized based on the disease scoring system,
described below (Supplementary Figure 1), and no deaths occurred in the cage. All SARS-CoV2 challenge studies were conducted in the West Virginia University Biosafety Laboratory Level 3
facility under the IBC protocol number 20-04-01. SARS-CoV-2 samples were inactivated with 1%
Triton per volume before exiting high containment.
Mouse vaccination
Female outbred CD1 mice were obtained from Charles River Laboratories (strain code: 022) at 4
weeks old and vaccinated at 8 weeks of age. Both male and female B6.Cg-Tg(K18ACE2)2Prlmn/J mice were purchased from Jackson Laboratory (stock no: 034860) at 8 weeks
old and vaccinated at 10 weeks old for the WA-1 challenge study. Female B6.Cg-Tg(K18ACE2)2Prlmn/J mice were vaccinated at 13 weeks old and were used in the Delta (B.1.617.2)
challenge study. Both CD1 and K18-hACE2 mice were administered 50μL immunizations through
either the intramuscular route or intranasal route. For intranasal immunization, mice were
anesthetized through intraperitoneal injection with ketamine/xylazine per approved protocols,
then administered 25uL of vaccine into each nare.
Production of antigen
Receptor binding domain (RBD) of the Wuhan original strain of SARS-CoV-2 was recombinantly
produced by transient transfection in HEK293T cells using a pCAGGS expression vector with
RBD construct with a C-terminal hexahistidine tag and codon optimized for mammalian
expression (pCAGGS vector catalog #: NR-52309 BEI Resources) (9). RBD was then chemically
conjugated to the carrier protein EcoCRM® by Fina Biosolutions LLC (Rockville,MD).
159

Determination of RBD-CRM ratio by mass spectrometry
Proteins RBD, CRM, RBD-CRM (1 µg each) were electrophoresed in SDS-PAGE gel. The protein
bands were excised and extracted protein was treated with trypsin. The resulting peptides were
analyzed on a Q Exactive™ Plus Hybrid Quadrupole-Orbitrap™ Mass Spectrometer and peptide
spectra matched (PSM) were aligned to RBD or CRM proteins. Unique peptides were determined
and the RBD to CRM ratio was determined. CRM and RBD individual resulted in 150 PSM or 16.2
per pmol of protein, respectively. Conjugated RBD-CRM resulted in 112 PSM (0.74pmol) of CRM
and 95 PSM (5.86 pmol) of RBD. 5.86/0.74 pmol results in a ratio of 7.92 RBD per CRM of
conjugated antigen.

Vaccine composition
20μg of RBD- EcoCRM® was used in the vaccine formulations. The adjuvants BECC 470 and
BECC 438 were obtained from Dr. Robert Ernst at the University of Maryland(17). Briefly, 50μg
BECC 470 or BECC 438 were sonicated in a water bath sonicator for 15 minutes prior mixing with
RBD-EcoCRM® for 2 hours before vaccination. IRI-1501 beta glucan was provided by
Immunoresearch. CpG adjuvant was acquired from Dynavax.

Luminex Magpix platform in vitro neutralization assay.
Neutralization assay was developed using the Luminex Magpix platform(29). Briefly, 1:2 dilution
of mouse serum was added to Greiner black non-binding 96 well plates. Serum was diluted 1:5
down the plate. Luminex Magpix® Microspheres (MC10012-YY) conjugated to RBD were added
to the serum dilutions. After a 2-hour incubation period, plates were washed 2X with 1X PBS-TBN
on a 96 well magnet, ACE2-biotin was added to the plates and incubated for 1 hour. Plates were
washed again 2X on the magnet, and Streptavidin-phycoerythrin was added to the plates and
incubated for 30 minutes at room temperature at 700rpm. After the Streptavidin-phycoerythrin
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incubation, plates were washed again, and 100μL of 1XPBS-TBN was added to plates and
analyzed on the Magpix to measure neutralizing ability of serum antibodies.

Serological analysis
ELISAs were performed to assess the total IgG (Novus Biologicals NBP1-75130), and IgA (Novus
Biologicals NB7504) in the serum, lung supernatant, and nasal wash (29,46). Total IgG titers were
quantified in the serum. High binding plates (Pierce 15041) were coated overnight at 4°C with
2μg/mL of RBD in phosphate buffered saline. Plates were then blocked with 3% non-fat milk in
PBS-0.1% Tween 20 overnight in the 4°C. After blocking, 1:20 dilution of serum from mice was
added in the first row and diluted 1:2 down two plates (15 dilutions total) in 1% non-fat milk in
PBS-0.1% Tween 20 leaving the last row on the last plate as a blank. Plates were incubated for
10 minutes at room temperature with shaking. Plates were then washed with PBS-0.1%Tween20
4 times, then either goat-anti-mouse secondary IgG HRP (1:2000 dilution) was added to the plates
and incubated as above (Novus Biosolutions). ELISAs were developed using TMB reagent
(Biolegend 421101) (1:1 ratio) in the dark for 10 minutes, and the reaction was stopped using
25μL 2N sulfuric acid. ELISAs were read using the Synergy H1 plate reader at 450nm. Nasal
wash, serum, and lung supernatant IgA titer quantification was performed using the same coating
and blocking procedures as mentioned above. In separate ELISA assays, 100μL of nasal wash,
1:20 dilution of serum and 1:5 dilution of lung supernatant was added to the first rows of high
binding plates and diluted down 2 plates at 1:2 dilution in 1% non-fat milk in PBS-0.1% Tween
20. Serum, nasal wash and lung supernatant samples were incubated for 2 hours at room
temperature with shaking. Plates were washed according to the protocol mentioned above.
Secondary goat-anti-mouse IgA HRP (1:10000) (Novus biologicals) was used in these assays
and incubated for 1 hour at room temperature with shaking. IgA ELISAs were developed with
TMB substrate (1:1) for 20 minutes in the dark before adding stopping solution and read on the
Synergy H1 plate reader at 450nm. Serological data was also analyzed as antibody titer, IC50
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and AUC. From our analysis, data followed nearly identical trends of titers per vaccine/control
group as well as have the same statistical significance (one-way ANVOVA using Tukey’s multiple
comparisons test) between each method analyzed. Titers were represented as Area Under the
Curve values calculated via GraphPad Prism v9.0.0.
SARS-CoV-2 propagation and mouse challenge.
SARS-CoV-2 USA-WA-1/2020 (NR-52281) (GenBank accession number: MN985325) or SARSCoV-2 Delta variant B.1.617.2 hCoV-19/USA/WV-WVU-WV118685/2021 (GISAID Accession ID:
EPI_ISL_1742834) were the challenge strains used in K18-hACE2 vaccine studies. SARS-CoV2 USA-WA-1/2020 (NR-52281) was obtained from BEI and hCoV-19/USA/WV-WVUWV118685/2021 was obtained from at patient sample at WVU. Both strains were propagated in
Vero E6 cells (ATCC-CRL-1586) and re-sequenced. K18-hACE2 mice were challenged with a
104 PFU/dose. Viral dose was prepared from the first passage of WA-1 at a concentration of
3.7x106 PFU/mL diluted to a working concentration of 106 PFU/mL. B.1.617.2 104 PFU/dose was
prepared from the first passage of a viral stock concentration of 8.25x105 PFU/mL. Briefly, mice
were anesthetized with IP injection of ketamine (Patterson Veterinary 07-803-6637) /xylazine
(Patterson Veterinary 07-808-1947), and a total of 50μL of 104 PFU SARS-CoV-2 WA-1 or Delta
was administered intranasally (25μL per nare).

Disease score of SARS-CoV-2 challenged mice
Challenged K18-hACE2 mice were evaluated daily through both in-person health assessments in
the BSL3 and SwifTAG Systems video monitoring for 12-14 days. Health assessments of the
mice were scored based on five criteria: 1) weight loss (scale 0-5), 2) appearance (scale 0-2), 3)
activity (scale 0-3), 4) eye closure (scale 0-2), and 5) respiration (scale 0-2) (Supplementary
Figure 1). All five criteria were scored based off a scaling system where 0 represents no symptoms
and the highest number on the scale denotes the most severe phenotype (52). Weight loss (0-5)
was scored based off percent weight loss from original weight before challenge using the scale
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0-5% (0), 5-10% (1), 10-15% (2) 15-20% (3), >20% (4-5). If mice reached 20% weight loss before
the termination of the study, mice were humanely euthanized at that time point. Appearance (02) was scored by observation of piloerection of fur, score of (0) indicative of groomed, healthy fur
whereas score of (2) represented ungroomed fur. Activity (0-3) was scored based off (0) normal
activity for the time of day observed and (3) collapsed or immobile. Eye closure (0-2) was
assigned (0) for mice with open eyes and (2) mice with eye discharge in both eyes in addition to
eye closure. Lastly, respiration was scored visually (0) mice with 80-200 breaths per minute and
(2) irregular breathing, or gasping marked by fewer than 80 or more rapid than 200 breaths per
minute. Additive disease scores of the five criteria were assigned to each mouse after evaluation.
Mice that scored an additive disease score of 5 or above among all 5 criteria, or weight loss of
20% or greater during the health assessment required immediate euthanasia. Cumulative disease
scoring was calculated by adding the disease scores of each mouse from the group. Morbid mice
that were euthanized during the study, before day 14, retained their disease score for the
remainder of the experiment.

Euthanasia and tissue collection
Challenged mice that were assigned a health score of 5 or above or reached the end of the
experiment were euthanized with an IP injection of Euthasol (390mg/kg) (Pentobarbital) followed
by secondary measure of euthanasia with cardiac puncture. Blood from cardiac puncture was
collected in BD Microtainer gold serum separator tubes, centrifuged at 15,000 x g for 5 minutes
and serum collected for downstream analysis. Nasal wash was acquired by pushing 1mL of PBS
through the nasal pharynx. 500 μL of nasal wash was added to 167 μL of TRI reagent for RNA
purification and the remainder of the nasal wash was frozen for serological analysis. Lungs were
separated into right and left lobes. Right lobe of the lung was homogenized in 1mL of PBS in
gentleMACS C tubes (order number: 130-096-334) using the m_lung_02 program on the
gentleMACS Dissociator. 300μL of lung homogenate was added to 167μL of TRI Reagent (Zymo
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research) for downstream RNA purification and 300 μL of lung homogenate was centrifuged at
15,000 x g for 5 minutes and the lung supernatant was collected for downstream analyses. Brain
was excised from the skull and separated into the right and left hemispheres. Right hemisphere
was homogenized in 1mL PBS in gentleMACS C tubes using the same setting as lung on the
gentleMACS Dissociator. 167μL of TRI Reagent was added to 500μL of brain homogenate for
RNA purification.

qPCR SARS-CoV-2 viral copy number analysis of lung, brain and nasal wash
RNA purification of the lung, brain and nasal wash was performed using the Direct-zol RNA
miniprep kit (Zymo Research R2053) following the manufacturer protocol. SARS-CoV-2 copy
numbers were assessed through qPCR using the Applied Biosystems TaqMan RNA to CT One
Step Kit (Ref: 4392938). We utilized nucleocapsid primers (F: ATGCTGCAATCGTGCTACAA; R:
GACTGCCGCCTCTGCTC);

and

TaqMan

probe

(IDT:/56-

FAM/TCAAGGAAC/ZEN/AACATTGCCAA/3IABkFQ/) that were synthesized according to
Winkler. et al, 2020 (23). The following final concentrations were used according to the Applied
Biosystems TaqMan RNA to CT One Step Kit manufacturer protocol: TaqMan RT-PCR Mix 2X,
Forward and reverse primers 900nM final, TaqMan probe 250nM final, TaqMan RT enzyme mix
40X and RNA template 100ng (with the exception of nasal wash). Nasal wash RNA
concentrations were not quantifiable on the Qubit 3 fluorometer; therefore, we used 5.4 μL of
nasal wash RNA per reaction instead of 100ng. Triplicates were prepared for each sample, and
samples were loaded into a MicroAmp Fast optical 96 well reaction plate (Applied Biosystems
4306737). Prepared reactions were run on the StepOnePlus Real-Time System machine using
the parameters: Reverse transcription for 15 minutes at 48°C, activation of AmpliTaq Gold DNA
polymerase for 10 minutes at 95°C, and 50 cycles of denaturing for 15 seconds at 95°C and
annealing at 60°C for 1 minute.
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Meso Scale Discovery COVID-19 ACE2 Neutralization assay
SARS-CoV-2 challenged serum was analyzed using the SARS-CoV-2 Plate 7 Multi-Spot 96-well,
10 spot plate following the manufacturer protocol (catalog #: N05428A-1) on the MSD QuickPlex
SQ120. The 10 spots contained: 1) CoV-2 Spike 2) RBD B.1.351 3) CoV-2 N 4) RBD P.1 5) BSA
6) RBD B.1.1.7 7) Spike P.1 8) Spike B.1.1.7 9) Spike B.1.351 and 10) CoV2 S1 RBD. Three
dilutions of serum, 1:5, 1:50, and 1:500 was analyzed on the MSD neutralization assay for each
mouse to perform Area Under the Curve analysis on the electrochemiluminescence using
GraphPad Prism.

Cytokine analysis.
R&D 5-plex mouse magnetic Luminex assay (Ref LXSAMSM) was used to quantify cytokines:
CXCL13, TNFα, IL-6, IFN-γ, and C reactive protein in the serum and lung supernatant.
Manufacturer protocols were followed in preparing samples. 5 plex mouse cytokine plate was
analyzed on the Luminex Magpix and pg/mL were calculated based off standard curves generated
for each cytokine in the assay.

Histopathology
Left lobes of lungs from each mouse in the NVC, IN and IM groups in the WA-1 challenge study
were fixed in 10mL of 10% neutral buffered formalin. Fixed lungs were paraffin embedded into 5
μm sections. Sections were stained with hematoxylin and eosin and sent to iHisto for pathological
analysis. The pathologist was blinded to the experimental groups but was aware of groups that
were challenged or not challenged with SARS-CoV-2. Lung samples were scored for chronic and
acute inflammation in the lung parenchyma, blood vessels, and airways. Each mouse was scored
individually using a standard qualitative toxicologic scoring criteria: 0-none; 1-minimal; 2-mild; 3moderate; 4-marked; 5-severe. Chronic inflammation was denoted by presence of lymphocytes
and plasma cells and acute inflammation was scored by the presence of neutrophils and edema.
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Illumina library preparation, sequencing, and bioinformatic analysis
RNA quantity was measured with Qubit 3.0 Fluormeter using the RNA high sensitivity (Life
Technologies) and RNA integrity was assessed on an Agilent Bioanalyzer 2100 Eukaryote Total
RNA Nano chip (Applied Biosystems). RNA was DNAased before library preparation. Illumina
sequencing libraries were prepared with KAPA RNA HyperPrep Kit with RiboErase (Basel,
Switzerland). Resulting libraries passed standard Illumina quality control PCR and were
sequenced on an Illumina NovaSeq s4 4000 at Admera Health (South Plainfield, NJ). A total of
100 million 2 x 150 bp reads were acquired per sample. Sequencing data will be deposited to the
Sequence Read Archive. The reads were trimmed for quality and mapped to the Mus
musculus reference genome using CLC Genomics Version 21.0.5. An exported gene expression
browser table is provided as supplemental materials Supplementary data 2. Statistical analysis
was performed with the Differential Gene Expression tool and genes were annotated with the
reference mouse gene ontology terms. Genes with an FDR p value of <0.05 were considered
differentially regulated. Volcano plot was generated with statistically significant genes. Genes of
interest were plotted in a heat map that was generated in GraphPad version 9.0. Genes that were
differentially regulated were further analyzed via the online WEB-based GEne SeT AnaLysis
Toolkit using over-representation analysis using the mouse enrichment category gene ontology
and biological process. Heat maps were generated using Morpheus (53).

IgG1/IgG2c subtypes
ELISAs were performed on the challenged serum to assay IgG1 (Novus Biologicals NB7511) and
IgG2c (Novus Biologicals NBP2-68519) titers. ELISAs were coated with RBD following the same
concentration and procedures mentioned above. Plates were blocked with 3% non-fat milk in
PBS-0.1% Tween 20 for one hour at room temperature with shaking at 480rpm. Serum
concentration (1:20) was used as above following a 10-minute incubation period. Secondary
IgG1-HRP and IgG2c-HRP were used at a 1:10000 dilution in 1% non-fat milk in PBS-0.1% Tween
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20 with a 10-minute incubation period. ELISAs were developed and stopped using the same
protocol as above. Titers were represented as Area Under the Curve values.

Statistical analyses and data availability
All statistical analyses were performed using GraphPad Prism version 9. Statistical analyses were
performed with n ≥ 8 for K18-ACE2 mice studies challenged with WA-1, n ≥ 3 for K18-ACE2 mice
studies challenged with Delta variant, and n ≥ 3 for the CD1 mice studies. Error bars represent

standard deviation. Ordinary one-way ANOVA with Dunnett’s multiple comparisons test or TwoWay ANOVA with Tukey’s multiple comparisons test were used with single pooled variance for
data sets following a normal distribution and Kruskal-Wallis with Dunn’s multiple comparisons test
for non-parametric distributed datasets. Kaplan-Meier survival curves were utilized, and Log-rank
(Mantel-Cox) test were used to test significance of survival between sample groups. The datasets
generated during and/or analyzed in this study are available from the corresponding author on
reasonable request. Raw Illumina RNAseq reads were deposited on SRA at accession number
PRJNA797362.
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4.7 Figures

Figure 1. Mouse immunogenicity studies to identify vaccine candidates.

7 COVID-19

vaccine formulations were administered intranasally (A) or intramuscularly (B) in CD-1 mice in
two doses. Heat map depicts the AUC450 values from RBD-IgG titers at 2 weeks post prime (left)
and 2 weeks post boost (right). The maximum AUC450 value is set at 300,000, and the minimum
is at 0.
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Figure 2. Analysis of antibody responses and neutralization capacity of IN and IM BreCCoV-2 vaccines.

CD-1 mice were IN or IM vaccinated with BECC470 with RBD or RBD-

EcoCRM® in two doses. A) Serum was taken at 1 week and 2 weeks post prime, 1 week and 2
weeks post boost and 22 weeks post boost. Log10 AUC450 values from RBD-IgG titers are
depicted for each vaccine.

Results shown as mean ± SD. B) In vitro neutralization assay

performed on the Luminex platform. Serum was obtained from 2 weeks post boost. Naïve
represents the group that received no vaccine, BReC-CoV-2 denotes mice immunized with RBDEcoCRM® adjuvanted with BECC 470, 470 represents BECC470 adjuvant, and receptor binding
protein (RBD).
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Figure 3. Intranasal administration of BReC-CoV-2 protected mice from SARS-CoV2
challenge. A) vaccine and challenge schematic in K18-ACE2 mice. Mice were primed and
boosted with either IN or IM BReC-CoV-2, and blood for serological analysis was collected 2
weeks post prime and boost. Mice were challenged intranasally with 104 WA-1 SARS-CoV-2, and
mice were monitored for 14 days post challenge. B) NVC (n=8), IN BreC-CoV-2 (n=9), and IM
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BreC-CoV-2 (n=10) vaccinated animals Kaplan Meier survival curve. NVC had 31%, IN had 89%,
and IM had 60% survival. Log-rank (Mantel-Cox) test were used to test significance of survival
between sample groups. C) Disease scores were calculated each day for each mouse and added
per group. If a mouse reached a disease score of 5 or above, the mouse was euthanized, but the
score was retained downstream for disease score analysis. D) % weight change from 100% of
the NVC, IN and IM groups. E) % temperature change from 100% of the NVC, IN and IM groups.
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Figure 4. Determination of viral RNA levels in challenged mice. 100ng of lung and brain
homogenate was used to perform qPCR analysis on the SARS-CoV-2 nucleocapsid RNA in the
lung. A) Violin plots depicting the SARS-CoV-2 viral RNA copies in the right lobe of the lung, with
white dotted line representing the median for each group plot. Ordinary one-way ANOVA with
Sidak’s multiple comparisons test was used to perform statistical analysis. P=0.0007***, and
P=0.0436* B) Violin plots depicting the SARS-CoV-2 viral RNA copies in the left lobe of the brain,
with white dotted line representing the median for each group plot. Unpaired T-test was performed
for statistical analysis. P=0.0230*. C) 500µL of nasal wash (NW) was assessed for qPCR
quantification of viral nucleocapsid RNA. Violin plots representing the SARS-CoV-2 viral RNA
copies.
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Figure 5. Serological analysis of serum, lung, and nasal antibodies. RBD IgG and IgA titers
represented by log10 AUC450 values. Results represented as mean ± SD. A) Pre-challenged
NVC, IN and IM RBD IgG titers at 2 weeks post prime (left column, circles) and 2 weeks post
boost (right column, squares). Two-way ANOVA with Tukey’s multiple comparisons test was used
to determine P values. p<0.0001 ****, p=0.0051** B) Serum RBD-IgG titers post challenge. One
way ANOVA performed for statistical analysis with Tukey’s multiple comparisons test. p<0.0001
**** C) Lung supernatant RBD-IgG titers post challenge. One way ANOVA performed for statistical
analysis with Tukey’s multiple comparisons test. p<0.0001 **** D) NW RBD-IgA titers post
challenge. Kruskal-Wallis test with Dunn’s multiple comparisons test performed for statistical
analysis. P=0.0009***, p<0.0108 * E) Lung supernatant RBD-IgG titers post challenge. KruskalWallis test with Dunn’s multiple comparisons test performed for statistical analysis. P=0.0009***,
P=0.0129* F) Serum RBD-IgA titers post challenge.
174

Figure 6. Analysis of RBD-ACE2 neutralization capacity of serum. MSD neutralization assay
with RBD and Spike of the variants of concern with ACE2 was performed. All values are
represented by the log10 AUC of the electrochemiluminescence emitted from the MSD plate
reader. A) Heat map depicts the neutralization capacity of challenged serum of NVC, IN and IM
groups against the RBD of different strains of SARS-CoV-2 (Wuhan, Alpha, Beta, and Gamma).
B) Heat map depicts the neutralization capacity of challenged serum of NVC, IN and IM group
against the Spike of different strains of SARS-CoV-2 (Wuhan, Alpha, Beta, and Gamma). C-D)
Individual values of the neutralization capacity of RBD from the heat map of RBD and spike
represented by the log10 AUC of ECL. Results represented as mean ± SD. Two-way ANOVA
with Tukey’s multiple comparisons test performed for statistical analysis. P=0.0261* (RBD-Wu),
P=0.0322* (RBD-Alpha), P=0.0062**, P=0.0009***(RBD-Beta) P=0.0361* (RBD-Gamma),
P=0.0376 * (Spike-Wu).
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Figure 7. Analysis of CXCL13 in serum or lungs in relation to immunization. A) CXCL13
(log10 pg/mL) in pre-challenged serum. Two-way ANOVA with Sidak’s multiple comparisons test
was performed for statistical analysis. P<0.0001 ****. Naïve baseline represented as dotted line
at 1.861183. B) Post challenged CXCL13 levels in the serum. Ordinary one-way ANOVA with
Tukey’s multiple comparisons test was performed for statistical analysis. P=0.0112*, P=0.0018**,
and P<0.0001****. All results represented as mean ± SD.
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Figure 8. Histopathological analysis of naïve or vaccinated mice challenged with SARSCoV-2. A) 40X magnification of the lung of NVC (scale bar = 300μm) B) 100X magnification of 8A
Inflammation in the parenchyma is denoted by the asterisk, inflammation surrounding the blood
vessel is marked by an arrowhead, and inflammation in the airways are denoted by an arrow
(scale bar = 125μm). C) 40X magnification of the lung of the IN BReC-CoV-2 vaccinated
representative mouse (scale bar = 300μm). D) 100X magnification of 8C. Arrows show
inflammation in the airways (scale bar = 125μm). E) 40X magnification of the lung of the IM BReCCoV-2 vaccinated representative mouse (scale bar = 300μm). F) inflammation in the parenchyma
is denoted by the asterisk, surrounding the blood vessels marked by an arrowhead and
inflammation in the airways represented by arrows (scale bar = 125μm). G) Chronic inflammation
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scores of each mouse. H) Acute inflammation score of each mouse. Results represented as mean
± SD. All statistical analysis was performed using Kruskal-Wallis test with Dunn’s multiple
comparisons test. P=0.0449* (chronic); P=0.0143, 0.150*, 0.0004*** (acute).
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Figure 9. RNAseq analysis reveals IN BReC-CoV-2 vaccination results in unique gene
expression signatures enriched for T cell responses. All analyses were performed on CLC
genomics workbench 21. A) Number of significant (FDR p<0.05) activated and repressed genes
in IN BReC-CoV-2 and IM BReC-CoV-2 groups. B) Volcano plot indicating significant gene
expression profile of IN BReC-CoV-2 compared to NVC. Red circles denote upregulated genes
and blue circles represent down regulated genes. C) Heat maps were generated by Morpheus.
Heat map represents gene counts of immunoglobulin genes in each mouse lung. D) Significant
fold changes of the immunoglobulin genes of interests in both IN and IM BReC-CoV-2 groups. E)
Heat maps were generated by Morpheus. Heat map represents gene counts of adaptive immune
response genes of interest in the mouse lung. F) Significant fold changes of adaptive immune
response genes in both IN and IM groups. IM BReC-CoV-2 did not have significant fold changes.
Red asterisks next to the sample ID indicate mouse morbidity before the termination of the study.
NVC3 and N1 euthanized on day 6, IM5 euthanized on day 7, IM3 euthanized on day 8, IM2
euthanized on day 9, and NVC6 and 7 euthanized on day 10. G) Gene set enrichment analysis
of IN BReC-CoV-2 compared to NVC was performed on WEB-based Gene SeT AnaLysis Toolkit.
Enrichment ratio of significant GO-terms compared to the number of genes in each enriched gene
set. Red represents activated genes and blue represents repressed genes.
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Figure 10. IM BReC-CoV-2 prime followed by IN boost afforded protection against SARSCoV-2 Delta variant challenge. A) Serological analysis of 2 weeks post prime and boost of RBD
IgG titers. Boost time points RB were significant compared to prime. RBD IgG titers represented
by log10 AUC450 values. B) Kaplan Meier survival curve of BReC-CoV-2 vaccinated mice.
Mantel-Cox test used to calculate significance between IN, IM and IM/IN BReC-CoV-2 compared
to NVC. C) Cumulative disease scores of NVC, IN, IM, and IM/IN throughout 12-day course of
study. D) % Weight change of NVC, IN, IM, and IM/IN BReC-CoV-2. E) % temperature change of
NVC, IN, IM, and IM/IN BReC-CoV-2. F) Violin plots depicting the SARS-CoV-2 viral RNA copies
in the brain, with white dotted line representing the median for each group plot. G) Violin plots
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depicting the SARS-CoV-2 viral RNA copies in the right lobe of the lung, with white dotted line
representing the median for each group plot. H) 500µL of nasal wash (NW) was assessed for
qPCR quantification of viral nucleocapsid RNA. Violin plots representing the SARS-CoV-2 viral
RNA copies. Ordinary One-way ANOVA with Tukey’s multiple comparisons test was performed
on the brain (P=0.0236 *), lung (P=0.0144*) and NW (P=0.0391*).
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4.7 Supplementary Figures

Supplementary

Table

1.

COVID-19

vaccine

formulations

and

routes

for

CD1

immunogenicity studies. 7 different COVID-19 vaccine formulations and administered routes
used in CD-1 mice immunogenicity studies.
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Supplementary Table 2. Statistical analysis of RBD IgG titers in CD1 mice vaccinated with
BREC-CoV-2 or RBD + BECC470 (figure 2). Two-way ANOVA with Tukey’s multiple
comparisons test was performed on the RBD IgG titers represented in AUC values on week 1, 2,
4 5 and 22 weeks.
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Supplementary Figure 1. Disease scoring schematic. 5 categories of disease manifestations
that are observed daily. Symptoms in each category are scored from 0 being no symptoms to the
highest number being the worst symptoms. All scores from each category are added up for each
mouse, and if a mouse scores a 5 or above, the mouse will be humanely euthanized.
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Supplementary Figure 2. BReC-CoV-2 vaccination demonstrated a balanced Th1/Th2
response. A) Serum IgG2c represented by log10 AUC450 in challenged mice. B) Serum IgG1
represented by log10 AUC450 in challenged mice. Results represented as mean ± SD. Ordinary
one-way ANOVA with Tukey’s multiple comparisons test was performed for statistical analyses.
P=0.0047** (IgG2c) and P<0.0001**** and P=0.0063** (IgG1).
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Supplementary Figure 3. IN BReC-CoV-2 decreased IFNγ in the lung. A) TNF-α (pg/mL) in
the lung supernatant. B) IL-6 measured in the lung supernatant. C) IFNγ measured in the lung
supernatant. Ordinary one-way ANOVA with Dunnett’s multiple comparisons test was used for
statistical analysis. P=0.0325*. D) CRP measured in the lung supernatant. Results represented
as mean ± SD. Ordinary one-way ANOVA with Dunnett’s multiple comparisons test was used for
statistical analysis P=0.0041 (NVC vs. IN) and P=0.0078 (NVC vs. IM).
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Chapter 5: Discussion
5.1 Overview
Emerging SARS-CoV-2 variants of concern have added additional challenges to COVID-19
vaccine and therapeutic development as well as impacted the efficacy of currently available
vaccines and therapeutics. Here, we utilized pre-clinical models to help understand the immune
response against SARS-CoV-2 to improve upon COVID-19 vaccines. The culmination of this
portfolio of work depicted in chapters 2-4 describes the utilization of the transgenic K18-hACE2
mouse model to establish a pipeline to: 1) study SARS-CoV-2 pathogenesis, 2) evaluate systemic
and mucosal immune responses against SARS-CoV-2, and 3) develop vaccines and assess
efficacy.
In chapter 2, we established a passive immunization model in K18-hACE2 mice to evaluate
human convalescent plasma (HCP) obtained from a patient infected with the ancestral strain of
SARS-CoV-2 against variants of concern, Alpha, Beta, and Delta. In this study, we evaluated
survival, disease burden, viral RNA in the lung and brain, SARS-CoV-2 HCP antibody duration in
systemic circulation, and histopathology in the lung post challenge. Passive immunization against
VOC challenge demonstrated that ancestral strain polyclonal antibodies protected mice against
ancestral SARS-CoV-2 (WA-1) (100% survival), and partially protected against Alpha (60%
survival) which corresponded with decreased lung inflammation (Ch.2, Fig.5), disease (Ch.2, Fig.
2), and viral RNA burden (Ch.2, Fig. 3) compared to mice treated with healthy human sera and
challenged with SARS-CoV-2. Mice treated with HCP and challenged with Beta resulted in high
viral RNA burden in the lung and brain leading to 100% morbidity despite having similar RBD and
nucleocapsid IgG titers in the serum and lung as the ancestral and Alpha challenged HCP treated
mice (Ch.2, Fig. 2, 4). As an attempt to enhance protection against Delta challenge, we
administered 6 consecutive doses of HCP to mice. Unfortunately, passively immunized mice did
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not survive challenge with a lethal Delta dose, demonstrating severe disease outcomes and high
viral RNA levels in the lung, brain, and nasal wash (Ch.2, Fig.6) Overall, the establishment of a
passive immunization model allowed us to understand the antibody responses against different
emerging VOC to better develop vaccines and therapeutics against COVID-19. Chapter 2 focused
on understanding the antibody response against different VOC and provided a model to study
emerging VOC in vivo.
In chapter 3, we utilized the VOC challenge model in K18-hACE2 mice from chapter 2 to evaluate
vaccines against Alpha and Beta challenge. In this study, four RBD-VLP vaccines composed of
RBD displayed on Hepatitis B surface antigen (HBsAg) adjuvanted with either Alum or SWE were
evaluated and compared to the standard Pfizer-BioNTech mRNA vaccine. The experimental
vaccines included: 1) β RBD HBsAg + Alum, 2) β/Wu RBD HBsAg +Alum, 3) β RBD HBsAg +
SWE, and 4) β RBD +SWE (Ch.3, Table S1). Mice were administered 3 doses of the experimental
vaccines or 2 doses of the mRNA vaccine intramuscularly and challenged with either Alpha or
Beta VOC. Results demonstrated that mice immunized with RBD HBsAg experienced higher
survival than mice immunized without the HBsAg; however, only mice immunized with β/Wu RBD
HBsAg +Alum, β RBD HBsAg + SWE, and mRNA had 100% survival against both Alpha and Beta
challenge (Ch. 3, Fig.2). Disease pathologies, viral RNA burden in the lung and brain, and lung
inflammation were consistent with survival results (Ch.3, Fig. 2,3). Furthermore, the serological
analysis revealed that β RBD HBsAg + SWE generated increased binding antibodies to multiple
VOC RBD compared to Alum adjuvanted RBD-HBsAg vaccines (Ch.3, Fig.1). Also, all RBDHBsAg vaccines elicited a broadly neutralizing antibody response against VOC RBD similar to
Pfizer-BioNTech mRNA (Ch.3, Fig.4, S2).
In chapter 3, we focused on evaluating the efficacy of intramuscular COVID-19 vaccines in the
K18-hACE model; however, in chapter 4, we shifted our emphasis to improving COVID-19
vaccines by developing an intranasal protein subunit vaccine. We developed a COVID-19 vaccine
composed of RBD conjugated to a carrier protein EcoCRM adjuvanted with a lipid A mimetic,
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BECC470 (BReC-CoV-2). Mice were primed and boosted with BReC-CoV-2 either through the
intramuscular route or intranasal route and challenged with the ancestral strain of SARS-CoV-2.
Results demonstrated that nasal administration of BReC-CoV-2 led to higher survival (89%)
compared to intramuscular administration of BReC-CoV-2 (60%) (Ch.4, Fig.3). Mice vaccinated
intranasally with BreC-CoV-2 also maintained weight and temperature throughout challenge and
had lowered viral RNA burden in the lung, nasal wash, and brain. Additionally, intranasal
vaccinated mice induced broadly neutralizing antibodies against VOC RBD, and elicited a robust
RBD IgA response in the respiratory tract compared to intramuscular vaccination (Ch.4,
Fig.3,4,5,6). Furthermore, bulk RNA sequencing revealed that intranasal administration of BreCCoV-2 generated both B and T cell signatures in the lung during SARS-CoV-2 challenge (Ch.4,
Fig. 9). In this study, we also evaluated a heterologous prime and boost vaccine approach with
BReC-CoV-2. Here, mice were primed intramuscularly with BReC-CoV-2 followed by an
intranasal boost with the same formulation and challenged with Delta VOC. Mice vaccinated via
the heterologous prime and boost vaccine strategy with BReC-CoV-2 were protected against
challenge, while homologous intranasal or intramuscular vaccination only resulted in partial
protection (60% and 40% respectively). (Ch.4, Fig. 10). Overall, chapter 4 demonstrates that
nasal vaccination can offer both localized and systemic protection against SARS-CoV-2 and a
nasal booster following an intramuscular prime can help induce protection against VOC.
We acknowledge that studies performed in chapters 2-4 contain limitations. All in vivo studies in
chapters 2-4 were performed in the K18-hACE2 mouse model. Despite the advantages of using
the lethal mouse model to evaluate vaccine protection against SARS-CoV-2 challenge, the over
expression of hACE2 in the brain leading to morbidity in the K18-hACE2 mouse is not reflective
of human COVID-19 disease progression. Other model organisms such as hamsters, ferrets, and
non-human primates have more similar COVID-19 symptoms and disease outcomes compared
to the K18-hACE2 model. In order to evaluate vaccine effectiveness against pneumonia like
symptoms caused by SARS-CoV-2 and transmission of the virus, future studies should utilize the
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Syrian hamster model. Chapters 2-4 utilized qRT-PCR for viral RNA quantification in the lung,
brain, and nasal wash. However, measuring total genomic viral RNA detected by qRT-PCR does
not specify the presence of infectious virions. Therefore, future vaccine and challenge studies will
focus on incorporating plaque forming unit (PFU) assays to the studies to measure infectious
SARS-CoV-2 virions in the lung, brain and nasal wash along with viral RNA quantification.
Additionally, all neutralization assays were performed using an in vitro RBD to hACE2 binding
assay. Even though the in vitro neutralization assay provided crucial information on serum
antibody neutralization across multiple RBDs from variants of concern, live virus neutralization
should also be performed to further support in vitro neutralization assays. Furthermore, IM/IN
studies performed with the BECC470 adjuvant in chapter 4 elicited highly immunogenic
responses which could have contributed to toxicity in mice. Future vaccine studies utilizing
BECC470 as an adjuvant should focus on titrating BECC470 to find the optimal immunogenic but
safe dose.
Chapter 5 reflects on the current COVID-19 pandemic responses and discusses the
repercussions caused by SARS-CoV-2. Overall, in this chapter, we apply the lessons learned
from the pandemic to develop novel vaccine approaches to improve vaccine immunity against
emerging SARS-CoV-2 VOC with the ultimate goal of preventing future outbreaks and pandemics
caused by SARS-CoV-2.
5.2 Pandemic response
Since the initial WHO declaration of the COVID-19 pandemic in March 2020, there has been over
535 million confirmed COVID-19 cases and over 6 million deaths worldwide (Our World in Data).
The availability of COVID-19 vaccines and treatments have alleviated hospitalizations and deaths;
but the pandemic is still ongoing. The COVID-19 pandemic united scientists worldwide to study
SARS-CoV-2 in order to develop vaccines, therapeutics and treatments, but also learn from the
challenges to improve upon future pandemic preparedness.
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As soon as China released the genomic sequence of SARS-CoV-2 in January 2020, COVID-19
vaccine development was underway. Previous research performed on the endemic causing
coronaviruses severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East
respiratory syndrome coronavirus (MERS-CoV) aided in the swift development of current COVID19 vaccines. Previous studies characterizing SARS-CoV and MERS-CoV as well as other
coronaviruses showed the mechanism of infection through spike protein binding to ACE2 similar
to SARS-CoV-2 infection (1). Therefore, characterizing the virology and pathogenesis of SARSCoV and MERS-CoV helped in the selection of the spike protein as a candidate vaccine antigen
for COVID-19 vaccine development. Furthermore, studies engineering the pre-fusion stabilization
spike protein for SARS and MERS also contributed to the development of the current pre-fusion
stabilized spike protein used in COVID-19 vaccines (2,3). COVID-19 mRNA vaccines were the
first vaccines to obtain emergency use approval in the United States in December 2020 and were
the first vaccines to gain FDA approval in the United States. The accelerated development of
COVID-19 mRNA vaccines also comprised over 30 years of previous research involving the
synthesis of mRNA, stabilization, and delivery of mRNA in lipid nanoparticles as therapeutics and
vaccines (4). The culmination of mRNA research led to the first mRNA vaccines for rabies and
influenza to enter clinical trials in 2013 and 2015 respectively before the utilization of mRNA
technology for COVID-19 (4). Overall, with the previous research performed on coronaviruses
and mRNA, companies and research institutes were able to quickly and safely develop potent
vaccines that could decrease deaths and hospitalization due to COVID-19. However, gaps in the
vaccine development response included limited research on the durability of the vaccine response
at the time, unclear dosing schedules, and inclusion of only the ancestral strain of SARS-CoV-2
antigens in vaccine formulations.
5.2.1 Repurposing of animal models
The global research effort to restrain COVID-19 also resulted in the repurposing of pre-clinical
animal models such as the K18-hACE2 mouse, ferret, and the non-human primate models to
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better understand pathogenesis, transmission, and immune responses against SARS-CoV-2
(5,6). Together, these pre-clinical models established platforms to evaluate vaccine and
therapeutic efficacy as well as provided the avenue to improve current vaccines and therapeutics.
5.2.2 Implementation of antibody-based therapeutics and antivirals to treat COVID-19
Along with vaccines, therapeutics and antivirals were also developed throughout the span of the
pandemic to treat SARS-CoV-2 infection. In the beginning of the pandemic, human convalescent
plasma from recovered SARS-CoV-2 patients was used as a treatment for severe COVID-19
cases. Currently, studies have demonstrated that convalescent plasma could improve severe
cases of COVID-19 (7,8). In December 2021, WHO recommended against the use of
convalescent plasma treatment for non-severe COVID-19 cases as studies have shown no
benefit but proposed that convalescent plasma treatment for severe cases should be further
investigated in clinical trials. The FDA also updated the guidelines on emergency use approval
(EUA)

on

high

titer

convalescent

plasma

treatment

to

only

be

administered

to

immunocompromised patients or patients taking immunosuppressive drugs. Overall, the use of
convalescent plasma for severe COVID-19 treatment still needs further evaluation in clinical trials
but could be used as emergency first response treatments for future pandemics or outbreaks until
vaccines or therapeutics are developed. EUA was granted to several monoclonal antibody
therapies targeting the spike protein such as Sotrovimab, REGEN-COV (Casirivimab and
Imdevimab), Bamlanivimab and Etesevimab, and Bebtelovimab in 2021 (CDC). In 2022, Omicron
became the predominant VOC, with over 30 mutations accumulated on the spike protein.
Therefore, because of the heavily mutated spike protein, monoclonal antibody therapies
Sotrovimab, REGEN-COV (Casirivimab and Imdevimab), Bamlanivimab and Etesevimab were
no longer efficacious against Omicron and EUA approval was revoked (FDA). However, the
cocktail antibody therapy Bebtelovimab, maintained effectiveness against Omicron and
subvariants and retained EUA approval. Lastly, the availability of antivirals also mitigated the
severity of COVID-19 in most developed countries. In the US, the FDA has authorized 3 antivirals
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to treat COVID-19: 1) Paxlovid, 2) Remdesivir, and 3) Molnupiravir (CDC). Paxlovid is a
combination of both nirmatrelvir and ritonavir and is used to treat mild-moderate COVID-19 (9).
Nirmatrelvir is a protease inhibitor that stops SARS-CoV-2 replication and ritonavir is a drug that
prolongs the half-life of nirmatrelvir to better increase activity of nirmatrelvir (9). Paxlovid is
prescribed orally and recommended to be taken within 5 days of symptom onset (9). Remdesivir
stops viral replication by inhibition of viral RNA dependent RNA polymerase (10). Unlike Paxlovid,
Remdesivir is reserved for high-risk patients with mild to moderate COVID-19 or hospitalized highrisk patients and is administered intravenously. Molnupiravir is a nucleoside analog antiviral drug
that stops viral replication prematurely by integration into the viral RNA during synthesis (11).
Additionally, Molnupiravir is recommended for high-risk patients with mild to moderate COVID-19
and is administered orally at least within 5 days of symptom onset.
5.2.3 Local community response to COVID-19
The focus of the initial responses of the research community included helping their local
community develop reagents and assays to detect SARS-CoV-2 in human samples. Here at West
Virginia University, a COVID-19 task force comprised of biochemists, virologists, immunologists,
and physicians were assembled by Drs. Laura Gibson and Clay Marsh and supported by the state
of West Virginia. The objective of the COVID-19 task force was to provide West Virginia with the
tools to mitigate the spread COVID-19. Reagents such as RBD and spike protein were produced
in house, for antibody detection assays (12). Additionally, viral genomic sequencing was
established for SARS-CoV-2 surveillance, and PCR assays were developed to detect
nucleocapsid RNA. As a result, WVU established the in-house WVU Rapid Development
Laboratory which provided the capability to test more residents of WV, provide better surveillance
of circulating VOC in WV, and offer faster turnaround times for PCR results.
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5.2.4 Global response to vaccine inequity
Lastly, the COVID-19 pandemic has intensified global health inequalities such as vaccine inequity.
Currently, 11.99 billion COVID-19 vaccine doses have been administered with approximately 66%
of the global population receiving at least one dose of a COVID-19 vaccine (Our World in Data).
However, only 17.8% of the population in developing countries are vaccinated with at least one
dose. For example, many countries in Africa have less than 10% of the population that has
received at least one vaccine dose. The sparse vaccine distribution into developing counties not
only is a large humanitarian crisis but scientists are worried that low vaccination and high
transmission rates of SARS-CoV-2 could allow for the emergence of new variants of concern (13).
To help achieve higher vaccination rates in developing countries, global organizations such as
the Bill and Melinda Gates Foundation have donated over 2 billion dollars to aid in the global
COVID-19 response (14). Funds from the Gates Foundation have been allocated to mitigate
transmission in sub-Saharan Africa and South Asia by providing tests, treatments, and vaccines.
Additionally, the Gates Foundation have funded grants to other programs for COVID-19 research,
as well as invested in companies that can provide medical supplies for low- and middle-income
countries (14). Furthermore, COVAX is one of the largest global collaboration programs with the
goal of bringing vaccine equity around the world with the focus on accelerating the development
of COVID-19 vaccines and through acquiring vaccines through large vaccine manufacturers to
distribute to developing countries (15). COVAX is comprised of the Coalition for Epidemic
Preparedness Innovations (CEPI), Gavi (Vaccine Alliance), the WHO, and UNICEF. The overall
goal of COVAX was to distribute 2 billion vaccine doses by 2021. However, due to challenges
such as vaccine hoarding by high-income countries, cold chain requirements, and supply chain
issues, COVAX fell short of their goal, but still was able to distribute over 1 billion doses to 148
countries and territories (16). Overall, COVAX predicts that it will need an additional 350 million
dollars to continue research and development on developing vaccines for emerging VOC,
increase vaccine supply and to continue clinical trials for COVID-19 vaccines.
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5.3 Manufacturability of COVID-19 vaccines for developing countries
Chapters 3 and 4 investigates RBD-based vaccines that could benefit developing countries. In
general, RBD serves as an optimal vaccine antigen choice that can be used to meet the vaccine
demands in developing countries. Utilization of RBD instead of the spike protein in vaccine
formulations can offer advantages such as cost efficiency, ease of production in large volumes,
and temperature stability (17–20). Additionally, RBD similar to full-length spike protein is an
immunogenic target which encompasses 90% of neutralizing antibody targets obtained from
convalescent pools (21). Furthermore, vaccine components disclosed in chapter 3 such as RBDHBsAg can be mass produced by the Serum Institute of India, and can be stored and transported
at 4°C. In chapter 4, components of the BReC-CoV-2 can also be easily scaled up for production
and require limited cold chain storage. In particular, BECC470 adjuvant can be lyophilized,
avoiding cold-chain requirements. Future ideal vaccine preparations could yield both lyophilized
vaccine antigen and adjuvant formulations to improve shelf life, and transportation and delivery
of vaccines into developing countries (22).
5.4 The impact of SARS-CoV-2 zoonosis and recombination events
Many infectious diseases throughout history originated from animal to human spillover events.
Coronavirus outbreaks caused by SARS-CoV from 2002-2003 and MERS-CoV in 2012 were
speculated to originate from bats and then moved into civics and dromedary camels as
intermediate hosts to jump into the human population (23). Bats were also hypothesized to be the
original reservoir to harbor SARS-CoV-2. Studies found that the coronavirus strain RaTG13
discovered in horseshoe bats had 96% genome similarity to SARS-CoV-2 (24). Intermediate
hosts such as pangolins and minks have also been considered as reservoirs that aided in the
SARS-CoV-2 spillover into humans (25) (Ch.5, Fig.1). The influenza pandemics were also caused
by spillover events from avian and swine origins. There has been a total of four influenza
pandemics that have occurred over the span of 100 years. The 1918 H1N1 pandemic was the
first recorded influenza pandemic, followed by the H2N2 in 1957, H3N2 in 1968, and another
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H1N1 pandemic in 2009 (26). Interestingly, the virus that caused the most recent H1N1 pandemic
in 2009 was a result of antigenic shift caused by the reassortment of three previous influenza
strains originating from birds, pigs and humans (27). Antigenic shift is defined as two or more flu
strains that can exchange entire genetic segments via reassortment to generate a new flu variant
with different antigen variations. Typically, humans have no pre-existing immunity to new flu
variants resulting from antigenic shift which can thus lead to pandemics and outbreaks.
Furthermore, reassortment events that happen during antigen shift can only happen in viruses
that possess segmented genomes such as influenza; however, coronaviruses, do not have a
segmented genome. Even though coronaviruses cannot undergo reassortment to generate new
strains, coronaviruses can undergo recombination events similar to reassortment during antigenic
shift. Studies showed that RaTG13, a betacoronavirus obtained from bat, possessed the highest
genomic similarity to SARS-CoV-2; however, the receptor binding motif found on RaTG13 was
genetically dissimilar. Nevertheless, coronaviruses found in pangolins were genetically divergent
from SARS-CoV-2 but harbored a receptor binding motif that could bind to human ACE2.
Therefore, data suggested that SARS-CoV-2 could have originated from the recombination of
both bat and pangolin coronaviruses that ultimately spilled over into humans (25,28) (Ch.5, Fig.1).
5.4.2 SARS-CoV-2 spillover and spillback events
Furthermore, genomic surveillance of SARS-CoV-2 have detailed human to animal transmission
in cats, dogs, lions, tigers (zoo setting), minks and white-tailed deer. From this spillover, animal
to animal transmission also have occurred between minks and deer (Ch.5, Fig.1). The SARSCoV-2 outbreak that occurred at the mink farm in Denmark in 2020 is an example of human to
mink spillover and subsequently mink to human spillback. The variant of SARS-CoV-2 that was
transmitted back from minks to humans contained a newly acquired Y453F mutation on the RDB
that could enhance the binding of spike protein to human ACE2 (29,30). SARS-CoV-2 also has
established a natural reservoir in the white-tailed deer population in North America with 30-40%
seroprevalence (31,32) (Ch.5, Fig.1). However, studies have demonstrated that SARS-CoV-2 did
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not acquire mutations that increased viral fitness in humans (31). Additionally, it is speculated
that Omicron originated from mice and then jumped back into humans (Ch.5, Fig.1). Mutations
accumulated following human to mouse transmission allowed for SARS-CoV-2 to acquire
mutations in the spike protein to increase binding affinity to mouse ACE2 (33,34). Further
evidence demonstrates that Omicron also accumulated mutations in the mouse that could cause
further immune evasion in human hosts.
5.4.3 Prediction on future emerging SARS-CoV-2 variants
Altogether, even though SARS-CoV-2 mutation rate is slower than influenza viruses, the ability of
SARS-CoV-2 to undergo recombination with other coronaviruses and establish reservoirs in
mammalian host generates concern for the future of the COVID-19 pandemic. The ability of
SARS-CoV-2 to establish animal reservoirs suggests that it will be difficult to fully eradicate SARSCoV-2 from circulation. Additionally, animal hosts can also provide an opportunity for SARS-CoV2 to undergo recombination with other variants to generate new strains of SARS-CoV-2. Despite
limited evidence demonstrating that SARS-CoV-2 can accumulate mutations in animal reservoirs
that could cause an increase of virulence and transmissibility in humans, potential spillback events
from animals to humans could occur and lead to emergence of variants of high consequence.
SARS-CoV-2 variant of high consequence are characterized as variants that can resist available
therapeutics and treatments, increase hospitalizations, evade vaccine protection, and cannot be
detected with available detection assays. To date, no variants of high consequence have been
reported. Overall, to prevent future zoonotic spillover events, increased genomic of surveillance
of animals, waste water, and humans are necessary to detect newly emerging variants (25).
Prompt responses to newly emerging variants could allow for more time to develop vaccines,
therapeutics, and antivirals to curb future coronavirus outbreaks and pandemics.
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Figure 1. SARS-CoV-2 zoonosis and VOC evolution. SARS-CoV-2 is classified as a zoonotic disease. Spillover into humans
is speculated to have originated in bats or through intermediate host such as the pangolin. SARS-CoV-2 transmission from
humans to companion animals (dogs and cats), zoo animals (lions and tigers), and to farmed minks have been documented.
Additionally, human transmission to animals in nature such as white-tailed deer and mice have also been documented. Spillover
and spillback cases of transmission could potentially result in recombination of different variants of the virus leading to emerging
variants of concern which could cause future SARS-CoV-2 outbreaks.

5.5 Improving COVID-19 vaccines
Current available COVID-19 vaccines have mitigated the severity of COVID-19 by reducing
hospitalizations and deaths. However, due to the accelerated development and production of
approved COVID-19 vaccines, limited studies have been performed to assess the longevity of the
vaccine response against SARS-CoV-2 as well as vaccine response against SARS-CoV-2
variants. COVID-19 vaccination and SARS-CoV-2 infection stimulate the optimal protection
against SARS-CoV-2 compared to vaccine alone (Ch.5, Fig.2). Optimal protection included the
production of broadly neutralizing antibodies against SARS-CoV-2, induction of mucosal IgA,
stimulation of CD4 and CD8 cellular immune responses and lastly generation of memory B and T
cells (35,36) (Ch.5, Fig.2). Therefore, in order to elicit long-term immunity and immunity against
VOCs, vaccination strategies that mirror vaccination and infection immune responses could be
investigated to increase protection against SARS-CoV-2.
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Figure 2. Mucosal and systemic immunity against SARS-CoV-2. The hybrid of both mucosal and
systemic immunity are needed to provide optimal protection against SARS-CoV-2 infection. During infection
or nasal vaccination, the mucosal immune response is initiated in the mucosal induction sites such as the
NALT. The NALT is composed of M-cells, dendritic cells, B-cell dominated follicles and parafollicular zone
surrounding the B-cell follicles largely inhabited by T-cells. Pathogen or vaccines are sampled by M-cells
and distributed to dendritic cells for processing which are used to activate T-cells and B-cells. Activated T
and B cells in the NALT then migrate through the cervical lymph node to effector sites, where T-cells help
B-cells differentiate into IgA secreting B-cells. During intermuscular vaccination, antigen presenting cells
process vaccine antigen and move into the draining lymph node to activate CD4 and CD8 T-cells. In the
lymph node establishment of germinal centers by T-cell help allow for the maturation of B-cells into high
affinity IgG secreting plasma cells. Activated cells can migrate to effector sites in the lung.
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5.5.1 Improving longevity
Recent studies evaluating the mRNA COVID-19 vaccines (Comirnaty and Spikevax), adenovirus
vectored vaccines (Ad26.COV2.S and Vaxzevria), and protein subunit vaccines (Nuvaxovid) have
assessed vaccine mediated immune responses out to 6 months in fully vaccinated individuals.
Studies overall demonstrated that after 6 months, vaccine immune responses begin to wane
(37,38). Neutralizing antibody titers decreased in all vaccines evaluated after 6 months post
vaccination, with the highest neutralizing titers belonging to individuals vaccinated with Spikevax,
followed by Comirnaty and Nuvaxovid, and lastly trailed by Ad26.COV2.S vaccinated individuals
with the lowest neutralizing titers (37). However, while neutralizing antibodies fell after 6 months,
all vaccine platforms induced detectable spike specific CD4+, CD8+ and B memory responses.
(37). Overall, mRNA vaccines were more immunogenic than protein subunit and adenoviral
vectored vaccinated individuals, stimulating either higher or similar memory responses compared
to Nuvaxovid and Ad26.COV2.S (37).
Despite available COVID-19 vaccines retaining spike specific cellular and humoral memory
responses against SARS-CoV-2, waning immunity remains an issue. Currently, the CDC
recommends for adults to receive three doses of mRNA vaccine, and a 4th dose for people 50 or
older. The vaccine schedule entails waiting 3-8 weeks after receiving the first dose of vaccine
before obtaining the second dose, followed by at least a 5-month interval before acquiring the
third dose. Constant boosting may elevate neutralizing titers and improve responses against
emerging variants but is not a feasible plan of action for the future (39–41). To circumvent frequent
dosing of COVID-19 vaccines, different approaches can be taken to improve longevity of COVID19 vaccines. Heterologous prime and boost strategies with either different vaccine formulations
or different routes of administration can be used to induce long-term immunity. In chapter 4, mice
were primed intramuscularly with BReC-CoV-2 then boosted intranasally with the same
formulation. The IM prime and IN boost strategy resulted in 100% survival from a lethal Delta
challenge compared to 60% survival in homologous IN BReC-CoV-2 vaccination and 40%
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survival in homologous IM BReC-CoV-2 vaccination (Ch.4, Fig.10). We hypothesized that the
heterologous IM prime and IN boost strategy operated as a push-pull system to generate
protection. IM vaccination pushed antibody magnitude and cellular responses and the IN boost
not only induced an IgA response in the respiratory tract but also pulled circulating antibodies and
effector cells generated from both IM and IN vaccination into the respiratory tract. Additionally, we
hypothesize that the immunity generated after heterologous IM prime and IN boost mimics hybrid
or vaccine breakthrough immunity. Studies demonstrated that the immunity generated from
COVID-19 vaccination and SARS-CoV-2 infection could lead to long-term protection against reinfection for more than 1 year unlike COVID-19 vaccination only (42–44).
Furthermore, implementation of different vaccine boosters could also improve long-term immune
responses. Heterologous prime and boost strategies have already been implemented into
COVID-19 vaccination approaches for adenovirus vectored based vaccines. Clinical studies have
shown that heterologous prime with ChAdOx1nCoV-19 and boost with mRNA generated
enhanced broadly neutralizing antibodies against VOC, increased spike specific IgG and IgA
responses, and elicited elevated levels of spike specific CD4 and CD8 T-cells compared to
homologous administration of mRNA or ChAdOx1nCoV-19 (45–47). Therefore, the opportunity to
stimulate both strong cellular responses from the adenovirus vaccine in combination with the
robust humoral responses from the mRNA vaccine could overall potentially increase vaccine
longevity. Overall, further studies need to be conducted in both the pre-clinical and clinical settings
to evaluate COVID-19 vaccines long-term effectiveness. Additionally, COVID-19 vaccines in
development currently should also focus on performing long-term studies in pre-clinical models
to assess the durability of the immune response. More studies should also be performed
assessing the effect of adjuvanted vaccines, administration strategies, timeline of dose
administration, and/or delivery strategies to promote longer and stronger immune responses.
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5.5.2 Improving vaccine responses against VOC
All current approved COVID-19 vaccines utilize the spike protein of the ancestral strain of SARSCoV-2. However, the ancestral strain that was circulating in 2019 and 2020 is essentially nonexistent. Approved COVID-19 vaccines have suffered a decrease in vaccine efficacy against past
and present VOC resulting in less protection against symptomatic disease (48,49). Fortunately,
COVID-19 vaccines were still effective at preventing hospitalizations and death due to infection.
With the emergence of new VOC, it is pertinent that COVID-19 vaccines provide broad protection
amongst all variants of concern. The arrival of Omicron and its subvariants revealed the need for
vaccine boosters to increase protection against infection. Two doses with mRNA or
ChAdOx1nCoV-19 were not able to protect against symptomatic infection with Omicron; however
a subsequent boost with either mRNA or ChAdOx1 provided an increase of vaccine efficacy
against Omicron but only for a few months until responses began to wane (50,51). Currently both
Pfizer and Moderna are developing Omicron specific mRNA vaccines to help increase vaccine
efficacy against Omicron. Moderna has developed a bivalent Omicron booster candidate mRNA1273.214 containing both the original Spikevax vaccine accompanied with candidate Omicron
specific mRNA. In a press release, Moderna announced that administration of mRNA-1273.214
booster in people who have already received 2-3 doses of an approved COVID-19 vaccine
resulted in an eight-fold increase of neutralizing antibody titers against Omicron above baseline
(52,53). Similar to the Moderna bivalent COVID-19 vaccine, we have shown in chapter 3, that
vaccination with both Beta RBD-HBsAg and Wuhan RBD-HBsAg adjuvanted with Alum in mice
resulted in 100% protection against both Alpha or Beta challenge whereas Beta RBD-HBsAg +
Alum alone resulted in 60% survival against Alpha challenge and 80% survival against Beta
challenge (Ch.3, Fig. 2).
Furthermore, developing variant specific boosters may alleviate short-term problems that arise;
however, do little to prevent future outbreaks or pandemics caused by coronaviruses that could
spillover from animal reservoirs. Therefore, the development of pan-coronavirus vaccines could
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help lessen the severity of future coronavirus outbreaks. Studies have demonstrated that humans
first infected with SARS-CoV then vaccinated with Comirnaty generated pan-coronavirus
neutralizing antibodies that could recognize SARS-CoV, SARS-CoV-2 Wuhan, Alpha, Beta, Delta
and 10 other coronaviruses found in animals (54). Pre-clinical development of pan-coronavirus
vaccines are underway. Currently, there are approximately four vaccines utilizing mosaic
nanoparticles and VLPs to display different coronavirus spike and RBD proteins (55,56).
5.6 Developing protective nasal COVID-19 vaccines
As mentioned in chapter 1, Flumist is the only approved intranasal vaccine. However, 12 nasal
COVID-19 vaccines are in clinical trials and even more nasal vaccines are currently being
evaluated in pre-clinical trials. Interestingly, the majority of COVID-19 vaccines in clinical trials are
live viral vectored vaccines. No protein subunit vaccines are currently in clinical trials, and less
than ten nasal vaccines in pre-clinical studies utilize the protein-based vaccine platform (57). We
hypothesize that nasally administered viral vectored vaccines can lead to greater induction of
mucosal immune responses since it shares similarity to a live infection. The mucosal tissue in
general maintains a high tolerance or lack of responsiveness to foreign antigens. Therefore, to
generate an immunogenic mucosal vaccine response, mucosal tolerance must be broken. T
regulatory cells drive tolerogenic mucosal immune responses after mucosal antigen exposure by
downregulating the activation of Th1 effector cells and decreasing the release of pro-inflammatory
cytokines such as INF-gamma. Infections in the mucosa can break mucosal tolerance by
releasing Pathogen Associated Molecular Patterns (PAMPs) that can trigger Toll-like Receptors
to stimulate and activate the mucosal immune response (58). Therefore, we speculate that the
mucosal immune response generated by viral vectored vaccines can be induced by intranasal
administration of adjuvanted protein-based vaccines to the same or greater magnitude.
In chapter 3, we evaluated the vaccine efficacy of the VLP-based vaccine antigen RBD-HBsAg in
mice. We showed that RBD-HBsAg VLP was needed to induce a protective immune response
against Alpha or Beta challenge and elicit broadly neutralizing antibodies against VOC (Ch.3,
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Fig.1,2,4). Additionally, in chapter 4, we evaluated intranasal administration of BreC-CoV-2, a
bacterial carrier protein-based vaccine adjuvanted with a strong TLR4 agonist BECC470. In the
same study, we showed that the RBD-CRM antigen was less immunogenic when administered
intranasally alone, or adjuvanted with CpG or IRI (Beta-glucan adjuvant) (Ch.4, Fig.1). Therefore,
in order to develop a more efficacious intranasal COVID-19 vaccine formulation we combined the
immunogenic RBD-HBsAg vaccine antigen evaluated in chapter 3 with the immunostimulatory
BECC470 adjuvant assessed in chapter 4. We assessed the vaccine efficacy of the new prototype
vaccine RBD-HBsAg+BECC470 in the K18-hACE2 mouse challenge model and found that RBDHBsAg+BECC470 protected mice (100% survival) against lethal Delta challenge as well as
induced broadly neutralizing antibodies against VOC (data not shown). Future studies with RBDHBsAg+BECC470 should focus on evaluating RBD-HBsAg+BECC470 as an intranasal booster
to mRNA vaccinations to increase the longevity of immune responses. Similar studies assessing
intranasal boost after mRNA prime has demonstrated stimulation of protective mucosal cellular
and humoral responses (Ch.5, Fig.3) (59). Additionally, RBD-HBsAg+BECC470 should be
studied in the context of transmission in either hamster or ferret models to evaluate the ability of
RBD-HBsAg+BECC470 to inhibit transmission of SARS-CoV-2.
Moreover, we also evaluated attenuated viral vectored vaccines as nasal vaccine candidates. We
collaborated with the Bloom lab at Fred Hutchinson Cancer Research Center to evaluate their
attenuated influenza expressing SARS-CoV-2 RBD vaccine candidate (RBD-Flu) in the K18hACE2 challenge model (Ch.5, Fig.3). The RBD-Flu vaccine antigen was generated by replacing
neuraminidase on the surface of influenza virions with RBD (60). Mice vaccinated with 2 doses of
RBD-Flu and challenged with Delta were partially protective against lethal Delta challenge (60%
survival) (data not shown). Future studies with RBD-Flu could include evaluating the RBD-Flu and
mRNA as a heterologous IN prime and IM boost strategy with the hypothesis that the live viral
vectored vaccine will stimulate robust cellular mucosal response and the IM boost with mRNA will
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boost neutralizing antibody responses against SARS-CoV-2 to generate improved immunity
against SARS-CoV-2 infection.
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Figure 3. Experimental vaccine approaches to improve COVID-19 vaccine efficacy.
Prototype intranasal boosters after mRNA prime with RBD-VLP, RBD-Flu and BreC-CoV-2 to
induce both mucosal and systemic immunity.
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5.5.1 Potential nasal adjuvants
In chapter 4, we evaluated IRI (beta glucan), CpG, and two forms of BECC adjuvants as potential
nasal vaccines (Ch.4, Fig.1). The BECC adjuvants were overall the most immunogenic adjuvants
followed by CpG and then IRI. In order to develop a protective mucosal vaccine, an immunogenic
vaccine formulation must be used to circumvent the quick mucosal clearance of antigen and
maintain vaccine retention in the upper respiratory tract. Therefore, for protein-based vaccines,
adjuvants are necessary to increase immunogenicity.
Even though the Beta glucan, IRI was not as immunogenic as BECCs, previous studies evaluating
improving intranasal Pertussis vaccines demonstrated that Beta glucan adjuvants obtained from
yeast could increase vaccine retention in the nasal cavity and induce long-lived antibody
responses (61,62). Other intranasal Pertussis vaccine studies have demonstrated the use of cdi-GMP, an intracellular receptor stimulator of interferon genes (STING agonist), along with
LP1569, a TLR2 agonist, as a combinatorial nasal adjuvant that can induce both Th1 and Th17
immune responses (63). Additional adjuvants that have shown immunogenic properties in nasal
vaccine formulations include Alum and CpG. Intranasal administration of inactivated SARS-CoV2 vaccine adjuvanted with Alum generated increased production of IgG and IgA in the mucosa
compared to intramuscular administration of the same formulation (64). Lastly, lipid A mimetic
adjuvants such as MPL and BECCs have been used in pre-clinical intranasal vaccine
formulations. BECC adjuvants have shown immunostimulatory properties in nasal COVID-19
vaccines and in nasal Pertussis vaccine formulations. However, since BECCs are derived from
Gram-negative bacteria, the toxicity of the Lipid A is a concern. Further toxicity and adjuvant
dosing studies with BECC adjuvants need to be performed to ensure safety. Additionally, the
generation of synthetic BECC molecules could also decrease the potential toxicity due to
biologically derived endotoxin. Altogether, adjuvants in nasal vaccines serve as a tool to climb
over the barriers of accelerated mucosal clearance as well as mucosal tolerance.
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5.5.2 Other uses for nasal vaccination
Conventional standards of administering antibody therapeutics in humans is through the
intravenous route. Approved monoclonal antibody therapies for COVID-19 are administered as
single IV dose, whereas convalescent plasma therapy is administered as an infusion. However,
there are no approved intranasal antibody therapeutics. Pre-clinical passive immunization studies
utilizing intranasal delivery of antibodies have demonstrated that IgM monoclonal antibody
therapy targeting RBD maintained nasal cavity retention, neutralized SARS-CoV-2 VOC,
protected mice against challenge, and was able to therapeutically treat mice with SARS-CoV-2
(65). RBD nanobody intranasal nebulization was also able to neutralize SARS-CoV-2 VOC in vitro
and therapeutically decrease COVID-19 associated symptoms in Syrian hamsters (66). Influenza
passive immunization studies also demonstrated that intranasal administration of Influenza
specific IgA was able to protect against H1N1 challenge in a human challenge model (67).
Furthermore, antivirals could also be administered intranasally to diminish the transmission and
spread of SARS-CoV-2 (68). We speculate that intranasal administration of antivirals, in theory,
could alleviate systemic viral dissemination if administered early during the infection course,
decrease transmission by eliminating viral replication at the site of infection and potentially help
decrease or alleviate respiratory symptoms faster. Altogether, more studies need to be performed
in order to evaluate the plausibility of intranasal antiviral delivery.
5.6 Concluding remarks
The emergence of SARS-CoV-2 VOC has driven the continuation of the COVID-19 pandemic.
Vaccines developed against the ancestral strain of SARS-CoV-2 towards the beginning of the
pandemic have experienced a decrease in vaccine efficacy against newly emerging variants.
Therefore, the development of improved COVID-19 vaccines and vaccine approaches are
necessary to improve immunity against emerging VOC. We have utilized the K18-hACE2 mouse
model to study the pathogenesis of VOC, characterize the antibody mediated responses against
emerging VOC, as well as assessed different vaccine delivery systems and administration routes
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to improve vaccine responses against VOC. Overall, we have demonstrated that the induction of
both systemic and mucosal immunity results in the optimal protection against SARS-CoV-2.
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